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In this study the diversity of mast cell proteases and some of the factors regulating mast cell growth and protease expression
were examined.
Five proteases were isolated from mouse small intestinal mucosa and characterised in terms of their substrate specificities,
substrate and inhibitor kinetics and immunohistochemical localisation. These studies revealed that the isolated proteases
were all of mast cell origin and that they were chymotrypsin-like in their substrate specificities. The proteases were all
identified as variants of mouse mast cell protease-1 which differed only in their carbohydrate moieties. Despite the fact that
these enzymes shared a common core polypeptide they all differed significantly in the rate at which they hydrolysed low
molecular weight synthetic substrates and in the rates at which they were inhibited by a,-proteinase inhibitor. A similar, but
distinct protease was isolated from peritoneal cavity mast cells of mice. This enzyme, also a chvmase, had N-terminal
sequence consistent with identification of the enzyme as mouse mast cell protease-4 which had previously only been
identified by N-terminal sequence analysis of electro-blotted protein and from cDNA sequencing. This enzyme was not
inhibited by, and actually degraded a] -proteinase inhibitor.
Some of the factors which regulate mast cell growth, proliferation, survival and protease expression were examined in the
rat. Stem cell factor (SCF) or cytokine-rich lymph node conditioned medium (LNCM) was administered to normal rats by
intraperitoneal injection and the effects on a defined cell populations, the connective tissue mast cells (CTMC) of the
peritoneal cavity were monitored. LNCM did not cause an increase in CTMC numbers but it did stimulate a switch in
protease expression from rat mast cell protease I (RMCP I) alone to dual expression of both RMCP I and RMCP II. SCF
alone caused a significant increase in CTMC numbers coupled with a decrease in RMCP I content and an increase in RMCP
II content. Treatment with both LNCM and SCF together caused an even greater increase in both CTMC numbers and
RMCP II expression than that seen with SCF alone. A second experiment was carried out where SCF was administered by
daily intravenous injection for 14 days to both normal and parasitised rats and the effects of the treatment on CTMC and
mucosal mast cell (MMC) populations was monitored. Intravenous SCF treatment resulted in a five-fold increase in
peritoneal mast cell numbers with a concomitant decrease in RMCP I content. There was no significant expression of RMCP
II in the CTMC of these animals.
An alternative approach in examining the role of SCF in regulating mast cell populations w as the use of polyclonal
antibodies raised against SCF to try and block SCF activity in both normal and parasitised rats.
In normal rats, treatment with anti-SCF antibodies caused an approximately 50% decrease in the number of mast cells
detected in the peritoneal cavity and totally ablated the MMCs from the small intestinal mucosa. In parasitised rats treated
with anti-SCF antibodies, the mucosal mast cell hyperplasia associated with infection was significantly delayed in rats
infected with Nippostrongvlus brasiliensis or Trichinella .spiralis and completely ablated in rats infected with Schistosoma
mansoni. The depletion of mast cells from the intestinal mucosa was accompanied by a reduction in the tissue concentration
of RMCP II. When anti-SCF antibodies were administered to rats which had already developed a mast cell hyperplasia
following N. brasiliensis infection, there was again a significant depletion of both mast cells and RMCP II from the small
intestine.
A sensitive ELISA test was developed to measure soluble SCF in blood. This assay showed that circulating SCF levels were
significantly increased by infection with both A. brasiliensis and '/'. spiralis. Taken together these results show that SCF and
the cytokines in LNCM play an important role in the regulation of mast cell populations and their expression of proteases.
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Mast cells are mononuclear granulocytes derived from bone marrow
haemopoietic progenitor cells that express the high affinity FceRI receptors for
immunoglobulin E (IgE) on their surface, through which they may be activated
(Ishizaka, Tomioka & Ishizaka, 1970). They are characterised by their content of
numerous compact, metachromatic granules which have a high affinity for basic,
thiazine and copper phthalocyanin dyes and have the capacity to synthesise, store and
secrete a large array of highly potent mediators of both inflammatory and immune
processes. A number of these mediators are pre-formed and are stored in the
secretory granules. These include proteoglycans, biogenic amines, cytokines,
glycosidases and proteases. In addition to the pre-formed mediators a number of
mediators are synthesised de novo when the mast cells are activated, these include
prostaglandins and leukotrienes which are metabolites of arachidonic acid, platelet
activating factor and a range of cytokines.
Mast cells are found in all species of mammals, birds, reptiles, amphibians and
fish so for investigated (reviewed by Riley, 1959; Selye, 1965; Chiu & Lagunoff,
1972), and are distributed throughout most tissues of the body, often in association
with loose connective tissue elements or at mucosal surfaces, particularly in the
gastrointestinal and respiratory tracts. Mast cell numbers are frequently increased in
parasitic infections and allergic conditions and, together with IgE, are the fundamental
components of immediate hypersensitivity reactions.
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Ehrlich (1878) first used the term mast cell when he described cells with an
"engorged" (mast) appearance, which contained numerous cytoplasmic granules with
unique metachromatic dye-binding properties. Since that time the metachromatic
staining properties of the granules has been considered the hallmark of the mast cell.
The mast cells located in connective tissue or mucosal sites, while sharing
morphological features such as metachromatic cytoplasmic granules, differ in a
number of aspects and are now considered to represent two distinct sub-sets which
have been named connective tissue or mucosal mast cells depending on their
anatomical site. There was considerable debate as to the existence of intestinal
mucosal mast cells after they were first noted by Maximow (1906) who described
cells which were smaller, less well granulated and poorly preserved compared with
mast cells from other anatomical sites. Michels (1938) later described such cells as
'atypical' mast cells. Enerback (1966a) established that mucosal mast cells (MMC) in
the intestinal mucosa of the rat had different morphology, sensitivities to fixation, dye
binding properties and responsiveness to secretagogues compared with mast cells
from other locations. The monoamine stored in MMC was also distinct from those
present in 'typical' connective tissue mast cells (CTMC; Enerback, 1966a-d), and thus
they represented two distinct sub-sets of mast cells.
One of the most reliable means of differentiating between MMC and CTMC is
by their content of neutral serine proteases. In the rat CTMC contain a strongly basic,
insoluble, chymotrypsin-like protease, rat mast cell protease (RMCP) I (Woodbury,
Gruzensky & Lagunoff 1978) whereas MMC contain the similar, but more soluble
and antigenically distinct RMCP II (Woodbury, ef a/, 1978; Gibson & Miller 1986).
1.2 Proteoglycans
The characteristic metachromatic staining of mast cell granules with basic
thiazine and copper phthalocyanin dyes, at low pH (< pH 0.5) indicates the presence
of highly sulphated proteoglycans. In rodents, connective tissue-type 'typical' mast
cells contain heparin proteoglycan (Enerback 1966b) whilst the 'atypical' mast cells
located at or near mucosal surfaces contain predominantly chondroitin sulphate E
(Enerback 1981). Both heparin and chondroitin sulphate E share a common core
protein which contains a Ser-Gly-repeat sequence (Kjellen, Pettersson, Lillhager,
Steen, Pettersson, Lehtonen, Karlsson, Ruoslahti & Hellman, 1989; Angerth, Huang,
Aveskogh, Pettersson, Kjellen & Hellman, 1990) and differ in the composition of the
repeating disaccharide units of their carbohydrate side chains which are attached to
the serine residues of the core protein (Stevens, Lee, Seldin, Austen, Befus &
Bienenstock, 1986). The presence of highly sulphated proteoglycan such as heparin in
the CTMC of skin can be readily detected by staining with thiazine dyes such as
toluidine blue or copper phthalocyanin dyes like astra blue at low pH (Enerback
1966b). When these dyes are used at pH 0.5 or less, only the strongly acidic sulphate
groups remain ionised and thus capable of binding the dye (Enerback 1966b).
However it is clear that the MMC in the small intestine of the rat differ from those in
skin since their staining properties with the above techniques is dependent on the type
of fixative used in the preparation of the tissue sections (Enerback 1966b).
1.3 Mast cell hyperplasia in parasitic infection.
Mast cell hyperplasia in association with parasitic helminth infection was first
observed in the gastrointestinal tract of rats by Taliaferro & Sarles (1939) who found
increased numbers of globule leukocytes and mast cells in the small intestine of rats
infected with Nippostrongylus maris (later re-named N. brasiliensis). Since that time
mast cell proliferation in the gastrointestinal mucosa has been recognised as a
characteristic feature of enteric parasitism in many species, including man (reviewed in
Miller, 1992). In murine rodents these mast cells have morphological, histochemical
and fixation properties which identify them as mucosal mast cells (Miller & Walshaw
1972; Enerback, 1981).
1.4 The activation of mast cells and their possible role in the rejection of
parasites.
Despite the fact that the mast cell hyperplasia in response to parasitic infections
has been recognised since the late 1930s the role they play in the hosts immune
response is not well understood and indeed there has been considerable debate as to
whether they have a significant role at all. Many studies have shown that parasite-
specific IgE is produced in response to infection (Jarrett & Miller 1982; Rothwell
1989) and that immediate hypersensitivity reactions are involved in the protective
response (Miller, Woodbury, Huntley & Newlands, 1983). In immediate
hypersensitivity-type reactions allergen-specific IgE binds to the high affinity IgE
receptor (Fc,;RI) which is expressed on the surface of mast cells and basophils. When
IgE molecules, bound in this way, are cross-linked by interaction with specific
allergen or with anti-IgE antibody, several processes are initiated. The mast cells are
stimulated to secrete pre-formed mediators such as histamine and proteases
(Wyczolkowska, Brzezinskablaszczyk & Maslinski, 1981, Miller el al 1983). Cross-
linking of surface-bound IgE also initiates signal transduction pathways which can
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result in de novo synthesis of numerous cytokines (Gordon, Burd & Galli, 1990) and
arachidonic acid metabolites e.g. prostaglandin D2 (Lewis, Soter, Diamond, Austen,
Oates & Roberts, 1982) through the cyclo-oxygenase pathway, and leukotriene C4,
(Razin, Menciahuerta, Lewis, Corey & Austen, 1982) through the lipoxygenase
pathway.
Evidence for activation of MMC in vivo is provided by the anaphylactic
release of RMCP II into both the blood and gut lumen of the rat following
intravenous treatment of primed (immune) rats with soluble worm antigen (King &
Miller, 1984; King, Miller, Woodbury & Newlands, 1986) which strongly suggests
that the mast cells are being activated through surface-bound IgE. It is also clear that
mast cells are functionally active during the period when parasites are expelled by
their host. This is shown most clearly by the systemic secretion of mast cell-specific
proteases into the blood of parasitised rats and mice during worm expulsion
(Woodbury, Miller, Huntley, Newlands, Palliser & Wakelin, 1984).
However, it may be that mast cells are not always an essential component of
the immune response to helminths. For example, there are substantial accumulations
of mast cells around the sites of persistent cestode infections in rats (Lindsay &
Williams 1985; Chernin, Miller, Newlands & McLaren, 1988) which have no apparent
detrimental effect on the parasites. In addition, both mast cell deficient W/W mice and
W*/W rats expel the intestinal nematode A. brasiliensis at virtually the same rate as
their congenic +/+ littermates in the absence of any significant mastocytosis (Reed
1989; Arizono, Kasugai, Yamada, Okada, Morimoto, Tei, Newlands, Miller &
Kitamura, 1993). The involvement of mast cells in the mouse may also be, at least to
some extent, dependent on the species of parasite since, in contrast with N.
brasiliensis, expulsion of Trichinella spiralis is significantly delayed in W/W mice
(Reed 1989) and totally abrogated in normal mice treated with anti-c-^/7 antibodies
which abolished the mast cell hyperplasia associated with infection (Grencis, Else,
Huntley & Nishikawa, 1993).
1.5 Regulation of mast cell differentiation and hyperplasia
There are at least two distinct mechanisms which regulate mast cell
proliferation, differentiation and survival in rats and mice. One of these is mediated by
stem cell factor (SCF) a cognate ligand for c-kit, which is a tyrosine kinase receptor
that is encoded by the c-kit proto-oncogene (Williams, Fletcher, Lyman & de-Vries,
1991; Besmer 1991; Galli, Zsebo & Geissler, 1994; Kitamura, Tsujimura, Jippo,
Kasugai & Kanakura, 1995). SCF is a growth factor produced by many cells including
fibroblasts and other stromal cells, some epithelial cells and vascular endothelial cells
(Galli et aI 1994; Kitamura el al 1995). This growth factor has multiple activities that
influence the development ofc-kii lineages, including haemopoietic progenitor cells
and mast cells as well as primordial germ cells, melanocytes and certain other cell
types (Williams et al 1991; Besmer 1991; Galli el al 1994). SCF is also known as
Steel factor, kit-ligand and mast cell growth factor (Williams et al 1991; Besmer
1991; Galli et al 1994). SCF is the designation that will be used in this thesis. Several
lines of evidence indicate that, under physiological conditions in vivo, SCF is critical
for the development and survival of all mouse and rat mast cells, including CTMCs
and MMCs (Galli el al 1994; Kitamura et al 1995). The other mechanism that
regulates mast cell development in mice and rats is mediated by T cells and possibly
other sources of interIeukin-3 (IL-3), IL-4, IL-9 and IL-10 which can promote and/or
co-promote the proliferation and/or survival of certain murine mast cell populations
including the MMC-like bone marrow-derived mast cells (BMMC) that can be
generated in vitro (Galli el al 1994; Kitamura et al 1995; Schmitt, Huls, Nagel &
Rude, 1990; Thompson-Snipes, Dhar, Bond, Mosmann, Moore & Rennick, 1991).
In murine rodents, infection with intestinal nematodes induces a striking
hyperplasia of intestinal MMCs, which is accompanied by increases in the levels of MMC-
associated proteases in intestinal tissues and increases in the concentrations of these
proteases in the blood (Miller & Jarrett 1971; Miller et al 1983; Huntley, MacKellar,
Newlands, Irvine & Miller, 1990; Huntley, MacKellar & Miller, 1993; Woodbury et al
1984). Previous work indicated that both SCF and T cell-dependent mechanisms
contribute to the intestinal MMC hyperplasia associated with nematode infection. In
comparison to normal mice or rats, those with mutations that markedly diminish c-kit
receptor tyrosine kinase activity, such as W/W mice (Reed 1989) or JV/W6 rats (Arizono et
al 1993), exhibit no or greatly diminished hyperplasia of intestinal MMCs in response to
infection with N. brasiliensis (Reed 1989; Arizono et al 1993), or T. spiralis (Reed 1989).
Both intestinal MMC hyperplasia and the spontaneous expulsion of the parasites are
diminished in T. s/j/ra/A-infected mice that have been treated with an antibody to the c-kit
receptor (Grencis et al 1993). Moreover, treatment of normal rats with E. coli-derived
recombinant rat SCF164, which represents virtually the entire extracellular ligand domain
of SCF and which possesses high biological activity (Galli et al 1994), induces significant
hyperplasia of gastrointestinal MMCs as well as connective tissue-type mast cells (Tsai,
Shih, Newlands, Takeishi, Langley, Zsebo, Miller, Geissler& Galli, 1991). The T cell-
dependent nature of the other mechanism, on the other hand, is demonstrated in athymic
'nude' mice which fail to develop MMC hyperplasia in response to nematode infection.
This response is restored in nude animals treated by adoptive transfer of T cells from
congenic normal +/+ littermates (Reed 1989). Moreover, in normal mice, treatment with
either anti-EL-3 or anti-IL-4 antibodies, or, even more effectively, treatment with both
antibodies together, significantly suppresses intestinal mast cell hyperplasia in response to
N. brasiliensis infection (Madden, Urban, Ziltener, Schrader, Finkelman & Katonal,
1991). Finally, in vitro evidence indicates that SCF and IL-3 can have synergistic effects
in promoting the proliferation of rat mast cells with phenotypic similarities to MMCs
(Haig, Huntley, MacKellar, Newlands, Inglis, Sangha, Cohen, Hapel, Galli & Miller,
1994; Tei, Kasugai, Tsujimura, Adachi, Furitsu, Tohya, Kimura, Zsebo, Newlands,
Miller, Kanakura & Kitamura, 1994).
Taken together, this evidence indicates that the cytokine-dependent regulation of
MMC hyperplasia during nematode infection in murine rodents, while complex,
importantly involves both SCF and T cell-derived cytokines such as IL-3 and IL-4.
1.6 Mast cell proteases
The first indication that mast cells contained proteases was the histochemical
localisation of esterase activity in the mast cells of skin by Gomori (1951). This was
confirmed some years later by the work of Benditt & Arase (1959) who found
enzymic activity similar to a-chymotrypsin in isolated rat peritoneal mast cells. Mast
cell granules, in fact, store a number of different types of proteases (Table 1). A major
granule component in rodents and man is the zinc metalloexopeptidase,
carboxypeptidase A (Reynolds, Stevens, Gurley, Lane, Austen & Serafin, 1989;
Goldstein, Kaempfer, Proud, Schwartz, Irani & Wintroub, 1987).
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Table 1 Mast cell serine proteases.
Species Protease Specificity Location
Mouse MMCP-1 chymase MMC
MMCP-2 chymase MMC





Rat RMCPI chymase CTMC
RMCP II chymase MMC
RMCP3 chymase RBL-1
RMCP 4 chymase RBL-1
RMCP 5 chymase CTMC
RMCP 6 tryptase CTMC
RMCP 7 tiyptase CTMC
RMCP 8 ? RBL-1 (?MMC)
RMCP 9 ? RBL-1 (?MMC)
RMCP 10 ? RBL-1 (?MMC)
Human Chymase chymase CTMC
Tryptase tiyptase MMC/CTMC
Dog tryptase A tryptase ?
tryptase B tryptase ?
chymase chymase ?
Sheep SMCP 1 chymase/tryptase MMC
SMCP2 chymase ? CTMC?
* Much of the work on canine mast cell proteases has been carried out on mastocytoma-derived
material and there is no definitive information available on the distribution of the proteases. RBL-1
is a rat basophilic leukaemia cell line with many similarities to MMC.
Neutral serine proteases have also been identified as major secretory granule
components in the mast cells of several species including mouse (Dubuske, Austen,
Czop & Stevens, 1984, Newlands, Gibson, Knox, Grencis, Wakelin & Miller, 1987),
rat (Lagunoff & Pritzl 1976; Woodbury, Gruzenski & Lagunoff, 1978), dog
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(Caughey, Viro, Ramachandran, Lazarus, Borson & Nadel, 1987; Vanderslice, Craik,
Nadel & Caughey, 1989) sheep (Huntley, Gibson, Knox & Miller, 1986; McAleese,
Pemberton, Huntley and Miller, unpublished) and man (Schwartz, Lewis & Austen,
1981; Schechter, Choi, Slavin, Deresienski, Sayama, Dong, Lavker, Proud & Lazarus,
1986). The distinctive, apparently tissue-specific, distribution of mast cell proteases
in man and rodents suggests that different mast cell populations may respond
according to the type of protease secreted.
The chymotrypsin-like proteases found in mast cell granules are structurally
similar to the granule-associated proteases, such as cathepsin G, granzyme B and
granzyme H, found in other cell types of haemopoietic origin like T cells and
neutrophils (Reviewed by Caughey 1995). These proteases are of similar size, 30-35
kDa and each contain 6 half-cystein residues indicating the probable presence of 3
intra-chain disulphide bonds (Le Trong, Parmelee, Walsh, Neurath & Woodbury,
1987). Bovine pancreatic chymotrypsin and a number of plasma serine proteases differ
from the secretory granule-associated proteases in that they have an additional
disulphide bond in the active site-substrate binding region (Le Trong eta! 1987). In
both mouse and man the genes which encode these granule-associated proteases are
clustered on chromosome 14 (Gurish, Nadeau, Johnson, McNeil, Grattan, Austen &
Stevens, 1993; Hohn, Popescu, Hanson, Salvesen & Ley, 1989) suggesting that they
may have arisen by gene duplication fairly recently in evolutionary terms. This is
supported by the similarities in the basic organisation of the introns and exons of the
genes which encode these proteases in that they share a common I, II, 0, 0 intron
phase pattern (reviewed by Caughey 1995).
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Rat CTMC, typified by those found at serosal surfaces, contain the
chymotrypsin-like enzyme rat mast cell protease 1 (RMCP I; Lagunoff & Pritzl
1976) while MMC, found predominantly in the mucosa of the gastrointestinal tract,
contain the similar, but antigenically distinct and more soluble enzyme, rat mast cell
protease II (RMCP II; Woodbury, et al 1978). These proteases share 74% amino acid
sequence identity (Le Trong et al 1987) but have substantially different physical and
enzymic properties. RMCP I is insoluble in physiological conditions, requiring 1 M
NaCl to solubilise it (Lagunoff & Pritzl 1976) whereas RMCP II is readily soluble
(Woodbury el al 1978). These properties are due, in part at least, to the net charge of
the proteases. RMCP I is highly basic with a net charge of + 18 whilst RMCP II has a
net charge of +3 (Le Trong et al 1987). In terms of function both proteases have
chymotrypsin-like substrate specificities (Lagunoff& Pritzl 1976; Woodbury et al
1978) but RMCP II is efficiently inhibited by the plasma serine protease inhibitor ar
protease inhibitor (cti-PI) while RMCP I is not inhibited by, and in fact hydrolyses,
oti-PI (Pirie-Shepherd, Miller & Ryle, 1991). Quantitation of the distribution and of
the systemic secretion of RMCP II during intestinal immunological reactions has
been facilitated by the development of highly sensitive enzyme linked
immunosorbent assays (ELISA; reviewed in Miller, Huntley, Newlands & Irvine,
1990) and it is clear from these studies that RMCP II serves a very different
function from that of RMCP I, for example it is synthesised and secreted in large
amounts during parasitic infections, whereas concentrations of RMCP I remain
relatively unchanged (Miller et a! 1990)
The genes encoding a number of other serine proteases have been cloned from
isolated peritoneal mast cells or from rat basophilic leukaemia (RBL) cell lines. In
addition to RMCP I and II, which are well characterised, RMCP 3-10 have now been
identified (Lutzelschwab, Pejler, Aveskogh & Hellman, 1997). RMCP-3 and -4, which
were cloned from RBL-1 cells and have been classified as chymases, do not appear to
be transcribed in either normal rat peritoneal mast cells or intestine (Lutzelschwab et
al 1997). RMCP-5, also a chymase originally described by Ide and colleagues (Ide,
Itoh, Tomita, Murakumo, Kobayashi, Maruyama, Osada & Nawa, 1995) as RMCP-3
is predominantly expressed in CTMC but is also expressed, at low levels, in normal
intestine (Lutzelschwab et al 1997). RMCP-6 and -7 were classified as tryptases, i.e.
they have trypsin-like substrate specificities, and appear to be expressed exclusively in
CTMC (Lutzelschwab el al 1997). RMCP-6 is the rat mast cell tryptase identified by
Lagunoff, Rickard & Marquardt (1991). RMCP-8, -9 and -10 appear to form a sub¬
family which may be more closely related to the T cell granzymes than to the other
mast cell proteases (Lutzelschwab et al 1997) and their substrate specificities have not
yet been determined. The RMCP-8 sub-family of enzymes were cloned from RBL-1
cells and are expressed in normal rat intestine (Lutzelschwab et al 1997).
Tryptases have also been found in the mast cells of several other species including
mouse, dog and man (Reynolds, Stevens, Lane, Carr, Austen & Serafin, 1990;
Caughey et al 1987; Schwartz et al, 1981).
Mouse mast cell protease (MMCP-1) isolated from the intestinal mucosa of mice
infected with the parasite T. spiralis, shares 74% amino acid sequence homology
with RMCP II and also has a very similar tissue distribution and biochemical
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properties (Newlands el al., 1987; Miller, Huntley, Newlands, MacKellar, Lammas &
Wakelin, 1988; Le-Trong, Newlands, Miller, Charbonneau, Neurath & Woodbury,
1989; Huntley, Gooden, Newlands, MacKellar, Lammas, Wakelin, Tuohy, Woodbury
& Miller, 1990). Murine bone marrow-derived mast cells (BMMC), often regarded
as in vitro analogues of MMC (Sredni, Friedman, Bland & Metcalfe, 1983), contain
four proteases in the molecular mass range 28-32 kDa including MMCP-1 as
determined by Western blotting and ELISA (Newlands, Lammas, Huntley, MacKellar,
Wakelin & Miller, 1991). Four esterases of similar or identical molecular weight
which bind the specific serine protease inhibitor [3H]-diisopropylfluorophosphate
(DFP) have also been found in BMMC (DuBuske et al., 1984). Five proteases
have been identified in CTMC and/or virus-immortalised mast cell lines on the basis
of N-terminal amino acid sequences and molecular weights and designated MMCP-
2 to MMCP-6 (Serafin, Reynolds, Rogelj, Lane, Conder, Johnson, Austen & Stevens,
1990; Reynolds el al, 1990). All but one of these proteases, MMCP-3, have been
cloned and sequenced. MMCP-1 is expressed only in MMC and MMCP-2 is
expressed in intestinal mucosa and Kirsten sarcoma virus-immortalised mast cells
(KiSV-MC; Serafin, Sullivan, Conder, Ebrahimi, Marcham, Johnson, Austen &
Reynolds, 1991). MMCP-4 is transcribed in CTMC and KiSV-MC (Serafin et al
1991) and MMCP-5 in CTMC and KiSV-MC (Huang, Blom & Hellman, 1991;
McNeil, Austen, Somerville, Gurish & Stevens, 1991). MMCP-6, identified as a
tryptase by its predicted amino acid sequence, appears to be exclusive to CTMC and
KiSV-MC (Reynolds, Gurley, Austen & Serafin, 1991). A second tryptase, MMCP-7
has been identified and found to be transiently expressed in immature, cultured
BMMC maintained in IL-3 (McNeil, Reynolds, Schiller, Ghildyal, Gurley, Austen &
Stevens, 1992). This tryptase has amino acid sequence homologies in the range 71-
76% with MMCP-6, dog and human tryptases but differs in its gene structure from
MMCP-6, having only 5 exons rather than the 6 in MMCP-6 (McNeil et al 1992).
1.7 Mast cell proteases; regulation of synthesis.
Rat BMMC, grown in IL-3 synthesise and store abundant RMCP II in their
granules (Haig, McMenamin, Redmond, Brown, Young, Cohen & Hapel, 1988) and it
is reasonable to suggest that IL-3 is responsible for regulating RMCP II synthesis in
the rat. However, co-culture of rat BMMC in both IL-3 and SCF depressed RMCP II
expression compared with IL-3 alone and did not induce expression of RMCP I (Haig
et al 1994). Thus it may be that IL-3 and SCF have opposite regulatory roles in the
protease expression of rat MMC. In contrast, when rat CTMC are co-cultured in IL-3
and SCF they switch from expressing RMCP I alone to co-expressing both RMCP I
and RMCP II (Haig et aI 1994). On the other hand in vitro murine BMMC grown in
IL-3 express little or no MMCP-1 (Ghildyal, McNeil, Gurish, Austen & Stevens,
1992), the mouse analogue of RMCP II, and are not induced to express this protease
until they are exposed to IL-10 (Ghildyal el al 1992). The BMMC grown in IL-3-
enriched medium express high steady-state levels of mRNA encoding for MMCP-5
but not MMCP-1, MMCP-2 or MMCP-4 (Xia, Ghildyal, Austen & Stevens, 1996).
However, nuclear run-on analysis shows that the genes for all four chymases are
transcribed (Xia et al, 1996) BMMC grown with the addition of IL-10 to the culture
medium, express high steady-state levels of the transcript encoding for MMCP-2 and,
in pulse-chase experiments, the half life of the MMCP-2 transcript was ~ 4-fold longer
than in replicate cells subsequently grown in the absence of IL-10 (Xia et a/, 1996).
Experiments with cycloheximide and actinomycin D indicate that IL-10 induces
expression of a /ram-acting factor(s) which stabilise the MMCP-2 transcript or in
some other way facilitate its processing (Xia et al 1996). When murine BMMC were
exposed to SCF they also expressed MMCP-4, the mouse analogue of RMCP I,
showing clearly that there are major differences between the two species in the
mechanism by which their protease expression is regulated.
1.8 Mast cell proteases; function.
Although mast cell proteases, particularly the chymases RMCP II in the rat and
MMCP-1 in the mouse, are synthesised and secreted in large quantities during
parasitic infections there is relatively little known about their in vivo function or their
native substrates. There is, however, some indication of the possible in vivo role of
the mast cell proteases in general from in vitro and ex vivo experiments. Human mast
cell tryptase has mitogenic effects on cultured fibroblasts (Ruoss, Hartmann &
Caughey, 1991), tracheal smooth muscle (Brown, Tyler, Jones, Ruoss, Hartmann &
Caughey, 1995) and bronchial epithelial cells in vitro (Cairns & Walls, 1996). The
mechanism by which tryptase stimulates growth is not certain but probably involves
cleavage of protease-activated receptors on the ceil surface. A receptor (PAR-2) has
been identified in both mouse and humans which, when activated through cleavage by
trypsin stimulates cell growth and proliferation (Nystedt, Emilsson, Wahlestedt &
Sundelin, 1994: Nystedt, Emilsson, Larsson, Strombeck & Sundelin, 1995). Thus far,
these 'tethered' receptors have been found to be expressed on endothelial cells,
fibroblasts, keratinocytes and neutrophils (Storck, Lusters, Vahland, Morys-
Wortmann & Zimmermann, 1996; Hou, Macey, Fox, Stone & Howells, 1996;
Howells, Macey, Hou & Stone, 1997). No such mitogenic function has been ascribed
to mast cell chymase but it is interesting to note that the sheep mast cell protease,
SMCP-1 has dual chymase and tryptase substrate specificities (Pemberton, Huntley &
Miller 1997), a characteristic it shares with cathepsin G, another granulocyte-
associated serine protease (Hof, Mayr, Huber, Korzus, Potempa, Travis, Powers &
Bode, 1996) suggesting that it could fulfil such a role. Chymases such as RMCP II
will degrade type IV collagen, a component of basement membrane (Sage, Woodbury
& Bornstein, 1979; Katunuma & Kido, 1988) and are able to activate other proteases
such as the matrix metallo-proteinases gelatinase (Gruber & Schwartz, 1990) and
stromelysin (Gruber, Marchese, Suzuki, Schwartz, Okada, Nagase & Ramamurthy,
1989), through proteolytic processing of the pro-enzymes (Suzuki, Lees, Newlands,
Nagase & Woolley, 1995) suggesting that it may have a role in remodelling and/or
wound repair.
Proteases may also have an important role in regulating inflammatory processes.
Human tryptase, for example, up-regulates synthesis and secretion, by epithelial cells
(Cairns & Walls), of IL-8, a chemo-attractant for neutrophils (Parsons, Fowler,
Heyers & Henson, 1985), and also increases epithelial expression of the intercellular
adhesion molecule ICAM-1 (Cairns & Walls, 1996) which has an important role in
recruitment of leukocytes to airways (Wegner, Gundel, Reilly, Hayes, Letts &
Rothlein, 1987). On the other hand, tryptase and chymase are reported to degrade a
number of regulatory neuropeptides such as vasoactive intestinal peptide (VIP) and
substance P (Caughey, Leidig, Viro & Nadel, 1988) which have pro-inflammatory
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activities in that they can stimulate release of the biogenic amines histamine and
serotonin from mast cells (Irman-Florjanc & Erjavec, 1983) as well as direct effects
on smooth muscle tone (Caughey et a! 1988).
More recently ex vivo perfusion studies have shown that RMCP II is released
a steady-state manner into the vasculature by the intestinal mast cells of rats
(Scudamore, Pennington, Thornton, McMillan, Newlands & Miller, 1995). The rate
of protease release was significantly higher in rats primed by previous infection with
N. brcisiliensis than that detected in uninfected controls, reflecting the higher mast
cells numbers present in the primed animals (Scudamore et al 1995a). The
concentration of RMCP II in vascular perfusate increased by 1000 fold within 2
minutes after the introduction of soluble N. brasiliensis antigen into the vascular
perfusate (Scudamore, Thornton, McMillan, Newlands & Miller, 1995b). After its
release the RMCP II rapidly reaches the gut lumen (Scudamore et al 1995a). This
process was accompanied by an increase in both vascular and epithelial permeability
which allowed the translocation of Evan's blue-labelled human serum albumin from
the vascular perfusate to the gut lumen (Scudamore, et al 1995b). The rapid
development of this macromolecular permeability of the vascular endothelium and
mucosal epithelium, in the absence of any gross epithelial lesions, suggests that
RMCP II increases permeability via a paracellular route by attacking the epithelial
junctional complex (Scudamore et al 1995b).
1.9 Aims of this thesis.
The mast cell proteases RMCP I and II, in the rat and MMCP-1, in the mouse, have
for some time, served as important markers of mast cell phenotype. There is now,
however, a considerable body of data which shows that these proteases are only part
of substantial multi-enzyme families. Much of the data on the diversity of rodent mast
cell proteases has been obtained by cloning and sequencing the genes which encode
for these proteases and relatively little is known about the functional properties of
these enzymes or about the mechanisms which regulate their expression in vivo.
MMCP-1 has been isolated from mouse intestine and partially characterised
(Newlands et al 1987) and there is now substantial evidence for a number of other
mast cell protease in the intestinal mucosa. The first aim of this study will be to
investigate the diversity of intestinal mast cell proteases in the mouse by isolating and
characterising the proteases present.
Mast cell proliferation, differentiation, survival and protease expression in rats and
mice is regulated through stem cell factor, derived from connective tissue elements
such as fibroblasts, and through the T cell-derived cytokines IL-3, -4, -9 and -10. In
this laboratory we have developed highly specific probes for the identification and
localisation of RMCP I and RMCP II which are expressed in CTMC and MMC
respectively. This means that the rat makes a suitable model for studying the effects of
cytokines on these mast cell sub-populations and on their protease expression. This
will be addressed by examining the effects of exogenously administered SCF or
cytokine-rich LNCM to normal animals and monitoring the effects on defined cell
populations, the CTMC of the peritoneal cavity and MMC in intestinal mucosa.
Another approach to examining the role of SCF in regulating mast cell populations
will be the preparation of polyclonal antibodies to SCF and the use of these antibodies
to try and block SCF activity in vivo. This will be carried out, initially, in normal rats.
Since mast cell hyperplasia is a prominent feature associated with intestinal
nematodiasis this procedure will be extended to examine the effects of polyclonal anti-
SCF on mast cell populations and mast cell protease expression in parasitised rats.
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2. MATERIALS AND METHODS
2.1 Mouse Mast Cell Protease-1 Glycoforms.
2.1.1 Animals and parasitic infection.
Male and female NIH mice, 8 to 10 weeks old, bred and maintained under
conventional conditions at the Department of Zoology, University of Nottingham,
were infected with 300 Trichinella spiralis muscle larvae as described previously
(Wakelin & Lloyd 1976). Female Balb/c mice, 6 weeks old, were infected with 300
Nippostrongylus brasiliensis L3 by subcutaneous injection.
2.1.1.1 Culture ofN. brasiliensis.
N. brasiliensis were cultured, by the following technique, by passage through
Wistar rats, maintained under conventional conditions at the Moredun Research
Institute, Edinburgh. Rats were infected with ~ 3000 third stage larvae (L3) by
subcutaneous injection and faeces from the rats was collected onto moist paper
towels, placed on a tray under the cage, between 7 and 9 days after primary infection.
The faecal pellets were soaked in tap water for approximately 1 hour after collection
and then thoroughly mixed with gas absorption grade, granular activated charcoal
(BDH, Poole, U.K.) in approximately equal volumes. The mixture was spread onto
moist, 7 cm diameter filter paper leaving a 1 cm clear margin, placed in a Petri dish
and incubated at 25°C for 5 to 7 days. Infective L3 migrated to the edge of the filter
paper where they were harvested by half filling the Petri dish with water at 37°C and
incubated at that temperature for 5 min, during which time the larvae migrated into
the water. The larval suspension was decanted into a Baerman apparatus lined with K-
Dex paper (Kleenaroll Ltd. London, U.K.) and filled with water at 37°C. Viable
larvae actively migrated through the paper and settled out at the bottom of the
Baerman funnel after about 1 hour. The larvae were collected and concentrated by
centrifugation at 100 xg for 3 min and subsequently washed x3 with physiological
saline containing penicillin (100 units/ml) and streptomycin (10 units/ml).
2.1.1.2 Calculation of larval dose.
Three 50 pi aliquots of the washed larval suspension were each spotted onto
microscope slides in a series of small drops and the larvae counted using a dissecting
microscope. The mean of the three counts was taken and the larval dose adjusted to
the desired volume.
2.1.1.3 Material collected post mortem.
The mice were killed by cervical dislocation 10 days after infection. The small
intestine of each mouse was removed and the lumen flushed through with Hanks
balanced salt solution (HBSS) to remove digesta before storage at -20°C or fixation
in Carnoy's fluid and subsequent processing to paraffin wax for immunohistochemistry
as described previously (Newlands, MacKellar & Miller, 1990). Porton mice, 6
months old, bred and reared at Moredun Research Institute were used for isolation of
murine serosal mast cell protease (MSMCP).
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2.1.2 Isolation of the variantforms ofmouse mast cell protease-1 from small
intestine.
Murine intestinal mast cell proteases were isolated by a modification of the
previously published method (Newlands et al., 1987). Briefly, after thawing, 10 g of
small intestine was chopped finely with scissors and homogenised in 20 mM Tris/HCl
pH 7.5 (3 ml per gram) with a Polytron homogeniser (Northern Media Supplies Ltd.
North Cave, North Humberside, UK.). The homogenate was centrifuged at 5000 xg
for 5 min and the supernatant was centrifuged at 50,000 xg for 15 min. The final
supernatant was applied to a 16 x 65 mm CM-Sepharose cation exchange column
(Pharmacia, Milton Keynes, UK) equilibrated with 20 mM Tris/HCl pH 7.5. Bound
proteins were eluted with aO-l.OM NaCl gradient over 90 ml. Fractions (5 ml) were
collected and screened for chymase activity against the synthetic substrate CBZ-L-
Tyrosine 4-nitrophenyl ester (CBZ-L-Tyr-4NPE) (Sigma) as described previously
(Knox, Gibson & Huntley, 1986). Those fractions which contained enzyme activity
were pooled and applied to a 16 x 160 mm column of Sephadex G25 (Pharmacia) to
rapidly desalt and exchange the buffer for 50 mM morpholinoethanesulphonic acid
(MES; Sigma) pH 6.0. The desalted material was applied to a Mono-S cation
exchange column (Pharmacia) equilibrated with 50 mM MES pH 6.0 and eluted with
a 50 mM-150 mM NaCl gradient over 20 ml. Individual peaks were collected and
those with activity against CBZ-L-Tyr-4NPE were diluted 5 fold with 50 mM MES
pH 6.0, re-applied to Mono-S and again eluted with 50-150 mM NaCl gradient
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2.1.3 Serosal Mast Cell Protease
Mice were killed by cervical dislocation following anaesthesia with Halothane
(May and Baker) and cells recovered from the peritoneal cavity by lavage with 5 ml
HBSS containing 0.1% w/v gelatin (Hanks/gelatin). Cells were sedimented by
centrifugation (400 xg for 10 min), washed once with Hanks/gelatin and re-suspended
in 1 ml Hanks/gelatin. Mast cell numbers were evaluated using a haemocytometer
after staining with 1% w/v methylene blue in 50% v/v propylene glycol. The cell
suspension was again sedimented by centrifugation, the supernatant fluid discarded,
and the cell pellet stored at -20°C. A mast cell granule preparation was made after the
method of Lagunoff & Pritzl (1976). Briefly, a thawed cell pellet was re-suspended in
1 ml distilled water and the cells fully disrupted by sonication (MSE, England) at 16
pm amplitude for 3 x 10 sec. with a 3 mm diameter probe. Granules were isolated
from the lysate by a differential centrifugation technique, first at 200 xg to remove
nuclei and larger cell debris followed by centrifugation at 50,000 xg for 15 min to
sediment the mast cell granules. The granule pellet was washed x2 with PBS and
finally solubilised in 1 ml of 2 M NaCl. The pellet extract was further centrifuged at
8000 xg for 2 min on an Eppendorf bench-top centrifuge and the supernatant fluid
applied to a Sephacryl-S200 (Pharmacia) size exclusion column (10 x 200 mm)
equilibrated with 1.0 M NaCl in 20 mM tris/HCl pH 7.5. Fractions (1 ml) were
collected and tested for enzyme activity against CBZ-L-Tyr-4NPE. Those containing
activity were pooled, diluted to a final concentration of 0.5 M NaCl with 20 mM
tris/HCl pH 7.5 and applied to the Mono-S cation exchange column equilibrated with
0.5 M NaCl in 20 mM tris/HCl pH 7.5. The column was eluted with a 0.5 - 1.0 M
NaCl gradient over 10 ml. All centrifugation and extraction steps were carried out at
+4°C.
2.1.4 Protein estimations
Protein concentrations were estimated using a Pierce BCA protein assay kit
(Pierce and Warriner, Chester, UK), using bovine serum albumin as standard, in
accordance with the manufacturer's instructions.
2.1.5 SDS-PAGE
Discontinuous SDS-PAGE was carried out as described by Laemmli (1970) on
15% mini slab gels (Mini Protein II, BioRad) run at 200 volts constant for 1.5 h or on
large format (Protean II xi, BioRad) 10% tricene-SDS-PAGE gels (Shagger & von
Jagow 1987) run overnight at lOOv constant to prepare samples for amino acid
sequence analysis. A range of molecular mass standards was included in each run:
Lysozyme (14.4 kDa), soybean trypsin inhibitor (21.5 kDa), bovine carbonic
anhydrase (30 kDa), ovalbumin (45 kDa), BSA (66.2 kDa), phosphorylase B (97.4
kDa). Protein bands were visualised by staining with Coomassie blue or by silver
staining.
2.1.6 Electroblotting
Proteins in SDS-PAGE gels were transferred to nitro-cellulose membranes
(Schleicher and Scheull, Dassel, Germany) or PVDF membrane (Immobilon P,
Millipore U.K. Ltd) using a semi-dry transfer apparatus (Kyhse-Andersen, 1984) with
a current of 1.0 mA/cm2 of gel for 1 hour. After transfer, nitro-cellulose membranes
were incubated in a solution of 0.1% w/v Tween 20 (Sigma) in PBS pH 7.5
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(PBS/T20) for 30 min at room temperature to block non-specific protein adsorption
to the membranes. Following the blocking procedure the membranes were rinsed in
fresh PBS/T20 (all subsequent washes and antibody dilutions were in PBS/T20) and
transferred to optimally diluted sheep anti-MMCP-1, rabbit anti-MMCP-1 or rabbit
anti-RMCP I for 1 h at room temperature. The membranes were subsequently washed
(3x5 min) and probed with optimally diluted pig anti-sheep IgG-horseradish
peroxidase (HRPO) conjugate prepared according to the method of Nakane &
Kawaoi (1974) or sheep anti-rabbit IgG-HRPO conjugate (Sera Lab., Crawley,
Sussex). Peroxidase activity was revealed with 3-3'-diaminobenzidine/H202 (Graham
& Karnovsky, 1966). PVDF membranes with protein bands for sequence analysis
were stained with Coomassie blue, immediately after transfer was completed, and de-
stained in methanol.
2.1. 7 Deglycosylation
Aliquots of the proteases in distilled water (20-25 pi), containing approximately 2 pg
of protein, were denatured by heating in a boiling water bath for 10 min and then
cooled to room temperature. Denatured samples were incubated with 10 pi of
deglycosylation buffer (150 mM phosphate buffer pH 7.0, 50 mM EDTA and 1% v/v
2-mercaptoethanol) and 1 pi (0.2 units) of peptide-N-glycosidase F (PNGase F) or
endo-a-acetyl-galactosaminidase; (both from Boehringer-Mannheim, Lewes, UK) at
37°C overnight. An additional 0.2 units of glycosidase were then added and
incubation was continued for a further 24h.
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2.1.8 Enzyme linked immunosorbent assay to quantify MMCP-1.
Mouse mast cell proteases were quantified by an antigen capture ELISA described
previously (Huntley et a/., 1990a) except that the capture antibody was affinity-




Plates were coated with a solution of sheep anti-MMCP-1 capture antibody
diluted to lp-g.mf1 with 0.1 M carbonate buffer pH 9.6. 50 |ul of diluted antibody was
loaded into each well and the plate tapped gently to ensure even distribution of the
antibody solution. The coated plates were incubated in a humid chamber at +4°C for
24h before use.
2.18 2 ELISA test.
1. Wash coated plates x6 with phosphate buffered saline (PBS) + 0.05%v/v tween 20
(Sigma).
2. Load standards (see below) and unknown sample (50 pl/well).
3. Incubate for 1.5h at room temperature. (All dilutions in 4% BSA in PBS/Tween
20).
4. Wash plates x6 with PBS/Tween 20.
5. Incubate plates with conjugate, optimally diluted with 4% BSA in PBS/Tween 20,
(50 pl/well) at room temperature for lh
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6) Wash plates x6 with PBS/Tween 20.
7) Incubate plates with OPD/H2O2 substrate (50 pl/well) for 20-25 min.
8) Stop reaction with 2.5M H2SO4 (25pl/well).
9) Read plates at 492 nm.
2.1.8,3 Preparation of standards.
MMCP-1 in seruin:-
Stock MMCP-1 was diluted to 50 |4g.ml"1 with normal mouse serum. This
solution was further diluted to 20 ng.ml"1 with PBS/Tween 20/BSA and used to make
up working standards, 0.25, 0.5, 1, 2, 4, 8, 10, 12 ng/ml. Standards were run in
duplicate on each plate.
MMCP-1 in tissue extracts:-
Stock MMCP-1 was diluted to 20 ng.mf1 with PBS/Tween 20/BSA and subsequently
diluted as for serum standards.
Volumes required to make up 100pl of standard
Cone, required (ng.mf1) 0.25 0.5 1.0 2.0 4.0 8.0 10.0 12.0
Vol. 20 ng.ml"1 stock (p.1) 1.25 2.5 5.0 10.0 20.0 40.0 50.0 60.0
Vol. Diluent (p.1) 98.75 97.5 95.0 90.0 80.0 60.0 50.0 40.0
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21.8.4 Buffer solutions for ELISA.
1) 0.1 M carbonate buffer pH 9.6
0.1 M NaC03; 0.1 M NaHC03 titrated to pH 9.6
2) Citrate/phosphate buffer pH 5.0
Stock solutions:-
0.1 M citric acid
0.2 M Na2HP04
Working buffer:-
0.1M citric acid 24.3 ml
Na2HP04 25.7 ml
distilled water 50 ml
3) Substrate
Citrate/phosphate buffer pH 5.0 100 ml
Ortho phenylene diamine (Sigma) 40 mg
H;02 40 pi
2.1.9 Histochemistry and Immunohistochemistry.
Tissue sections were stained with toluidine blue pH 0.5 (Enerback, 1966b) or
with sheep anti-MMCP-1, directly conjugated to FITC (Harlow & Lane, 1988), by
the following method; re-hydrated sections (5 pm thick) were incubated in 5% w/v
BSA (Sigma, Grade IV) in PBS for 30 min before transfer to sheep anti-MMCP-1-
FITC, optimally diluted in 5% BSA/PBS for 1 hour at room temperature. After
28
washing (3x5 min in PBS) sections were mounted in citifluor non-fluorescent
mountant (Citifluor Ltd. London, UK.)
2.1.10 Specific anti-protease antibodies
Rabbit antiserum to MMCP-1 was prepared as described previously (Newlands
et cil., 1987). Rabbit anti-RMCP I antibodies were raised, absorbed against MMCP-1-
sepharose and affinity purified on RMCP I-sepharose as described previously (Miller
et a/., 1988). Antiserum to MMCP-1 was raised in sheep by intramuscular injection of
100 pg MMCP-1 in Freund's complete adjuvant. Two subsequent injections of
MMCP-1 in Freund's incomplete adjuvant were given 4 and 7 weeks after the first.
The sheep was bled at 2 week intervals after the final injection and batches of serum
with an antibody titre > 1/16 by double diffusion against MMCP-1 were applied to an
MMCP-1 sepharose affinity column and eluted anti-MMCP-1 antibodies were cross
absorbed against RMCP I as described for rabbit anti-MMCP 1 (Miller et al 1988).
2.1.11 Binding offH] diisopropylfluorophosphate (fHJ-DFP).
Protease samples (40 pi) containing 4-8 pg of protein were incubated with 10 p
Ci ['Hj-DFP (5.8 Ci/mMol; Amersham International pic., UK) at 37°C for 15 min.
The samples were prepared for electrophoresis by the addition of 50 pi of reducing
sample buffer (Laemmli, 1970) and heated to > 90°C for 3 min. 5 pi aliquots of
sample were loaded to each lane of the gel. After electrophoresis the gels were
prepared for auto-radiography by the method of Laskey & Mills (1975). Radiographs
were exposed at -70°C and developed after 21 days.
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2.1.12 Specific activities ofenzyme preparations.
Specific activity was determined by measuring the rate of hydrolysis of the
synthetic substrate, CBZ-L-tyrosine 4-nitrophenyl ester (CBZ-L-tyr-4NPE). The assay
was performed as follows;
20 mM tris/HCl, pH 7.8 195 pi
4 mM CBZ-L-tyr-4NPE in DMSO 5 pi
Enzyme preparation 5 pi
Incubate at 22°C for 5 min and read at 405 nm.
Specific activity was calculated from the initial rates of substrate hydrolysis as
follows.
Equation 1, Calculation of specific enzyme activity.
AA /
4°%econd x v0'ume reach°n mixture in litres
1.884 x mg of enzyme in reaction mixture
The molar extinction coefficient of nitrophenol was taken as 1,884/l/mole/cm at
405 nm and pH 7.8.
Enzyme activity is expressed in nkat/mg of protein; 1 nkat is that activity which
hydrolyses 1 nMol of substrate in 1 second. All activities were corrected for
spontaneous alkaline hydrolysis of the substrate by subtraction of a parallel blank
which contained no enzyme.
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2.1.13 Substrate Kinetics.
All kinetic measurements were made using a Beckman DU 600
spectrophotometer. Rates of hydrolysis of 5 concentrations (0.125 to 2 mM) of the
chymotryptic substrate Succ-AJa-Ala-Pro-Phe-4NA were measured by adding 2 pi of
substrate solution to 48 pi of enzyme solution in 0.1M tris/HCl pH 7.5. The increase
in absorbance was continuously measured at 410 nm and the spectrophotometer's on¬
board software used to calculate the kinetic constants Km and kcat from the initial rates
of substrate hydrolysis.
2.1.14 Active site titration
Concentrations of protease were determined by active-site titration of the
MMCP-l-like proteases against the fluorogenic substrate 4-methyl umbelliferyl-p-
(NNN trimethylammonium) cinnamate; (MUTMAC; Sigma, Poole, UK; Jameson,
Roberts, Adams, Kyle & Elmore, 1973). Fluorescence was measured on a Perkin
Elmer 3000 fluorescence spectrophotometer with an excitation wavelength of 365 nm
and an emission wavelength of 445 nm. Unknown samples were measured, in
triplicate, against a standard curve prepared from 4-methyl-umbelliferone (7-hydroxy-
4-methylcoumarin; Aldrich Chemical Co. Ltd.).
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The buffer was 8.695 mM KH2P04, 30.43 mM Na2HP04, pH 7.41. The
MUTMAC, and enzyme were mixed and incubated at room temperature for 5, 10, 15
or 20 min before addition of buffer and methanol and read on the spectrofluorimeter
with an excitation wavelength of 365 nm and an emission wavelength of 445 nm.
Initial tests showed that maximal fluorescence was obtained after 15 to 20 min and
therefore all subsequent incubations were for 20 min before reading. The standard
curve was prepared from the following range of standard dilutions of 4-methyl-
umbelliferone; 0.25, 0.5, 1.0, 2.0, 3.0 and 6.0 pM in methanol from a 10 pM stock.
4-Methyl-umbelliferone standard. 20 pi
phosphate buffer 1980 pi
These were also read on the spectrofluorimeter with an excitation wavelength of
365 nm and an emission wavelength of 445 nm. The standard curve was linear over
the whole range tested and linear regression analysis was therefore used to calculate




Sensitivity of isolated enzymes to the following specific protease inhibitors was
studied using CBZ-L-Tyr-4NPE as substrate; 2.0 mM phenyl-methyl-sulphonyl-
fluoride (PMSF), 20 mM 3,4-Dichloro-isocoumarin (3,4 DCI), 200 mM N-[N-(L-3-
Trans-carboxyoxirane-2 carbonyl)-L-leucyl] -agmatine (E64), 2 mM 1,10-
phenanthroline (1,10-Phe), 1 mM pepstatin. (All reagents supplied by Sigma, Poole,
U.K.). The assay of enzyme activity was as follows; 2.5 pi of enzyme preparation and
2.5 pi of inhibitor were pre-incubated with 40 pi of 0.1M tris/HCl buffer pH 7.5 at
22°C for 1 h. The enzyme concentration in the incubation mixture was 50 nM and the
inhibitor concentrations were those given above. After pre-incubation 5 pi of
substrate was added and incubated for a further 3 min. Enzyme activity was quenched
by the addition of 450 pi of 70% v/v methanol. Absorbance was measured at 405 nm
and percentage inhibition calculated in comparison with an enzyme preparation
incubated without inhibitor.
2.1.15.2 Inhibition kinetics with oq-proteinase inhibitor.
The association constant (kass) for the reaction between the MMCP-l-like
proteases and human arproteinase inhibitor (op-PI; Sigma) was determined by pre-
incubating equimolar enzyme and cp-PI for periods of 15 to 120 s before continuous
measuring the rate of hydrolysis of the substrate Succ-Ala-Ala-Pro-Phe-4NA. The kass
for each reaction was calculated by non-linear regression as described previously
(Pirie-Shepherd, Miller & Ryle; 1991). The inhibition constant (Kj) for the reaction
between each protease and ai-PI was determined by incubating protease with varying
inhibitor concentrations (0.25 to 1.75 molar equivalents) for 35 times Ua ( the time to
half inhibition for an equimolar reaction calculated from the equation X\a = l/kass.E0
where E0 is the initial enzyme concentration). The apparent Kj (Kjapp) was calculated
by non-linear regression, as described previously (Pirie-Shepherd et a! 1991) and the
true Kj calculated from the equation Kj = Kjapp /l+So/Km, where S0 is the initial
substrate concentration.
2.1.16 N-terminal sequence analysis.
Amino terminal sequence analyses ofMMCP-lA-E were performed on soluble
proteins in 50 mM MES directly from ion-exchange on an Applied Biosystems 477A
protein microsequencer by the Welmet protein characterisation facility, Biochemistry
Department, University of Edinburgh. MSMCP, immobilised on Immobilon P
following tricene-SDS-PAGE and Western blotting was sequenced by the
Microchemical facility, AFRC Institute of Animal Physiology and Genetics Research,
Babraham, Cambridge, UK.
2.2 The role of stem cell factor in regulating mast cell growth and function in
normal, or parasitised rats.
2.2.1 Animals
Random-bred female Wistar rats weighing 250 to 300 gm, and maintained under
conventional conditions at Moredun Research Institute, were used in all experiments
to study the role of SCF in regulating mast cell growth and function.
2.2.2 Parasites
Rats were infected with 2500-3000 N. brasiliensis third stage larvae by sub¬
cutaneous injection (Huntley el al, 1993) or with 750-1000 T. spiralis muscle larvae
per os (Woodbury et al, 1984). In both of these procedures the rats were
anaesthetised with halothane (May and Baker, Dagenham, Essex, U.K.). The T.
spiralis muscle larvae were kindly provided by Mr. H. Urquhart, Centre for Tropical
Veterinary Medicine, University of Edinburgh.
2.2.3 Intraperitoneal treatment of rats with Stem Cell Factor and/or Lymph Node
Conditioned Medium.
2.2.3.1 Preparation of Lymph Node Conditioned Medium (LNCML
LNCM was prepared from mesenteric lymph node cells of normal rats after the
method of Haig, et al (1988). Aliquots (200 ml) of 4 x 106 per ml viable nucleated
MLN cells were prepared in Iscove's serum-free medium, which contained 5 x 10"5 M
2-mercaptoethanol (2-ME), 100 U/ml penicillin, 50 pg.ml"1 streptomycin, 100 pg.mf1
bovine serum albumin (BSA; Sigma, Poole, U.K.), 80 gg.mf1 phosphatidyl choline
(Sigma), 25 pg.ml"1 transferrin (Sigma) and 2 pg.ml"1 concanavalin A (Con A; Miles,
Slough, U.K.). Cultures were incubated for 48 hours at 37°C in 120 cm2 tissue culture
flasks (Nunc, Paisley, U.K.) in an atmosphere of 5% CO2. LNCM was harvested by
centrifugation and sterilised by filtration through a 0.22 pin filter (Millipore, Harrow,
U.K.) prior to storage at -70°C. Batches of LNCM and dilutions of them were tested
for their ability to generate mast cells from Wistar rat bone marrow and were used in
the experiments described below at the optimal concentration (20 - 50%).
2.2.3.2 Treatment of rats with LNCM or SCF
Female Wistar rats, 10 months old were used in these experiments. Groups of 4
rats were injected intraperitoneally with;
1. 0.5 ml LNCM diluted to 1 ml with serum-free IMDM;
2. 0.5 ml LNCM plus 320 pi pegylated recombinant rat stem cell factor, from a
bacterial expression system (rrSCF164; 10 pg.ml"1) diluted to 1 ml with serum-free
IMDM;
3. 320 pi SCF (10 pg.mf1) diluted to 1 ml with serum-free IMDM;
4. 1.0 ml serum-free IMDM;
5. 1.0 ml serum-free IMDM containing 3 pg.mf1 Concanavalin A, the same initial
concentration as was present in the LNCM.
The rats in groups 1-3 were injected daily for 2, 4 or 7 consecutive days and
those in groups 4 and 5 were injected for 7 consecutive days. Inoculations were
carried out under halothane anaesthesia and the rats were killed by overdose of
halothane/C02 followed by cervical dislocation. Peritoneal cells were harvested by
lavage of the peritoneal cavity with 15 ml of HBSS containing 1% w/v BSA. The
peritoneal cells were washed with HBSS/BSA and cyto-centrifuge preparations were
made and either fixed 4% Paraformaldehyde in PBS for lh at 45°C followed by 70%
ethanol for lh or over night as required or stained with Leishman's stain by the
following procedure. Slides were prepared in the cyto-centrifuge and allowed to air-
dry for 5 min. 1 ml of undiluted Leishman's stain (BDH, Poole, U.K.) was applied to
the slide for 3 min. After this initial staining period the stain was diluted with 3 ml of
tap water and the slide was stained for a further 9 min. The slides were subsequently
washed in tap water to remove excess stain and allowed to air-dry. Dried, stained
slides were cleared by immersion in xylene and mounted with a synthetic resin
mountant before examination with a Leitz Dialux microscope (Leitz, Wetzlar,
Germany).
2,2.3.3 Paired Immunofluorescence for detection of RMCP I and RMCP II in cyto-
centrifuge preparations.
1. Re-hydrate cyto-centrifuge preparations.
2. Incubate sections in diaminobenzidine (4 mg/10 ml in Phosphate buffered saline
(PBS) + 50 pi H2O2) for 15 min. to quench endogenous fluorescence of
eosinophils. Wash well in distilled water.
3. Incubate sections in 5% w/v Bovine serum albumin (BSA) in PBS for 30 min.
4. Incubate sections in affinity-purified rabbit anti-RMCP I, cross-absorbed against
RMCP II and diluted to approximately 2 pg/ml for lh at room temperature.
5. Wash 3x5 min in PBS.
6. Incubate sections with optimally diluted sheep anti-rabbit-tetra-methylrhodamine
isothiocyanate (TRITC) conjugate *.
7. Wash 3x5 min. in PBS.
8. Incubate sections with monoclonal mouse anti-RMCP II, developed at Moredun
Research Institute (Huntley el al 1990b) diluted to approximately 2pg/ml for lh at
room temperature.
9. Wash 3x5 min. in PBS.
10.Incubate with optimally diluted sheep anti-mouse IgG-fluorescein isothiocyanate
(F1TC) conjugate containing 2% normal rabbit serum *.
1 l.Wash 3x5 min. in PBS and mount in non-fluorescent mountant.
Dilutions.
All primary antibody and conjugate dilutions were made in 5% BSA in PBS.
* conjugates were centrifuged well to remove debris.
2.2.4 Intravenous treatment of rats with Stem Cell Factor
Recombinant rat stem cell factor164 (rrSCF164: Amgen Inc. Thousand Oaks ca.
U.S.A.) modified by the covalent attachment of polyethylene glycol (Tsai et al, 1991)
was administered intravenously to anaesthetised rats for 14 consecutive days in 1 ml
physiological saline at the rate of 25pg/kg of body weight/day, control rats were sham
treated with physiological saline alone. These inoculations were carried out by Prof.
H.R.P. Miller of the University of Edinburgh.
2.2.5 Antibodies to SCF.
Polyclonal anti-rrSCF164 antibodies were produced by inoculating a sheep with
100 pg of rrSCF1 4, suspended in 4 ml of Freund's complete adjuvant intramuscularly,
into both hind legs. This procedure was repeated 4 and 8 weeks after the initial
injection except that Freund's incomplete adjuvant was used for the subsequent
inoculations. Blood samples were taken 3 weeks after the final inoculation and the
serum tested by ELISA for anti-rrSCF164 activity. Immune sera that gave absorbances
more than five-fold greater than the background absorbance of pre-immunisation
serum when tested at dilutions of up to 1/80,000 by ELISA were used to prepare
specific antibody. The anti-SCF antibody preparation virtually abolished the effects of
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rrSCF164 on the survival and proliferation of in v/7/ o-derived rat mast cells, but had no
detectable effect on the IL-3 dependent proliferation of these cells (MacDonald,
Thornton, Newlands, Galli, Moqbel & Miller, 1996).
An immuno-affinity column was prepared by coupling 1.6 mg of rrSCF164 to
CNBr-activated Sepharose-4B (Pharmacia Biotech, St. Albans, Herts. U.K.) in
accordance with the manufacturer's instructions. Aliquots of serum (5 ml) were
applied to the column, which had been equilibrated with phosphate buffered saline
(PBS) and the column was subsequently eluted with 0.1M citric acid pH 2.2 + 0.5M
NaCl to recover bound, specific antibody. For control purposes, sheep
immunoglobulin was prepared by precipitation of normal sheep serum with 50%
saturated ammonium sulphate followed by gel filtration chromatography of the re-
dissolved precipitate on Sephacryl S-200 (Pharmacia Biotech). Immunoglobulin
preparations were concentrated by vacuum dialysis in a collodion thimble apparatus
(Sartorious, Epsom, Surrey, U.K.) against PBS.
2.2.6 Treatment with anti-SCF antibodies
Rats were inoculated intraperitoneally with 1 mg sheep anti-rrSCF164 or normal
sheep IgG in 1 ml phosphate buffered saline (PBS). Normal rats were treated daily for
each of 4 or 7 days to determine the effects on resting mast cell populations. Because
of the tissue and pulmonary migration of the L3 and L4 larval stages ofN. brasiliensis,
rats infected with this parasite were treated on day 3 of infection when the L4 larvae
first reached the intestine and on days 5, 7, 10 and 12 thereafter. A further experiment
was carried out with N. brasiliensis-infected rats to determine whether treatment with
anti-SCF had an effect on mast cell populations already expanded in response to
parasitic infection. In this experiment rats were treated with anti-SCF daily on days 10
to 13 after infection. For rats infected with 71 spiralis, treatment commenced on day 0
and continued on days 3, 5, 7 and 10. Normal rats were killed 24 hours and
parasitised rats 24 or 48 hours after the final inoculation by exsanguination under deep
halothane anaesthesia followed by cervical dislocation.
2.2. 7 Haematological studies
Blood samples were obtained by tail-snip under halothane anaesthesia with the
blood collected into heparinised tubes. Total red cell and leukocyte counts were
performed on a model ZM Coulter counter, haemoglobin concentrations were
measured on a Coulter haemoglobinometer and packed cell volume by micro-
haematocrit. Blood films were stained with Leishman's stain (2.1.3) for differential
cell counts in which 100 leukocytes were counted per blood film.
2.2.8 Material collected post mortem
Peritoneal cells were collected by lavage of the peritoneal cavity with 20 ml of
PBS containing 0.1% w/v BSA (PBS/BSA). Small intestine (mid-jejunum), stomach,
lung, liver and tongue were also collected for analysis and the tissues were either fixed
by immersion in 4% u/v paraformaldehyde in PBS for 6 hours followed by 70% v/v
ethanol overnight (Newlands el a/, 1987) before processing to paraffin wax or stored
frozen at -20°C before further processing. Serum was also stored at -20°C. Peritoneal
lavage samples were sedimented by centrifugation at 1000 xg for 20 min at +4°C. The
cells were re-suspended in 1 ml PBS/BSA, re-centrifuged at 1000 xg for 5 min and
finally re-suspended in 1 ml PBS/BSA for estimation of mast cell numbers. Mast cell
counts were performed by diluting a 10 pi aliquot of the cell suspension with 90 pi of
a mast cell stain containing 0.5% w/v methylene blue in 50% v/v propylene glycol. Blue
staining mast cells were counted using an Improved Neubauer haemocytometer.
Concentrations of Rat mast cell proteases I and II (RMCP I and II) were
measured in serum and tissue homogenates by Enzyme Linked Immunosorbent
Assays (ELISA).
2.2.9 RMCP I ELISA PROTOCOL
2.2.9.1 Plate coating:-
Coat plates with a solution of capture antibody diluted to lpg/ml in 0.1 M
carbonate buffer pH 9.6 load 50 pl/well
2.2.9.2 Sample preparation:-
Tissue homogenates prepared in 1.5M NaCl buffered with 20 mM Tris pH 7.5.
Subsequent sample and standard dilutions in 4% BSA in PBS/0.05% Tween 20 +
0.5 MNaCl.
2.2.9.3 ELISA test.
1) Wash coated plates x6 with PBS/Tween 20
2) Load standards and samples (50 pl/well) and incubate for lh at room
temperature.
3) Wash x6 with PBS/Tween 20
4) Incubate plates with rabbit anti-RMCP I (50 pl/well) for lh at room temp
5) Wash x6 with PBS/Tween 20
6) Incubate plates with optimally diluted anti-rabbit-HRPO conjugate (50 pl/well) lh
at room temp.
7) Wash x6 with PBS/Tween 20
8) Incubate plates with 0PD/H202 substrate.(50 pl/well)
9) Stop reaction with 25 pi 2.5 M H2SC>4
10) Read plates at 492 nm.
2,2,9.4 Standards
Dilute stock RMCP I initially to lpg/ml and then to 20 ng/ml and use this
solution to prepare a range of standard dilutions (0.5, 1, 2, 4, 6, 8, 10, 12 ng/ml)
Volumes required to make up 100pi of standard (ml)
Cone.
required (ng/ml)
0.5 1.0 2.0 4.0 6.0 8.0 10.0 12.0
Vol. 20 ng/ml stock (pi) 2.5 5.0 10.0 20.0 30.0 40.0 50.0 60.0
Vol. Diluent (pi) 97.5 95.0 90.0 80.0 70.0 60.0 50.0 40.0
2,2.9,5 Solutions
1)0.1 M carbonate buffer pH 9.6
0.1 M NaCO?; 0.1 M NaHCCh titrated to pH 9.6
2) Citrate/phosphate buffer pH 5.0
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2.2.9.6 Stock solutions:-
0.1 M citric acid
0.2 M Na2HP04
Working buffer:- add 24.3 ml 0.1 M citric acid, 25.7 ml 0.2 M Na2HP04 and 50 ml
distilled water
3) Substrate: -
Citrate/phosphate buffer pH 5.0 100 ml
Ortho phenylene diamine (Sigma) 40 mg
H202 40 pi
4) Diluent for samples and standards:-
Phosphate buffered saline containing 4%w/v Bovine serum albumin (Sigma),
0.05%v/v Tween 20 (Sigma) and 0.5 M NaCl.
5) Diluent for antibody reagents:-
Phosphate buffered saline containing 4%w/v Bovine serum albumin , 0.05%v/v
Tween 20.
6) Wash buffer-




Coat plates with a solution of monoclonal antibody diluted to 1 pg/ml with
0.1M carbonate buffer pH 9.6. Load 50pl of diluted antibody into each well and
tap the plate gently to ensure even distribution. Incubate the coated plates in a
humid chamber at +4°C for 24h before use (coated plates can be stored at +4°C for
several days before use).
2,2,10.2 ELISA test.
1) Wash coated plates x6 with phosphate buffered saline (PBS) + 0.05%v/v tween
20 (Sigma).
2) Incubate plates with 4% w/v Bovine serum albumin (BSA; Sigma) in
PBS/Tween 20 for 30 min at room temperature.
3) Wash plates xl with PBS/Tween 20 and load standards (see below) and
unknown sample (50pl/well). Incubate for 1. 5h at room temperature (all dilutions in
4% BSA in PBS/Tween 20).
4) Wash plates x6 with PBS/Tween 20.
5) Incubate plates with conjugate optimally diluted with 4% BSA in PBS/Tween 20
(50j.il/well) at room temperature for lh
6) Wash plates x6 with PBS/Tween 20.
7) Incubate plates with OPD/H2O2 substrate (50j.il/well).
8) Stop reaction with 2.5M H2S04 (25j.il/well).
9) Read plates at 492 nm.
2.2.10.3 Standards
2.2.10.3.1 RMCPII in serum
Dilute stock RMCP II to 2pg/ml with normal rat serum. Further dilute this 2
pg/ml stock to 20 ng/ml with PBS/Tween 20/BSA and use this to make up
working standards, 0.25, 0.5, 1, 2, 4, 8, 10, 12 ng/ml. Standards are run in duplicate
on each plate.
2.2.10.3.2 RMCP II in tissue extracts:-
Dilute stock RMCP II to 2pg/ml with PBS/Tween 20/BSA then proceed as for
serum standards.
Volumes required to make up 100pi of standard (pi)
Cone.
required (ng/ml)
0.5 1.0 2.0 4.0 6.0 8.0 10.0 12.0
Vol. 20 ng/ml stock (pi) 2.5 5.0 10.0 20.0 30.0 40.0 50.0 60.0
Vol. diluent (pi) 97.5 95.0 90.0 80.0 70.0 60.0 50.0 40.0
2.2,10,4 Solutions.
1) 0.1 M carbonate buffer pH 9.6
0.1 MNa2C03; 0.1M NaHCO, titrated to pH 9.6
2) Citrate/phosphate buffer pH 5.0
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2.2.10.5 Stock solutions:-
0.1 M citric acid
0.2 M Na2HP04
Working buffer-
add 24.3 ml 0.1 M citric acid, 25.7 ml 0.2 M Na2EEP04 and 50 ml distilled water.
3) Substrate:-
Citrate/phosphate buffer pH 5.0 100 ml
Ortho phenylene diamine (Sigma) 40 mg
H2O2 40pl
2.2.11 Assessment of rat anti-sheep antibodies
Because ruminant proteins are likely to have been included in the rats' diet and
the experimental rats may mount an immune response against sheep proteins, an
ELISA was developed to quantify the antibody response against sheep
immunoglobulins. ELISA plates (Dynatech M129B) were coated with a solution of
normal sheep immunoglobulin, prepared as described above, in 0.1 M carbonate
buffer pH 9.6 (50 plAvell). The plate was incubated at +4°C overnight and then
washed x6 with PBS containing 0.05% v/v Tween 20 (Sigma, Poole, Dorset, U.K.)
before loading with samples. Sera from the animals which had been treated with anti-
rrSCF164 or normal sheep IgG and pre-treatment serum samples from the same rats
was prepared in serial dilutions in PBS and loaded, in triplicate, onto the plate (50 p
1/well) and then incubated at room temperature for 1 hour. The ELISA plate was
washed x6 with PBS/Tween 20 and a sheep anti-rat IgG-horse radish peroxidase
conjugate (Sigma), optimally diluted with PBS/Tween 20, was applied. The plate was
again incubated at room temperature for 1 hour, washed x6 as before and the colour
reaction developed, using ortho-phenylenediamine (0.4 mg.mf1 in citrate/phosphate
buffer, pH 5.0, at the rate of 50 plAvell) as substrate, for 10 min and the reaction was
terminated by the addition of 25 pi of 2.5 M H2SO4. The plate was read on a Titertek
Multiskan MC ELISA plate reader (Titertek, Paisley U.K.) at 492 nm. Samples which
had absorbances which were significantly higher, by Student's t-test, than the pre-
treatment control samples were considered to be positive.
2,2,11,1 Histological assessment.
Histological sections (5 pm thick) were stained with Toluidine blue (0.5%
w/v, pH 0.5) and mast cells in the jejunal mucosal epithelium and lamina propria were
enumerated on a Leitz Dialux microscope with a x25 objective lens and xl2.5
eyepieces equipped with a 100 mm2 graticule. A minimum of 5 fields were counted
per section.
2.2.12 Data presentation and analysis
Unless otherwise specified, all data are presented as the mean ± s.e.m. The 2-
tailed Students t-test was used to analyse data that were normally distributed, whereas
the Mann-Whitney U test was used as the non-parametric test. The time course of
responses in different groups of rats were examined for statistical significance by
using analysis of variance (ANOVA). p < 0.05 was taken to indicate a significant
difference.
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2.3 Studies on the role of SCF in mast cell regulation in S. mansoni-infected
rats.
2.3.1 Animals.
Fischer F344 inbred female rats, purchased from Harlan Olac (Bicester Oxon),
6 to 8 weeks old and weighing approximately 150g, were used in this experiment. The
rats were maintained under standard conditions at the Department of Biology,
University of York, with water and pelleted diet freely available.
2.3.2 Parasites.
Infection with approx. 2500 S. mansoni cercariae via shaved abdominal skin
was by the ring technique (Smithers & Terry 1965), carried out under anaesthesia
with optimal doses of Hypnorm/Hypnovel administered by intra-peritoneal injection.
2.3.3 Blood samples.
Blood samples were taken on days 18, 21, 24, 27, and 30 after infection by tail-
snip. Approx. 300 pi of blood was obtained from each rat under halothane anaesthesia
and allowed to clot at room temperature. Serum was harvested and stored at -20°C.
2.3.4 Anti-SCF antibody treatment.
The rats were treated with 1 mg sheep anti-SCF or normal sheep IgG on days
21, 24, 27 and 30 by intraperitoneal injection. An interval of at least 2h was allowed
between blood-sampling and administration of antibody.
2.3.5 Material collectedpost-mortem.
On day 32 the rats were anaesthetised by intraperitoneal injection of
Hypnorm/Hypnovel and blood samples taken as before. The hepatic portal system was
perfused to recover adult worms (Smithers & Terry 1965). The liver was excised and
a portion weighed prior to storage at -20°C. Slices were cut from the remainder and
immersed in 4% paraformaldehyde for 6 h and subsequently in 70% ethanol
(Newlands et al 1987). Similarly, a portion ofjejunum was also excised, flushed
through with PBS and divided into two parts for storage at -20°C or fixation. These
procedures were carried out by Prof. R.A. Wilson and Dr. P.S. Coulson at the
University of York. Fixed tissues were subsequently processed and embedded in
paraffin wax before sectioning and staining with either toluidine blue for the
demonstration of mast cells or carbol chromotrope for eosinophils. Rat mast cell
proteases I and II were measured in serum and tissue extracts by antibody capture
ELISA as described previously (Huntley et al 1990). Cell counts were performed as
described previously (Miller et al 1994) and the results expressed as cells per 0.2
mm2. Data are presented as mean ± sem and were analysed by Student's two sample
t-test or, for time course data by analysis of variance (ANOVA) using the Minitab
statistics programme.
2.4 Development of an ELISA test to measure SCF in the sera of normal or
parasitised rats.
2.4.1 Animals
Random-bred female Wistar rats weighing 250 to 300 gm, and maintained under
conventional conditions at Moredun Research Institute, were used in all studies.
2.4.2 Parasites.
Infection of rats with N. brasiliensis or T. spiralis was as described in section
2.2.2.
2.4.3 Stem Cell Factor.
Treatment of rats with rrSCF164 was as described in section 2.2.4.
The total blood volume of rats weighing approximately 250g has been estimated at 50
ml for each kg of bodyweight and the total plasma volume at 30 ml for each kg of
bodyweight (Schalm, Jain & Caroll, 1975); thus the SCF dose/ml/day can be
calculated from the following equation.
Equation 2. Calculation of SCF concentration in serum.
Dose (pg/kg bodyweight) x bodyweight (kg) _ 25 x0.25 _ 0.833 pg.ml"1
Serum volume (ml/kg bodyweight) x bodyweight (kg) 30 x0.25 of serum
2.4.4 Antibodies
Polyclonal antibodies to rrSCF164 were produced and purified by immuno-
affinity chromatography as described previously (Section 2.2.5). For control
purposes, sheep immunoglobulin was prepared by precipitation of normal sheep serum
with 50% saturated ammonium sulphate also as described (Newlands, Miller,
MacKellar & Galli, 1995). Biotinylation of affinity purified sheep anti-SCF was by the
technique described by Goding (1983).
2.4.5 Treatment with anti-SCF antibodies
Treatment with polyclonal antibodies was as described in section 2.2.6.
2.4.6 Optimisation ofSCF ELISA
The format of the ELISA was that of antigen capture with polyclonal anti-SCF
and of detection of captured SCF with the same antibody which had been biotinylated,
followed by streptavidin-FlRPO (Boehringer-Mannheim, U.K.).
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The capture antibody, affinity purified polyclonal sheep anti-SCF, was coated onto the
test plates (Dynatech M129B) at the rate of 0.1, 0.5, 1.0, 5.0 or 10.0 pg rnf' in 0.1M
carbonate buffer pH 9.6.
The optimum dilution of the biotinylated, sheep anti-SCF, secondary antibody
for the standard concentration range, was determined by titration at 1/125, 1/250,
1/500 and 1/1000 of stock antibody which had a concentration of 1 mg.ml"1. Final
detection in the titration of both capture and secondary antibodies was with
streptavidin-FfRPO, standardised at a dilution of 1/500 in accordance with the
manufacturers recommendation, and utilising orthophenylenediamine (Sigma, Poole,
UK) at a concentration of 0.4 mg.mf1 and H2O2 (60 pl/10 ml) as substrate. Plates
were read at 492 nm on a Titertek MC ELISA plate reader (Titertek-Flow, Paisley,
UK).
Samples and standards were diluted 1:20 with 5% w/vbovine serum albumin
(Sigma) in phosphate buffered saline (BSA/PBS). Standard curves were prepared
which covered the range 0.5 pg to 20 ng.mf1. In order to determine whether the assay
would detect physiological concentrations of SCF in serum, normal rat serum was
spiked with rrSCF164 at a concentration of lpg.mf1. A range of dilutions of this spiked
serum, in the range 5 to 750 pg.ml"1 were prepared in BSA/PBS for assay.
The different coating antibody densities gave a concentration dependent increase in
absorbance at 492 nm up to 1.0 pg.mf1, with a standard curve which covered the
range 5 to 750 pg.mf1, and did not increase significantly at higher concentrations.
Further optimisation of the test was therefore based on plates coated at the rate of 1.0
fig-mf1.
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Dilutions of biotinylated sheep anti-SCF at 1/125, 1/250 and 1/500 gave very
similar results, with somewhat lower absorbances for the 1/1000 dilution. A 1/500
dilution of the biotinylated, sheep anti-SCF, secondary antibody was therefore used in
later tests.
2.4. 7 Data presentation and analysis
Unless otherwise specified, all data are presented as the mean ± s.e.m. The 2-
tailed Student's t-test was used to analyse data that were normally distributed and the
Mann-Whitney U test was used as the non-parametric test. The time course of
responses in different groups of rats were examined for statistical significance by
using analysis of variance (ANOVA). p < 0.05 was taken to indicate a significant
difference. Statistical analyses were performed using either Microsoft Excel version
5.0 or Minitab version 9.
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3. MOUSE MAST CELL PROTEASE-1; ISOLATION OF
GLYCOFORMS
3.1 Introduction
MMCP-1 isolated from the intestinal mucosa of mice infected with the parasite
Trichinella spiralis, shares 74% amino acid sequence homology with RMCP II and
also has a very similar tissue distribution and biochemical properties (Newlands et al
1987; Miller el al 1988;LeTrong et al 1989; Huntley et al 1990a). Murine bone
marrow-derived mast cells (BMMC), often regarded as in vitro analogues of MMC
(Sredni et al 1983), contain four mast cell proteases in the molecular mass range 28-
32 kDa including MMCP-1 as determined by Western blotting and ELISA (Newlands
et al 1991). Four esterases of similar or identical molecular weight which bind the
specific serine protease inhibitor [3H]-diisopropylfluorophosphate (fHJ-DFP) have
also been found in BMMC (DuBuske el al 1984). Five proteases have been identified
in CTMC and/or virus-immortalised mast cell lines on the basis ofN-terminal amino
acid sequences and molecular weights and designated MMCP-2 to MMCP-6 (Serafin
et al 1990; Reynolds et al 1990). All but one of these proteases, MMCP-3, have been
cloned and sequenced. Transcripts for MMCP-1 are expressed only in MMC and
MMCP-2 is expressed in intestinal mucosa and Kirsten sarcoma virus-immortalised
mast cells (KiSV-MC) (Serafin et al 1991). MMCP-4 is transcribed in CTMC and
KiSV-MC (Serafin et al 1991) and MMCP-5 in CTMC and KiSV-MC (Huang et al
1991; McNeil et al 1991). MMCP-6, identified as a tryptase by its predicted amino
acid sequence, appears to be exclusive to CTMC and KiSV-MC (Reynolds el a!
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1991). A second tryptase has also been identified from a transiently expressed cDNA
in BMMC and designated MMCP-7 (McNeil et al 1992)
The original isolation of MMCP-1, from a homogenate of T. spiralis-infected
mouse small intestine (Newlands et al 1987), showed that the enzyme activity, which
hydrolysed a chymotrypsin substrate, was distributed over several peaks of the final
Mono S cation exchange chromatogram, in addition to that originally identified as
MMCP-1. This suggested that one or more of the other murine mast cell proteases
could also be present in the intestinal tissue extract. The proteases present in
homogenates from nematode-infected intestine were therefore further analysed to
establish their identity. In this chapter the isolation by cation exchange
chromatography and biochemical and immunological characterisation of five MMCP-
1 -like proteases are described and identified as variant forms of MMCP-1 which differ
only in their glycosylation. The isolation and partial characterisation of a serosal mast




Cation exchange chromatography (2,1.2) of small intestinal homogenate in 20
mM Tris/HCl buffer pH 7.5 on CM-Sepharose, when eluted with a linear 0-1.0 M
NaCl gradient, gave one major peak, which contained all the detectable enzyme
activity against the synthetic substrate CBZ-L-Tyr-4NPE. After buffer exchange into
50 mM morpholinoethane sulphonic acid (MES) pH 6.0 (2.1.2) the enzyme activity
was resolved into 5 distinct peaks by FPLC cation exchange chromatography on
Mono-S (Figure 1). Each peak containing enzyme activity was collected separately
and, after five-fold dilution in 50 mM MES, re-chromatographed on Mono-S where
each eluted at a different molarity (88, 92, 103, 109 and 115 mM NaCl for peaks 1 to
5 respectively). These fractions were labelled MMCP-1A to IE, in order of elution,
for identification.
Analysis of the peaks by SDS-PAGE under reducing conditions (2.1.5; Figure 2a)
showed MMCP-1 A to contain 2 polypeptides of 32 and 33 kDa of different staining
intensities, which were not resolved by the techniques used, MMCP-1B and 1C each
contained single proteins of 31 kDa, MMCP-1D and IE each contained a single band
of 30 kDa.
3.2,1,2 Serosal mast cell protease;
Size exclusion chromatography of a serosal mast cell granule extract in 20 mM
tris/HCl, pH 7.5, 1.0 M NaCl, on sephacryl S-200 resolved two major peaks the
second of which contained enzyme activity which hydrolysed CBZ-L-TYR-4NPE. When
this material, diluted with 20 mM tris/HCl, pH 7.5 to 0.5 M NaCl, was applied to
Mono-S cation exchanger a single peak of bound material was eluted at 0.77 M NaCl.
The protein resolved by cation exchange chromatography hydrolysed CBZ-L-TYR-
4NPE and contained a single 28 kDa polypeptide by SDS-PAGE (Figure 2a).
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Figure 1. Typical FPLC chromatogram showing the resolution of five peaks of
chymotrypsin-like enzyme activity from homogenate of small intestine by Mono-S cation
exchange.
Approximately 4.8 ing of protein, eluted from a CM-sepharose cation exchange column,
was loaded onto a Mono-S cation exchange column which was equilibrated with 50 mM
MES pH 6.0 and eluted with a segmented gradient over 50 to 150 mM NaCl. The peaks
of enzyme activity, indicated by arrow heads, were detected by using the chromogenic
substrate CBZ-L-Tyr-4NPE. The peaks were designated MMCP-1 A (arrowhead on left)
to MMCP-1 E (arrowhead on right) for identification purposes. The peaks were collected
separately, re applied to Mono-S, and eluted in highly purified form. The peaks, in order
of elution contained the following protein concentrations; A, 2.5 ml @ 77 pg.ml1; B, 1.5
ml @112 pg.ml1; C, 3.0 ml @ 106 pg.ml1; D, 2.5 ml @ 146 pg.ml1; E, 3.5 ml @ 147
pg.ml ; (full details are given in section 2.1.2 of Materials and Methods).
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Figure 2. Characterisation of MMCP-1 peaks from Mono S cation exchange by
SDS-PAGE and Western blotting.
The proteins were run on 15% discontinuous SDS-PAGE gels. 2A; Peaks 1A-E
from Mono S are loaded in lanes 1-5 respectively. Mouse serosal mast cell
protease is in lane 6 and rat mast cell protease 1 in lane 7. The proteins were
detected by silver staining. 2B and 2C; Western blot analysis showing MMCP
peaks 1A-E from Mono S in lanes 1-5 respectively, mouse serosal mast cell
protease in lane 6, 104 purified mouse serosal mast cells in lane 7 and RMCP I in
lane 8 probed with B, rabbit anti-MMCP-1 or C, sheep anti-MMCP-1 absorbed
to remove anti-RMCP I activity. Rabbit and sheep immunoglobulins were
detected with sheep anti-rabbit HRPO or pig anti-sheep HRPO conjugates
respectively and HRPO activity was revealed by using 3,3" diaminobenzidine as
substrate. Isolated enzymes were loaded at the rate of 40-60 ng per lane. Details
of the protocols are given in sections 2.1.5 and 2.1.6 of Materials and Methods.
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3.2.2 Biochemical characterisation
The MMCP-1 polypeptides in the 30 to 33 kDa range all bound the group-specific
inhibitor [JH]-DFP (Figure 3) indicating the presence of serine esterase activity
(2.1.11). The autoradiograph of the labelled proteins showed the same pattern as the
silver-stained SDS-PAGE gel (Figure 2a) except that MMCP-1D had an additional
polypeptide of 27 kDa labelled with ['HJ-DFP which was not detectable on the
stained gel (Figure 3). This additional polypeptide may represent a degradation
product generated during incubation with [Ti]-DFP. The five MMCP-1-like enzymes
and MSMCP were screened against a range of low molecular weight, synthetic,
protease substrates (2.1.15.1) and were found to exhibit chymotrypsin-like esterase
activity, as reported previously for MMCP-1 (Newlands et al 1987), the results of
which are summarised in Table 2. MSMCP also had chymotrypsin-like substrate
specificities (Table 2). All five intestinal MMCPs and MSMCP were completely
inhibited by PMSF and 3,4 DCI, both inhibitors of serine proteases, but not by 1,10
phenanthroline, E64 or pepstatin, which inhibit metallo-, thiol- and aspartyl proteases
respectively (Table 3; 2.1.15.1). The MMCP-l-like proteases were also inhibited by
human arPI (2.1.15.2) while MSMCP, like RMCP I in the rat (Pirie-Shepherd el al
1991), was not.
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Figure 3. Autoradiograph of MMCP-1 peaks 1A-E labelled with the specific
serine esterase inhibitor [3H]-DFP.
Labelled proteases were loaded at 2 pg/lane on a 12% SDS-PAGE gel and run
under reducing conditions.
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Table 2. Substrate specificities of multiple forms of MMCP-1 and of MSMCP.
Activity (nkat/mg)
Substrate 1A IB 1C ID IE MSMCP
Chymotryptic Cbz -L-Tyr- 63 42 31 33 21 259
(esterase) 4NPE
Cbz -L-Phe- 14 10 6 5 4 9
4NPE
Cbz -L-Trp- 0.3 0.9 NA 0.2 NA NA
4NPE
Elastinolytic Cbz -L-Ala- 15 6 4 9 4 41
(esterase) 4NPE
Cbz -D-Ala- 8 2 2 5 2 22
4NPE
Tryptic Cbz -L-Lys- NA NA NA NA NA NA
(esterase) 4NPE
Chymotryptic Bz-L-Tyr-4NA 1 NA NA NA NA 2
(amide)
Succ-Phe-4NA 0.8 0.2 NA NA 0.3 5
Tryptic (amide) cbz-L-Arg- 2 NA NA 0.4 NA 8
4NA
Bz-DL-Arg- 1 0.3 0.001 NA NA NA
4NA
Enzyme activity is expressed in nkat/mg of protein; 1 nkat is that activity which hydrolyscs 1 nMol
of substrate in 1 second. NA = no activity (2.1.12).
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Table 3. Inhibition characteristics of mast cell proteases MMCP-IA-E and
MSMCP.
Inhibitor 1A IB 1C ID IE MSMCP
PMSF 100 100 100 100 100 100
3,4 DCI 100 100 100 100 100 100
E64 5 18 5 9 0 0
1,10 Phe 8 5 11 5 0 0
Pepstatin 13 0 0 0 7 0
Percentage inhibition after 60 min incubation with inhibitor, n = 3 for each preparation. PMSF,
phenyl-methyl-sulphonyl-fluoride (serine protease inhibitor); 3,4 DCI, 3,4-Dichloro-isocoumarin
(serine protease inhibitor); E64, N-[N-(L-3-Trans-carboxyoxirane-2 carbonyl)-L-leucyl] -agmatine
(thiol protease inhibitor); 1,10-Phe, 1,10-phenanthroline (metallo-protease inhibitor); pepstatin
(aspartic protease inhibitor). The relative concentrations of inhibitors and proteases is described in
Materials and Methods section 2.1.15.1.
3.2.3 Immunological analysis
The isolated MMCPs were all detected with the rabbit antiserum raised against
MMCP- (Newlands el al., 1987; Figure 2b; Materials and Methods, 2.1.10) on
Western blot as was the 28 kDa MSMCP (Figure 2b). When a similar blot was probed
with sheep anti-MMCP-1, cross-absorbed against RMCP I (2.1.10), only the highly
soluble antigens isolated from small intestine were identified (Figure 2c).
The five MMCP-1-like enzymes shared complete lines of identity in gel
diffusion against sheep anti-MMCP-1 whereas no precipitation occurred with
MSMCP (Miller et al 1990). When sheep anti- MMCP-1 was substituted with sheep
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anti- RMCP I a precipitin line was uniquely present against MSMCP and there was no
reaction against MMCP-1 (Miller et al 1990).
The five intestinal MMCPs (0.5 to 12 ng/ml) were detected by ELISA (2.1.8),
using sheep anti-MMCP-1 as capture antibody, whereas MSMCP, RMCP I and
RMCP II were not detected at 270 ng, 2.5 mg and 5.0 mg/ml respectively. After
establishing the specificity of the ELISA, homogenates of small intestine from N.
brasiliensis-mfected mice were assayed (2.1.8) and MMCP-1 concentrations were
found to be increased 14 fold when compared with uninfected control mice (Table 4).
In contrast, homogenates of tongue from control mice had no detectable MMCP-1
despite being rich in mast cells (Table 4; Figure 4). Small quantities of MMCP-1 were
detected in tongue of infected mice (Table 4) and, as described previously this is
probably derived from blood, where levels of MMCP-1 are raised in nematode
infection (Huntley et al., 1990a).
Immunohistochemical studies using the directly labelled sheep anti-MMCP-1 -
FITC confirmed the ELISA results in that there were increased numbers of mast cells
in the intestinal mucosa of parasitised mice which fluoresced after incubation with
sheep anti-MMCP-1-FITC conjugate when compared with uninfected controls
(Figure 4, Table 4). There was no cellular immunofluorescence in tongue of either
control or parasitised mice despite the presence of abundant mast cells which stained
with toluidine blue (Figure 4).
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Figure 4. Photomicrographs showing normal mouse small intestine, T. spiralis-
infected small intestine and normal mouse tongue stained with toluidine blue
pII 0.5 (A-C respectively) or sheep anti-MMCP-l-FITC (D-F respectively).
Table 4. MMCP concentrations and mast cell numbers in N. brasiliensis-infected
and normal mice.
Control Infected
Jejunum Tongue Jejunum Tongue
MMCP (pg/g)* 13+3.6 0 183 ±23.7 0.5 ±0.12
Mast cell/vcu
(tol. blue)
1 ±0.2 A* 7 ±0.7 A*
Mast cell/vcu
(fluorescence)
1 ±0.3 0 6 ±0.3 0
Jejunal mast cell counts are expressed as cells per vi 11 us/crypt unit (vcu). A* = mast cells were
abundant but were not counted. * pg/g wet weight of tissue.
3,2.3,1 N-terminal sequencing
To determine whether the five intestinal mast cell proteases were separate gene
products or differed because of post-translational processing, the amino-terminal
amino acid sequence was determined for each protease, the results of which are
summarised in Figure 5. The first 15 to 29 amino-terminal residues of the intestinal
mast cell proteases proved to be identical in each case and were in agreement with the
previously published sequence for mouse intestinal mast cell protease (Le Trong et
al., 1989). The amino acid sequence determined for MSMCP showed complete




To further investigate whether the differences between MMCP-1 A-E were
post-translational and a consequence of differential glycosylation, samples of each
enzyme preparation were incubated with endo-a-acetyl galactosaminidase to remove
o-linked carbohydrate or with peptide-N-glycosidase F (PNGase F) to remove N-
linked carbohydrates. The protocols are described in Materials and Methods, section
2.1.7. Briefly, 2 pg of protein were denatured by heating in a boiling water bath,
cooled and incubated with 0.2 units of the appropriate glycosidase at 37°C overnight.
No change in the apparent molecular weight of any of the MMCPs, as determined by
SDS-PAGE was detected even after prolonged treatment with o-glycosidase.
Following treatment of the five MMCPs with PNGase F, however, there was
degradation of each MMCP resulting in the appearance of a new polypeptide with an
apparent molecular weight of 28 kDa (Figure 6). This 28 kDa polypeptide remained
strongly antigenic on Western blot when probed with sheep anti-MMCP 1 (not
shown).
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Figure 6. Treatment of MMCP-1 glycoforms with PNGase F to remove N-linked
carbohydrate.
Silver-stained 15% SDS-PAGE gel showing MMCP 1A to IE before (lanes 1, 3,
5, 7 and 9 respectively) and after (lanes 2, 4, 6, 8, and 10 respectively)
removal of N-linked carbohydrate with PNGase F. The enzymes were loaded at
20 ng/lane.
3.3 Discussion
The five proteases isolated from T. spiralis-infected mouse small intestine can
be identified as MMCP-1 by several criteria. Like MMCP-1, they are highly soluble,
chymotrypsin-like proteases active at neutral pH. They are closely related
antigenically both on Western blot and by Ouchterlony double diffusion and are
readily distinguished from MSMCP on the basis of their antigenicity. Finally, they
share complete amino acid sequence identity over the first 15-29 N-terminal residues
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(Le Trong el al 1989) which further distinguishes the MMCP-1 group of proteases
from MMCPs-2-6 (Serafin el al 1990; Reynolds el al 1990) all of which differ from
MMCP-1 within the first 10 N-terminal residues.
The differences in electrophoretic mobility between these variant forms of
MMCP-1 are probably a result of variable glycosylation since removal ofN-linked
carbohydrate moieties produced a new polypeptide of approximately 28 kDa from
each of MMCP-1 A-E which was antigenically similar to native MMCP-1. Analysis of
the carbohydrate content of each enzyme preparation might prove helpful in further
distinguishing between the different glycoforms of MMCP-1. It may be that each is
produced by mast cells in different regions of the intestine or, more likely, by mast
cells at varying stages of maturation since intestinal nematodiasis induces massive
mucosal mastocytosis with extensive recruitment and differentiation of intestinal mast
cells (Miller el al 1988).
Variable glycosylation occurs in other serine proteases notably in the sub-units
of human mast cell tryptase (Cromlish, Seidah, Marcinkiewicz, Hamelin, Johnson &
Chretien, 1987) and tissue plasminogen activator (t-PA) (Wittwer, Howard, Carr,
Harakas, Feder, Parekh, Rudd, Dwek & Rademacher, 1989). Human tissue
plasminogen activator is synthesised in two forms, I and II, which share N-terminal
amino acid sequences but have disparate carbohydrate side groups, the composition of
which appears to be dependent on the cell line from which the tPAs are derived
(Wittwer el a/., 1989). In the presence of a fibrinogen fragment stimulator, t-PA II
will catabolise a synthetic substrate up to five times faster than t-PA I (Wittwer el al.,
1989) whilst type I is more resistant to cleavage by plasmin (Wittwer & Howard
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1990). Human mast cell tryptase has also been described as having variable Mr of
between 28 and 37 kDa and an isoelectric point of between 5.0 and 6.5, properties
which depend on glycosylation (Benyon, Enciso & Befus, 1993).
MSMCP, isolated from peritoneal CTMC, is the first murine CTMC protease to
be isolated in its native form and characterised biochemically. MSMCP is a neutral 28
kDa serine protease with chymotrypsin-like substrate specificities, properties it has in
common with MMCP-1. It differs from MMCP-1 in that it is highly insoluble and, on
cation exchange chromatography, behaves like RMCP I which has a net charge of + 18
(Le Trong et al., 1987). In contrast, MMCP-1 has similar chromatographic properties
to RMCP II and has a net charge of +3 at neutral pH (Le Trong et al., 1989). N-
terminal amino acid sequence analysis of MSMCP shows complete identity over the
first 20 residues with the CTMC protease, MMCP-4 (Reynolds et al., 1990; Serafin et
al., 1991), differing at residues 7 and 19 from MMCP 1 A, C, D, and E (MMCP-1B
was not sequenced beyond residue 15). Based on this evidence we can identify
MSMCP as MMCP-4.
Immunological techniques have proved to be particularly useful in the analysis
of protease distribution and function. For example, Woodbury and colleagues (1978)
showed that RMCP I and II were readily distinguished by gel diffusion although they
share 74% amino acid sequence homology. However it was not possible to determine
the cellular distribution of RMCP I and II without first preparing monospecific
polyclonal antibodies by cross-absorption (Gibson & Miller, 1986) or by raising a
monoclonal antibody against RMCP II (Huntley et al., 1990b). The distinction
between the MMCP-1 family and MMCP-4 was, however, readily achieved with
polyclonal sheep anti-MMCP-1 cross-absorbed against RMCP I and affinity purified
on MMCP-l-Sepharose 4B. This was true by gel diffusion, Western blotting, ELISA
and immunohistochemistry. It was thus possible, using this antibody for
immunohistochemistry, to confirm ELISA results (Huntley et al., 1990a) showing that
the MMCP-1 family of proteases is not present in CTMC. As yet no antibodies are
available which allow distinction between MMCPs 1 A-IE so it is not clear whether
the different glycoforms are present in distinct regions of the small intestine or are
being produced by MMC of varying maturity.
Using cDNA probes and Northern blotting, Serafin and colleagues (1991)
detected expression of MMCP-4 in the intestines of parasitised mice. This may be in
agreement with our finding of an RMCP I-like antigen expressed in mast cells in the
gastrointestinal mucosae of T. spiralis-infected mice (Miller et al 1988) although, in
the rat, RMCP I is not present in intestinal mucosal mast cells (Huntley et al., 1990b).
Serafin and colleagues (1991) were, however, unable to detect MMCP-4 transcripts
in bone marrow-derived cultured mast cells by Northern blotting, although
transcription of MMCP-4 has recently been reported in BMMC grown in medium
containing the c-kit ligand growth factor (Gurish, Ghildyal, McNeil, Austen, Gillis &
Stevens, 1992). An RMCP I-like antigen in murine BMMC, detected with anti-RMCP
I by immunofluorescence and by immunoblotting of cell lysates, has a very similar or
identical electrophoretic mobility to the mouse CTMC protease now identified as
MMCP-4 (Newlands et al., 1991). It is therefore probable that MMCP-4 is present in
BMMC grown in T cell conditioned medium and the failure to detect it by Northern
blotting may simply be due to the low levels of transcription. For example, murine
BMMC contain <120 ng MMCP-1/106 cells (Newlands et a/., 1991) compared with
up to 34 pg RMCP II/106 rat BMMC (Haig et a/., 1988). These results again
emphasise the potential value of highly specific antibodies in the analysis of protease
distribution.
In summary, the five proteases isolated from mouse small intestine are identified
as variant glycoforms ofMMCP-1 and the novel CTMC protease is identified as
MMCP-4. The biological significance of so many forms of MMCP-1 will only become
clear when their native substrates and specific inhibitors are identified and their
interactions characterised.
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4. MOUSE MAST CELL PROTEASE-1; SUBSTRATE AND
INHIBITOR KINETICS
4.1 Introduction
The identification of several different glycoforms of MMCP-1 (chapter 3) that
differ only in their carbohydrate moieties raises interesting questions about the
possible effects of variable glycosylation on the functional properties of these
enzymes. Many aspects of serine protease function can be modified through their
carbohydrate side chains including secretion, affinity for co-factors, substrate affinity,
activation rate, susceptibility to inhibition and clearance time from the circulation.
The presence ofN-linked glycosylation at one specific site of several potential
glycosylation sites is essential for the efficient secretion of a recombinant human anti¬
thrombotic protease, protein C from a mammalian cell line (Grinnell, Walls & Gerlitz,
1991), whilst the affinity of antithrombin for its co-factor heparin, which enhances
enzymic activity, is increased or decreased depending on the degree of glycosylation
of the enzyme (Bjork, Ylinenjarvi, Olson, Hermentin, Conradt & Zettlmeissl, 1992).
The rate at which plasminogen is converted to plasmin, on a fibrin substrate, by
tissue-type plasminogen activator (t-PA) is significantly increased with decreased
sialation of the carbohydrate side-chains (Pirie-Shepherd, Jett, Andon & Pizzo, 1995).
Interestingly, t-PA is itself secreted in two glycoforms (discussed in chapter 3) which
will hydrolyse a synthetic substrate at significantly different rates (Wittwer el al 1989)
whilst one form is more resistant to inactivation (Wittwer et al 1989). It is also
suggested that a non-glycosylated, recombinant plasminogen has a decreased
circulation time in vivo compared with the glycosylated form of the enzyme
(Gonzalez-Gronow, Grenett, Fuller & Pizzo, 1990). Taken together this evidence
shows that glycosylation influences most aspects of serine protease function and it is
therefore important to determine the effects of variable glycosylation on MMCP-1
function.
In order to establish whether these variations in glycosylation modified MMCP-
1 activities a number of kinetic parameters were examined; the Michaelis constant
(Km) which indicates the affinity of the enzyme/substrate (ES) complex, the catalytic
constant or turnover number (kcat), which represents the rate of substrate hydrolysis at
saturating substrate concentrations and the kcat /Km ratio, a measure of the overall
catalytic efficiency (Voet & Voet 1991).
A major factor in regulating the function of proteolytic enzymes is the presence
of effective inhibitors which inactivate the enzyme once it has fulfilled its function.
Rodent mast cell chymases are inhibited by the al-proteinase inhibitor (ai-PI) family
of serine proteinase inhibitors (serpins) present in blood (Irvine, Newlands, Huntley &
Miller, 1990; Pirie-Shepherd el'a! 1991) and therefore the second order association
rate constant (kass) and dissociation constant for the enzyme/inhibitor complex (Kj),
which represent the rate of enzyme inhibitor complex formation and the stability of
that complex respectively, for the reaction between the MMCP-1 proteases and ai-PI
were determined. Protein inhibitors of the a-i PI class function as inhibitors as a
consequence of binding of the substrate-binding, active site region of the protease to a
corresponding, substrate-like, reactive-site region on the surface of the inhibitor
(Travis & Salvesen 1983). Near the centre of the reactive-site there is an amino acid
residue, recognised by the target protease's substrate-binding active-site, termed the
PI residue (Travis & Salvesen 1983). The protease cleaves the peptide bond between
the PI residue and the residue immediately adjacent to it on the carboxy terminal side,
termed the P'l residue. Hydrolysis of this reactive site peptide bond does not proceed
to completion but rather an equilibrium is formed between the intact and cleaved
forms of the inhibitor which forms a stable complex with the protease (Travis &
Salvesen 1983). To accurately calculate these parameters it was important initially to
establish the precise concentration of each of the enzyme preparations. Since a
proportion of the enzyme present in solution could well be inactive, using an estimate
of the protein content to determine enzyme concentration was inappropriate and the
concentration was determined by active site titration with a suitable substrate.
4.2 Results
4.2.1 Active site titration
Concentrations of functional protease were determined by spectrofluorimetric
titration of the active-sites of the MMCP-l-like proteases against the substrate 4-
methylumbelliferyl-p-(NNN trimethylammonium) cinnamate (MUTMAC; Jameson et
a/ 1973; 2.1.14). Chymases form stable, inactive, acyl compounds with this substrate
and liberate 4-methylumbelliferone (7-hydroxy-4-methylcoumarin) with a negligible
rate of de-acylation (Jameson et a/ 1973). A standard curve was prepared from 7-
hydroxy-4-methylcoumarin and the relationship between concentration and
fluorescence intensity was linear over the range 2.5 to 40 nM (Figure 7).
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Unknown samples were assayed, in quadruplicate, and concentrations of
proteases were calculated from linear regression Equation 3.
Equation 3 Linear regression of fluorescence intensity on enzyme concentration.
y — -9.8 + 223x.
Where y is fluorescence intensity and x is the protease concentration.
The concentrations of protease, as determined by spectrofluorometric titration
were similar to those estimated from the total protein assay and are summarised in
Table 5. This method of active site titration compares very favourably with
colourimetric methods in terms of sensitivity e.g. the spectrofluorimetric titration of




Figure 7 Standard curve prepared from 7-hydroxy-4-methylcoumarin for active
site titration of MMCP-1 proteases.
The standard curve was prepared as described in Materials and Methods
section 2.1.14 (R = 0.99, p < 0.0001) and the concentration of unknown samples
were calculated from Equation 3.
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A colourimetric titration, carried out at pH 3.2 of the same enzyme preparation
with CBZ-L-Tyrosine-4-nitrophenyl ester as substrate (Kezdy & Kaizer, 1970) would
have an absorbance of < 0.0001 at 340 nm given that the molar extinction of the
reaction product is 6360 M^.cm"1. This is at the extreme lower end of the working
range of most spectrophotometers and could not be regarded as an accurate or
reproducible means of determining the concentration of active sites.






by Protein assay (pM)
1 A 2.91 ±0.10 2.37
1 B 3.99 ±0.03 3.61
1 C 2.36 ±0.05 3.42
1 D 5.09 ±0.18 4.87
1 E 4.53 ±0.04 4.90
The results of the spectrofluorometric titration of the MMCP-1 enzymes are mean ±
sem of four replicate tests.
4.2.2 Substrate Kinetics
All kinetic measurements were made using a Beckman DU 600
spectrophotometer. Rates of hydrolysis of 5 concentrations (0.125 to 2 mM) Succ-
Ala-Ala-Pro-Phe-4NA were measured by adding 2 pi of substrate solution to 48 pi of
enzyme solution in 0.1M tris/HCl pH 7.5. The increase in absorbance was
continuously measured at 410 nm and the spectrophotometer's on-board software
used to calculate the Michaelis constant (Km), and maximum velocity (Fmax) from the
Michaelis-Menten rate equation by non-linear regression, where v is the reaction
velocity and 5 the substrate concentration.





Figure 8 Plot of substrate concentration versus reaction velocity used to
calculate Km and Vlliax by non-linear regression.
This plot is derived from the Michaelis-Menten equation as described in Equation 4
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From these parameters it is possible to calculate the catalytic constant or turnover
number (kcat) from





where is the enzyme concentration in the reaction mixture as determined by
active site titration.
Using Succ-AJa-Ala-Pro-Phe-4NA as substrate (2.1.13), kinetic constants were
calculated for each of the five MMCP-l-like enzymes. There were significant
differences in Kra values (p = 0.025) with this substrate and highly significant
differences in both kcat and kcat/Km (p<0.0001 for each) by one-way analysis of
variance. These results are summarised in Table 6. The pH optima lay in the range pH
7.5-7.8 for all of the isolated enzymes.
4.2.3 Inhibitor kinetics
The second order association rate constant (kass) for the reaction between the
MMCP-l-like proteases and human cti proteinase inhibitor (ai-PI; Sigma) was
determined by pre-incubating equimolar enzyme and ai-PI for periods of 15 to 120s
before measuring the rate of hydrolysis of the substrate Succ-Ala-Ala-Pro-Phe-4NA
(2.1.15.2). The kass for each reaction was calculated by non-linear regression (Figure
9) as described previously (Pirie-Shepherd el at 1991) from the following equation
Equation 6 Calculation of the association rate constant kass.
"idfco
where E is the residual active enzyme, E? the initial enzyme concentration and t
the time in seconds. The kass values for the reaction between MMCP-1A - IE and ai-
PI were significantly different by ANOVA (p = 0.001) with results in the range of 3.3
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Figure 9 Plot of residual active enzyme versus time used to determine the
enzyme/inhibitor association constant, kass for the reaction between MMCP-1A
and cti-PI by non-linear regression using Equation 6.
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The inhibition constant (Kj) for the reaction between each protease and ai-PI
was determined by incubating protease with varying inhibitor concentrations (0.25 to
1.75 molar equivalents) for 35 times Ua, the time to half inhibition for an equimolar
reaction, (2.1.15.2), calculated from:-
Equation 7; Time to half inhibition for equimolar enzyme and inhibitor.
'i/2 = l'kass.E°
where E° is the initial enzyme concentration. The apparent K; (Kjapp) was calculated by
non-linear regression (Figure 10), as described previously (Pirie-Shepherd et al 1991)
from Equation 8;
Equation 8 Calculation of K; by non-linear regression.
E ([g0]+[/0] + ^)-V([g,') + [/°] + ^)'-(4[£0][/''])
E° 2[E°]
(Bieth 1974) and the true K; calculated from Equation 9;
Equation 9 Formula for calculation of the true K; from the apparent Kj.
V aPP
K
where S° is the initial substrate concentration
The MMCP-l-like proteases were all inhibited by human ai-PI while MSMCP,
like RMCP I in the rat, was not (Pirie-Shepherd et a/ 1991). The kassfor the reactions
between the MMCP-l-like proteases and ai-PI showed highly significant differences
by one way analysis of variance (p = 0.001). Inhibition constants obtained for the
interaction of the MMCPs with aj-PI showed K,s in the 0.8 - 45 pMolar range with
the Kj of MMCP-1C being almost 60-fold greater than that of MMCP-1A (p<0.0001;
Table 6).
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Figure 10 Plot of inhibitor/enzyme ratio versus fractional activity for the
reaction between MMCP-1A and ai-PI used to determine Kjby non-linear
regression using Equation 8.
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Table 6 Substrate and inhibitor kinetic parameters of the MMCP-l-like
proteases.
MMCP Km kcat kcat / Km kass K;
(t-iM) (s"1) (x103M"1.s"1) (xio5 ivr'.s"1) (pM)
1A 922 ±73.7 2.33 ±0.10 2.5 ±0.09 7.67 ± 1.50 0.76 ±0.18
IB 991 ±59.9 1.66 ±0.04 1.7 ±0.07 12.30 ±0.35 1.02 ± 0.10
1C 663 ±49.9 2.84 ±0.12 4.3 ±0.22 3.29 ±0.48 45.40 ±7.90
ID 936 ±83.9 2.54 ±0.12 2.7 ±0.13 4.07 ±0.62 2.20 ±0.34
IE 832 ±56.9 1.25 ±0.04 1.5 ±0.07 11.40 ±0.22 1.51 ±0.12
n 4 4 4 3 3
ANOVA P=0.026 P0.0001 0<0.0001 P=0.001 P<0.0001
Conditions for substrate kinetics; 0.1M tris/HCl pH 7.5 at 22°C.
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4.3 Discussion
The MMCP-1 proteases, designated here MMCP-1A to IE, have been
identified as probably having an identical polypeptide core by several different criteria,
and differing only in their carbohydrate side chains (Newlands, Knox, Pirie-Shepherd,
& Miller, 1993; chapter 3). It was the aim of the work reported in this chapter to
determine whether these differing carbohydrate moieties exert an influence on the in
vitro functional properties of the enzyme glycoforms in their interactions with
synthetic peptide substrate and with a specific protein inhibitor of serine proteases.
The kinetic data presented here show that there are significant differences in the
Km values obtained for the MMCP-1 proteases with the low molecular weight,
synthetic peptide substrate Succ-Ala-Ala-Pro-Phe-4NA. These were in the range 663
- 991 pM which was similar to the Km values for RMCP II which were in the range
840 - 910 pM with similar substrates (Powers, Tanaka, Harper, Minematsu, Barker,
Lincoln, Crumley, Fraki, Schechter, Lazarus, et al 1985). The kca,/Km ratio for the
isolated proteases is in the range 1.5 - 4.3 xlCP M^.s"1 indicating that enzymes are
moderately efficient in hydrolysing this low molecular weight, synthetic substrate.
This is in contrast with rates in the range 108 - 109 M'Vs"1 achieved by some enzymes
such as acetylcholine esterase or carbonic anhydrase when acting on their native
substrates, rates limited only by the diffusion rates of the reactants (Stryer, 1981).
Since the core polypeptide is probably identical in each enzyme, as determined by the
studies in chapter 3, it is likely that the differences in catalytic properties are due to
the carbohydrate moieties. This may be because the carbohydrate groups which
comprise 14-22% of the total native molecule, based on the predicted Mr of the core
polypeptide (Huang et al, 1991) and the estimated Mr of the individual glycoforms
(3.2.2) may alter the folding of the polypeptide chain and thus changing the
conformation of the active site cleft or, more likely by direct steric hindrance of
substrate binding to the catalytic triad by the carbohydrate. The latter possibility
suggests that glycosylation may be even more important in the catalysis of larger,
more complex macromolecular protein substrates, possibly by aiding recognition of
specific cleavage sites. The influence of glycosylation on the catalytic properties of
MMCP-1 will not be fully understood until their native substrates are identified and
characterised.
The inhibition studies of the various glyco-forms of MMCP-1 with human ai-PI
show second order association rate constants in the range 3.3 - 12.3 xlO5 JVT'.s"1
which are similar to the 0.3 - 6.0 xlO5 M'Vs"1 values reported for RMCP II, trypsin
and chymotrypsin with the rat serine proteinase inhibitors RS I and RS II (Pirie-
Shepherd el al 1991). These association constants for the interaction of both rat and
mouse mast cell proteases with ai-PI inhibitors are ten-fold less than that for elastase
and ai-PI (Beatty, Bieth, & Travis, 1980) which could suggest that whilst the mast
cell proteases are inhibited by ai-PI they may not be the main target proteases for
these inhibitors On the other hand, the main plasma inhibitors of human mast cell
chymase are ai-antichymotrypsin (at-AC) and ai-PI (Schechter, Sprows,
Schoenberger, Lazarus, Cooperman & Rubin, 1989). The kass values for the
interactions between human chymase and arAC and ai-PI are 10-fold and 100-fold,
respectively less than that for the rodent chymases with ai-PI (Schechter et al 1989).
Similarly ai-PI is also the main plasma inhibitor of sheep mast cell protease-1 and the
k..,ssfor this reaction is of the order of 1 x 10" IVf'.s"1 (Pemberton, Huntley & Miller
1997) Therefore, while it is true that MMCP-1 reacts less rapidly with aj-PI than
neutrophil elastase the kass value for the reaction is still substantially greater than the
rates for the mast cell chymases of other species with their homologous inhibitors,
which have been demonstrated to be the main plasma inhibitors of chymases
(Schechter et aI 1989; Pemberton et al 1997), indicating that ai-PI is probably the
principal inhibitor ofMMCP-1. The inhibition constant, Kj, for the MMCP-1
proteases is in the low pM range (7.6 xlO"10- 2.2 x 10"9) which is also similar to the
interaction of RMCP II with the rat serpins (Pirie-Shepherd et al 1993). The
exception to this is MMCP-1 C which has a K; of 4.5 xlO"8, more than ten-fold greater
than the others. These data clearly show that the catalytic properties of these enzymes
are modified through their carbohydrate moieties with highly significant variations in
how rapidly they associate with inhibitor and how tightly they are bound. This may be
important in prolonging enzyme activity in situations where immediate
hypersensitivity reactions have increased vascular permeability bathing surrounding
tissues in serum containing high concentrations of serine proteinase inhibitors.
The rat mast cell chymase RMCP II has many similarities with MMCP-1. Both
enzymes are associated with the secretory granules of mucosal mast cells and their
concentrations in small intestine and in blood increase greatly during the mast cell
hyperplasia associated with nematode parasite infections (Reviewed by Miller et al
1990). MMCP-1 and RMCP II share several physical characteristics; both are highly
soluble basic proteins with net charges of +3 and +4 respectively (Huang et a! 1991,
Le Trong et al 1987) and share 74% amino acid sequence homology (Le Trong et a!
1989, as well as having similar enzymic properties including very similar substrate
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specificities and susceptibility to inhibitors (Reviewed by Miller et al 1990). Thus it is
probable that MMCP-1 and RMCP II have very similar in vivo functions in the mouse
and rat respectively. Similarly, the rat connective tissue mast cell protease RMCP I
has many features with the murine CTMC protease MMCP-4 described in chapter 3.
They are both highly insoluble, with similar net charge, as determined by their
chromatographic properties, share 89% amino acid sequence homology and appear to
be expressed exclusively in CTMC. Because of these striking biochemical similarities
and because ELISA assays for both RMCP I and RMCP II have been developed in
this laboratory, the studies described in the remainder of this thesis addresses the
regulation of expression of RMCP I and RMCP II and their relationship to helminth
infection.
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5. IN VIVO REGULATION OF GROWTH AND PROTEASE
EXPRESSION OF PERITONEAL MAST CELL
POPULATIONS; EFFECTS OF EXOGENOUS STEM CELL
FACTOR AND T CELL-DERIVED CYTOKINES.
5.1 Introduction
Mast cell development and survival, in rats and mice are apparently highly
cytokine dependent processes with regulatory mechanisms mediated both by the T
cell-derived cytokines interleukin (IL)-3, -4, -9 and -10 (Ihle, Keller, Oroszlan,
Henderson, Copeland, Fitch, Prystowsky, Goldwasser, Schrader, Palaszynski &
Lebel, 1983; Schmitt, Fassbender, Beyreuther, Spaeth, Schwarzkopf & Rude, 1987;
Schmitt et al 1990; Thompson-Snipes et al 1991) and by the c-kil ligand, stem cell
factor (SCF; Anderson, Lyman, Baird, Wignall, Eisenman, Rauch, March, Boswell,
Gimpel & Cosman, 1990). Much of this information has been derived from in vitro
studies but its relevance to the in vivo survival of mast cells and phenotypic
expression of granule proteases has yet to be determined.
The mechanisms regulating rat and mouse mucosal mast cells may differ. The
mast cell hyperplasia which accompanies parasitic infection is readily abrogated in the
rat by treatment with corticosteroids and this is accompanied by a decrease in serum
content of the mucosal mast cell protease, RMCP II (Newlands et al 1990). In
contrast, mouse intestinal mast cell populations and serum MMCP-1 concentrations
are apparently unaffected by such treatment (Newlands et a! 1990). There are also
apparent differences in the in vivo expression of mucosal mast cell-associated
proteases in these species. In the rat, RMCP II is not only expressed in intestinal mast
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cells but may also be expressed in the mast cells of lung parenchyma (Huntley el al
1990) and, interestingly, in peritoneal cavity mast cells (PMC) following parasitic
infection (Huntley et al 1990b). In the mouse however, MMCP-1 is expressed almost
exclusively in the mast cells of the intestinal mucosa and not in other mast cell-rich
tissues such as tongue or ear pinna (chapter 3, Newlands et al 1993).
In vitro, rat bone marrow-derived mast cells (BMMC) develop and increase in
number when cultured with IL-3 alone, whereas PMC do not (Haig et al 1994). In
contrast, SCF supports the in vitro growth both of IL-3-dependent BMMC, and of
isolated PMC (Tsai et al 1991a). However, when SCF and IL-3 are used in
combination they act synergistically to promote the in vitro growth of both BMMC
and PMC (Haig et al 1994). In vivo SCF-treatment of rats results in growth of mast
cell populations in both connective tissue and mucosal locations (Tsai, Takeishi,
Thompson, Langley, Zsebo, Metcalfe, Geissler & Galli, 1991) and, in the mouse,
connective tissue-type mast cells proliferate in skin around the site of SCF injection
(Tsai et al 1991b).
Protease expression in vitro is also regulated by cytokines. Mouse BMMC
grown in IL-3 alone express MMCP-5 mRNA but the mRNAs for the mucosal mast
cell proteases MMCP-1 and MMCP-2 could not be detected in Northern blots until
the BMMC were exposed to IL-10 (Ghildyal et a! 1992a; Ghildyal, Friend,
Nicodemus, Austen & Stevens, 1993). Interestingly, MMCP-1 protein was detectable,
by immunofluorescence and EL1SA, in low concentrations, in murine BMMC grown
in supernatant from the WEHI-3 cell line (Newlands et al 1991), a constitutive
producer of IL-3 (I hie et al 1983). Similarly, the serosal mast cell-associated protease
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MMCP-4 mRNA was only detected in murine BMMC, developed in IL-3, when the
cells were sequentially cultured or co-cultured in IL-3 and SCF (Gurish el al 1992),
whilst a protein similar or identical to MMCP-4 was found to be co-expressed with
MMCP-1 in WEHI-3-derived murine BMMC (Newlands el al 1991).
In the rat, the mechanism may be somewhat different since rat BMMC, cultured
in IL-3 alone, express abundant RMCP II (Haig el al 1988) and do not express
RMCP I even when co-cultured or sequentially cultured with SCF (Haig el al 1994).
However, isolated rat peritoneal mast cells cultured in the presence of both IL-3 and
SCF will synthesise and store the mucosal mast cell-associated protease RMCP II
(Haig el al 1994).
5.2 Experimental Design
The in vitro data raise several important questions about the regulation of
rodent mast cell growth and expression proteases in vivo. In this chapter the role of T
cell-derived cytokines, in the form of lymph node conditioned medium, and of
rrSCF164 in regulating defined populations of mast cells; those in the peritoneal cavity
and the small intestinal mucosa of the rat, will be examined.
Experiment 1.
N. brasiliensis infection in rats promotes RMCP II expression in PMC
(Huntley et al 1990b), this experiment was therefore carried out to determine whether
IL-3-rich conditioned media up-regulated the expression of RMCP II in vivo. To
determine the in vivo effects of IL-3 and other T cell-derived cytokines and/or SCF on
peritoneal mast cells, rats were dosed with lymph node conditioned medium (LNCM),
with LNCM + SCF or SCF alone by daily intraperitoneal injection. Controls were
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dosed with vehicle alone and groups of 4 rats each were killed on days 2, 4 and 7.
Peritoneal mast cells were harvested by lavage. The protocols for treatment of the rats
and the validation of the functional properties of the LNCM and rrSCF164 are detailed
in Materials and Methods (2.2.3.2).
Experiment 2.
Since infection with N. brasiliensis promotes the expression ofRMCP II in rat
PMC (Huntley et al 1990b) the possibility that exogenously administered SCF might
alter the expression ofRMCP II was investigated. Nippos/rongyhis-infected and
normal rats were injected daily with rrSCF164 in PBS, at a rate of 25 pg/kg
bodyweight/day, by intravenous injection. Infected and normal controls were dosed
with vehicle only and groups of treated and control rats were killed on days 8, 10 and
15. Peritoneal mast cells were harvested by lavage.
Peritoneal mast cells were also harvested from a group of normal female Wistar
rats, of similar age and body weight to the experimental animals to establish normal
parameters for the peritoneal mast cell population of these rats. These data are
summarised in Table 10 and are referred to as baseline values throughout.
For each peritoneal lavage sample, mast cells were enumerated, protease
expression was determined by immunocytochemistry and the protease content
measured by ELISA.
The effects of intravenously administered rrSCF164 on intestinal mucosal mast
cell populations was also examined in these rats.
Segments of mid-jejunum were collected and either fixed in 4%
paraformaldehyde in PBS as described (2.2.8) for histological examination or stored
92
frozen at -20°C for subsequent ELISA assay to measure RMCP I (2.2.9) or RMCP II
(2.2.10). In addition, blood samples were collected, for measurement of RMCP II by
ELISA, either by tail-snip (2.2.7) or when the rats were exsanguinated.
Data are presented as median and range and were analysed by the Mann-
Whitney non-parametric test. Time course data were analysed by ANOVA. The full
protocols for this experiment are detailed in Materials and Methods (2.2.4).
5.3 Results
5.3.1 Effects of Intraperitoneal Injection ofSCF and/or Lymph Node Conditioned
Medium on Peritoneal Mast Cells.
Control groups of rats were treated with IMDM cell culture medium or IMDM
plus concanavalin A at the same concentration as that present in the conditioned
medium (2.2.3). There were no significant differences between these two control
groups for any of the parameters tested and therefore only the data from the IMDM
controls are presented here.
LNCM can generate mast cells from bone marrow precursor cells and is thus
considered to be a source of the cytokines IL-3 and IL-4 (Haig, McMenamin,
Gunneberg, Woodbury & Jarrett, 1983). Injection of LNCM into the peritoneal cavity
caused an increase in the total number of cells recovered by peritoneal lavage when
compared with the IMDM controls after 7 days of treatment (p < 0.05; Table 7).
However there was no change in either the number of mast cells in the lavage or in the
mast cell RMCP I content. RMCP II was increased in the peritoneal mast cells as
early as day 2 of treatment and showed a > 11-fold increase compared with IMDM
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controls (p < 0.05) on day 7 (Table 7). The increase in RMCP II content was also
reflected in the proportion of mast cells which stained for the presence of RMCP II,
by immunofluorescence, which was significantly increased on both days 4 and 7 of
treatment compared with controls (Table 7, p < 0.05 for both).
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Table 7. Effects of intraperitoneal injection of SCF and/or lymph node
conditioned medium on peritoneal mast cell populations.
Day n Total Total Mast RMCPI RMCP II % RMCP II+
Cells/Lavage Cells/Lavage (pg/Mast Cell) (fg/Mast Cell) Mast Cells
(xlO7) (xlO6)
LNCM 2 4 2.7 1.2 96.1 64 3.6
only (2.3-3.3) (1.0 - 1.4) (72 -185) (36 - 131) (1.5-4.3)
4 4 2.7 0.9 118 122* 11*
(1.9-3.6) (0.7 - 1.2) (95 - 179) (57 - 321) (5 -17)
7 4 4.2* 1.4 90 302* 22*
(1.8-3.9) (0.9 - 1.9) (68 - 115) (236 -418) (13 -25)
LNCM + 2 4 2.0 0.7* 130 57* 1.5
SCF (1.8-2.3) (0.6-0.8) (119 - 130) (39 - 73) (0.5 - 2.4)
4 4 2.4 1.6 65 271* 17*
(1.0-3.6) (0.3 -2.3) (42 - 95) (134 -435) (10- 18)
7 4 4.4* 5.6* 34 325* 30*
(3.1-5.6) (2.4-8.5) (27 -65) (210 -576) (24 - 38)
SCF only 2 4 1.8 1.0 103 20 1
(1.5-2.4) (0.9 - 1.2) (76 - 136) (7 - 37) (0-2)
4 4 1.5* 1.4 63 52 10*
(1.3-2.3) (1.2-2.1) (59 - 94) (36 - 79) (7-11)
7 4 2.3 3.4* 38* 85* 7*
(1.8-3.9) (2.0 - 3.8) (27 - 47 (58 -251) (2 - 16)
Medium 7 4 2.3 0.9 137 28 1.5
only (1.6-2.9) (0.8 - 1.2) (46 - 227) (18-37) (0.5 - 2.4)
control
ANOVA p = 0.001 NS NS p = 0.001 p <0.001
Data are presented as median and range. For each parameter the data were analysed by one way
analysis of variance to determine whether there were differences between the treatment groups. The
data were further analysed by Mann-Whitney non-parametric test where each group was compared
with the medium only control; * = p < 0.05.
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Figure 11. Photomicrograph of peritoneal mast cells from rats treated with
LNCM + SCF and dual labelled for the presence of RMCP I and RMCP II by
immunofluorescence.
Cytocentrifuge preparation of peritoneal lavage cells stained with a) rabbit anti-
RMCP I and visualised with TRITC-anti-rabbit conjugate and b) the same
preparation concomitantly stained with FITC-conjugated monoclonal anti-
RMCP II. Magnification x 300.
When rats were treated with a combination of both LNCM and SCF there was a
slight increase in the total number of cells recovered by lavage at day 7 compared with
controls (p > 0.05, Table 7). In contrast with the LNCM-treated rats, those which
received both LNCM and SCF showed an initial decrease in the number of mast cells
recovered at day 2, compared with controls (p < 0.05), before increasing at day 7,
where there were 5.5-fold more mast cells than were present in the controls (Table 7).
The growth in mast cell numbers was followed by a decline in their RMCP I content
to 34 pg/cell compared with 137 pg/mast cell in the controls (p > 0.05; Table 7).
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Unlike RMCP I, the RMCP II content of the mast cells from the LNCM + SCF-
treated group was increased by 2-fold at day 2 compared with controls (p < 0.05;
Table 7) and continued to rise throughout the course of the experiment until the
RMCP II content was almost 13-fold greater than controls at day 7 (p < 0.05; Table
7). The rise in RMCP II content, as measured by ELISA, was again reflected in the
percentage of mast cells which stained for the presence of RMCP II by
immunofluorescence; rising to 30% of all mast cells showing the RMCP l7ll+
phenotype by day 7 of the experiment (Figure 11, Table 7, p < 0.05).
The group which were treated with SCF alone did not exhibit any overall
increase in peritoneal cell numbers compared with IMDM-treated controls, indeed
there was a significant reduction in total cell numbers at day 4 (p < 0.05; Table 7).
There was, however, an increase in mast cell numbers at both days 4 and 7 compared
with controls (p < 0.05 on day 7; Table 7), similar to the LNCM + SCF-treated
group. There was also a decrease in the RMCP I content of these mast cells; by as
much as 75% on day 7 compared with controls (p < 0.05; Table 7). Like the groups
treated with LNCM alone or LNCM + SCF, the group treated with SCF alone
showed an increase in the RMCP II content of their serosal mast cells, when
compared with controls, although to a lesser extent than that seen in the other groups
(p = 0.001 by ANOVA, Table 7). Similarly the RMCP II immunofluorescence showed
a significantly increased proportion of the serosal mast cells were RMCP IF at both
days 4 and 7 compared with controls (p < 0.05 for both) but fewer than either the
LNCM alone of LNCM + SCF-treated groups (Table 7).
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5.3.2 Intravenous injection of rrSCF164 and infection with N. brasiliensis; Effects
on peritoneal mast cell populations.
Administration of SCF alone for 15 days caused a 5-fold increase in the number
of mast cells present in the peritoneal lavage (p < 0.0001, Table 8, Figure 12a and b)
when compared with rats treated with vehicle only, while no difference was noted in
the total number of cells recovered by lavage from either group (Table 8). The
increase in the mast cell population was accompanied by a significant (p < 0.01)
reduction in the mean peritoneal mast cell RMCP I content from 26 to 17 pg/mast cell
(Table 8). Only trace amounts of the mucosal mast cell-associated protease, RMCP II
was detected in the peritoneal lavage cell pellet (Table 8) and none of the cells stained
for the presence of RMCP II by immunofluorescence (Table 8).
Infection with N. brasiliensis significantly depleted the number of mast cells in
the peritoneal cavity over the course of the infection when compared with the day 15
vehicle-treated controls (p < 0.05 for days 8 and 15 and p < 0.01 for day 10 of
infection) while no reduction was seen in the peritoneal cell population in general
(Table 8). SCF-treated rats infected with N. brasiliensis, on the other hand, showed
no corresponding decrease in mast cell numbers at days 8 and 10 and a slight increase
at day 15 of infection/treatment, when compared with vehicle-treated controls,
although this did not achieve statistical significance (Table 8). This was accompanied
by a general increase in the peritoneal cell population when compared with vehicle-
treated controls (p < 0.05; Table 8). Comparison of the mast cell numbers, over the
course of infection with N. brasiliensis, for the two treatments, showed a highly
significant difference between infected animals treated with vehicle alone and those
treated with SCF (p < 0.0005 by ANOVA; Table 8).
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In N. hrastlioisi.s-infeeted rats the RMCP I content of the PMC was somewhat
increased during infection when compared with vehicle-treated controls (Table 8).
However these values were still significantly lower than baseline values, from normal
animals, on days 8 and 15 (p < 0.01 for each; Table 8, Table 10). There was no
increase noted in the PMC content of RMCP I in infected animals treated with SCF
when compared with medium only-treated controls, but again, these values were
significantly lower than baseline values (Table 8, Table 10). Comparison of the RMCP
I content of the PMC from SCF-treated and -untreated rats over the course of the N.
brasiliensis infection showed that there was significantly less enzyme in the SCF-
treated rats (p = 0.006 by ANOVA; Table 8).
The most striking differences between SCF-treated and -untreated rats were in
the expression of RMCP II, a mucosal mast cell-associated protease, in what are
regarded as the typical connective tissue mast cells of the peritoneal cavity. Vehicle-
treated control rats contained no or very little RMCP II in the peritoneal cavity, with
0-8 fg/mast cell being detected. This was not significantly altered by treatment with
rrSCF164. The RMCP II content of the serosal mast cells ofN. brasi/iensis-mfected
rats was significantly increased by day 8 of infection (p < 0.05) and reached a peak at
day 10 and although still increased, when compared with vehicle-treated controls, at
day 15 (Table 8) the RMCP II content had begun to decrease. This effect was even
greater in the infected animals treated with SCF where the RMCP II content of the
PMC was increased to 86 fg/cell at day 8 and continued to increase to over 5000
fg/cell at day 15 of infection (Table 8).
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Table 8. The effects of intravenous injection of SCF 011 peritoneal mast cell
populations in normal and parasitised rats.





(pg/Mast Cell) (fg/Mast Cell) Mast Cells
D 8 Nb only 3 2.0 0.2* 79 20* 80
(2.0-2.9) (0.1 -0.3) (52 - 98) (20 - 23) (64 - 100)
D 10 Nb only 4 3.6 0.3** 114 355* 100
(0.9 - 14.0) (0.2-0.7) (92 -221) (25 - 2820) (100 - 100)
D 15 Nb only 4 2.6 0.6* 83 49* 28
(2.1-5.4) (0.1 - 1.0) (39 - 108) (13 -8080) (0 - 100)
D 8 Nb-SCF 3 2.2 1.6 36 86* 96
(1.7-2.9) (1.1 -2.2) (28-51) (73 - 158) (92 - 100)
D 10 Nb-SCF 4 2.4 2.2 51 218* 25
(1.9-3.1) (1.2-3.0) (23 - 95) (115 -7390) (14 - 100)
D 15 Nb-SCF 7 3.5 4.5 33 5050** 69
(1.6-5.8) (0.5-6.2) (25 - 44) (45 - 10800) (0.8 - 100)
D 15 SCF only 8 2.3 7 7*** 17**(n=5) 2(n=5) 0
(1.6-2.5) (6.4-8.9) (16-20) (0 - 10) (0-0)
D 15 medium 7 2.1 1.6 26(n=5) 0(n=5) 0
only control (1.7-3.0) (0.7-2.2) (23 - 78) (0-8) (0 - 0)
ANOVA NS p < 0.0005 p = 0.006 NS NS
Data are presented as median and range. For each parameter the data from each treatment group
were analysed by one way analysis of variance to determine whether there were differences between
the treatments. The data were further analysed by the Mann-Whitney non-parametric test where each
group was compared with the appropriate medium only control; * = p < 0.05. ** = p < 0.01, *** = p
<0.001.
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However, the difference in RMCP II content between SCF-treated and -
untreated rats over the course of infection was not statistically significant. These
marked increases in RMCP II content were reflected in the immunohistochemical
staining of cyto-smears for the presence ofRMCP II (Figure 12c).
Figure 12, Photomicrographs of peritoneal lavage cells from rats treated with
rrSCF164 for 15 days or from vehicle-only-treated controls.
Toluidine blue stained cytocentrifuge preparations from a) rrSCF164-treated or
b) vehicle-only-treated control rats. FITC-labelled anti-RMCP II-stained
cytocentrifuge preparations from c) rrSCFI64-treated or d) vehicle-only-treated
control rats. Magnification, x 300.
a
- - j» — - b
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There were no RMCP Iff mast cells detected in cyto-smear preparations from
vehicle only-treated controls or from rats treated with SCF alone (Table 8, Figure
12d), although mast cells in preparations from both these groups stained strongly for
the presence of RMCP I. In rats infected with N. brasiliensis 80% of the mast cells in
cyto-smear preparations were RMCP II+ by day 8 of infection, rising to 100% by day
10, before falling again to < 30% on day 15 (Table 8). Mast cells in infected, SCF-
treated animals showed maximum fluorescence earlier than those in the vehicle-
treated group, at day 8 of infection, with 96% of all mast cells staining for the
presence of RMCP II (Table 8). The fluorescence thereafter decreased to levels
similar to that seen in the vehicle-treated, N. 6ras/V/£/?.S7'5'-infected group (Table 8).
Over the course ofN. brasiliensis infection there was no significant difference in the
percentage of mast cells staining for the presence of RMCP II between SCF-treated
and -untreated rats.
The peritoneal mast cells of the control group, treated for 15 days with vehicle
alone, had similar values to those of the baseline group (Table 8) for all the
parameters measured except that their RMCP I content was significantly lower at <
36 pg/cell compared with a baseline value of 143 pg/mast cell (Table 8, Table 10).
5.3.3 Effects of rrSCF164 on jejunal MMC numbers and mast cell-associated
proteases in N. brasi 1 iensis-infected rats
Infection with N. brasiJiensis causes an initial depletion of MMC from the
jejunum of the rat followed subsequently by substantial MMC hyperplasia. The data in
Table 9 confirm that mast cells were completely depleted from the jejunum at day 8 of
infection (n = 3) compared with control values in non-infected rats (n = 5, p < 0.05;
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Table 9). By day 15 of infection mast cell densities in jejunum were increased nine¬
fold over control values (Table 9). The concentrations of RMCP II reflect the MMC
counts in the jejunum with a 5.8 fold increase on day 15 when compared with control
values in rats not treated with rrSCF164.
Treatment of rats with rrSCF164 for 15 days, resulted in a significant (~85%; p
< 0.001) elevation in mean jejunal mast cell density when compared with untreated
controls, a result which is in good agreement with previously published values (Tsai el
cil 1991a). The mast cell densities at 8, 10 or 15 days of N. brasi/iensis infection in
rrSCF-treated or -untreated animals were not significantly different. There were more
mast cells at day 8 in specimens from rrSCF 164-treated vs. -untreated rats, but with a
group size of 3 this difference was not significant. On the other hand, the large
difference in RMCP II content on day 8 between rrSCF 164-treated and -untreated
parasitised rats is significant (p < 0.05; Table 9).
Data for RMCP I content confirm previous findings and show that the
concentration of RMCP I in the jejunum is several orders of magnitude less than that
of RMCP II and these values change to a lesser extent than values for RMCP II as a
result of N. brasiliensis infection (Table 9).
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Table 9 Effects of SCF treatment on jejunal mast cell density and mast cell
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426159 1914.7 423 1 181 24641607
470 160 375 179* 776 1281 8711 13839
* = p < 0.05, *** = p < 0.001 by two-tailed Student's t-test versus value for SCF-untreated animals at
the same time point.
5.3.4 Effects of rrSCF164 on systemic secretion ofRMCPII during infection.
Daily intravenous injection of rrSCF164 had no effect on the systemic secretion
of RMCP II in control (uninfected) rats in which serum values remained at = 300
ng/ml in both SCF-treated and -untreated controls throughout the course of the
experiment (Figure 13). The concentration of RMCP II increased to 2350 ng/ml in
the control parasitised group on day 10 of infection but the peak serum RMCP II
values occurred earlier, on day 8, in the rrSCF!64-treated group. The day 8 value in
the SCF-treated group (4650 ng/ml) was significantly higher than the corresponding
value (1670 ng/ml) in the SCF-untreated rats (Figure 13, n = 5, p < 0.05, ). Together
with the data in Table 9, this result shows that at day 8 of infection, rrSCF164
treatment results in both increased jejunal RMCP II content and increased secretion of
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this mast cell protease. Moreover, by ANOVA, serum levels of RMCP II over the
entire time course of the infection were significantly higher in the rrSCFI64-treated
than in the control group not treated with the cytokine (p = 0.001).
Days after Infection
Figure 13, Serum concentrations of RMCP II in rats treated with rrSCF164.
Comparison of uninfected animals treated with rrSCF164 (•) or vehicle alone (H
) and N. brasiliensis-'mfected animals treated with rrSCF164 (♦) or vehicle
controls (A).
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5.3.5 Effect of rrSCF164 on parasitefecundity.
The effect of the administration of rrSCF164 on the fecundity ofN. brasiliensis
was determined by monitoring egg output in the faeces of the rats. Egg output was
maximal on day 6 of infection in both rrSCF 164-treated and vehicle-treated (control)
rats and diminished until no eggs were detected by day 11 in either group (Figure 14).
While values for faecal egg output were greater in the rrSCF164-treated as opposed to
control rats at many intervals of the infection, these differences did not achieve
statistical significance.
Day after Infection
Figure 14, Faecal egg counts from N. brasiliensis- infected rats treated with
rrSCF164.
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Table 10; Baseline Peritoneal Mast Cell Parameters for a Group of Normal
Rats.
11 Total Mast RMCP 1 RMCP II % RMCP If
Cells/Lavage Cells/Lavage (pg/Mast Cell) (fg/Mast Cell) Mast Cells
(xlO7) (xlO6)
5 1.9 + 0.12 0.8 ± 0.07 143 ±8.1 6 ± 1.0 0 ± 0.0
5.4 Discussion
The increase in numbers of PMC after intravenous treatment with SCF confirms
the previous in vivo and in vitro findings that SCF is a potent growth factor for PMC
(Tsai el al 1991a, Haig et al 1994). However, unlike the previous studies which
showed the concentrations of the PMC-associated protease RMCP I to be maintained
(Haig et al 1994) or increased (Tsai et al 1991a), the results described here show the
RMCP I content of the peritoneal mast cells to be decreased by about 50% compared
with controls. This raises the possibility that, while SCF provides a potent
proliferative and/or recruitment signal for PMC it does not stimulate, and may even
down-regulate synthesis and/or storage of RMCP I.
Following infection with the intestinal nematode parasite N. brasiliensis the
mast cell population of the peritoneal cavity was greatly reduced (Table 8), possibly
as a result of degranulation (Wilson & Bloch 1968), although the mean RMCP I
content of the remaining mast cells was increased compared with vehicle treated
controls. These data demonstrate that infection has profound effects on mast cell
populations in locations remote from the site of infection. The depletion of peritoneal
mast cells was accompanied by a substantial increase in the RMCP II content of the
remaining mast cells as measured by both ELISA and immunofluorescence. A similar
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result was obtained when N. brasi/iensis-mfected rats were treated with SCF, except
that the induction of the peritoneal RMCP II response was even greater in the SCF-
treated animals (Table 8). These results are in accord with the previously reported
finding that IL-3 and SCF act in synergy not only to stimulate mast cell growth but
also to cause a sub-population of serosal mast cells, in vitro, to synthesise and store
RMCP II (Haig et al 1994). The intestinal mastocytosis associated with nematode
infection involves the activities of both the T cell-derived cytokines IL-3 and IL-4
(Madden el al 1991) and the connective tissue-derived factor SCF and its receptor, c-
kit (Grencis et al 1993, Newlands et aI 1995) and thus it is probable that these
cytokines also have synergistic effects in vivo which lead to the induction of RMCP II
synthesis by serosal mast cells. Groups of rats treated intraperitoneally with LNCM or
SCF either singly or in combination confirmed the results from the parasitic model.
Treatment with the cytokine-rich LNCM did not cause any expansion of the serosal
mast cell population and did not alter the mean mast cell RMCP I content but it did
stimulate increased synthesis of RMCP II. Treatment with SCF alone caused an
increase in PMC numbers coupled with a decrease in RMCP I content and,
surprisingly, an increase in RMCP II content. This increase in RMCP II may be due to
either a synergistic effect of the rrSCF with background levels of IL-3 or, perhaps to
some effect of the rrSCF being infused directly into the peritoneal cavity, such as
greater local concentration, than in the systemic treatment. Combination of LNCM
and SCF substantially increased mast cell numbers but again the presence of SCF
depressed the mean mast cell RMCP 1 content. This is in contrast with in vitro murine
BMMC which showed an increase in mRNA for the PMC-associated chymase
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MMCP-4, the mouse analogue of RMCP I, when sequentially cultured or co-cultured
in IL-3 and SCF (Gurish et al 1992).
In confirmation of previous reports (Tsai el al 1991a), treatment of uninfected
rats with rrSCF164 at 25 pg/kg/day, i.v. for 14 days produced a significant (85%)
increase in jejunal MMC numbers. However, the elevation in jejunal RMCP II content
in rrSCFI64-treated vs. vehicle-treated rats did not achieve statistical significance. On
the other hand, rrSCF164 treatment had only modest effects on the changes in jejunal
MMC numbers, or on the jejunal or serum levels of RMCP II, that were associated
with N. brasiliensis infection. Compared to vehicle-treated rats, rrSCF164-treated rats
had higher levels ofjejunal MMCs and significantly higher levels of jejunal RMCP II
at day 8 of infection. Also, the peak mean levels of serum RMCP II occurred earlier
(day 8 vs. day 10) and reached a roughly 2-fold higher maximum in rrSCF164-vs.
vehicle-treated rats. These findings indicate that administration of exogenous SCF can
alter the kinetics and increase the magnitude ofjejunal MMC development and RMCP
II production during N. brasiliensis infection. However, later during infection,
numbers of jejunal MMCs and serum levels of RMCP II were quite similar in rrSCF164
and vehicle-treated rats, and, due to the broad range of individual values, the higher
mean levels of RMCP II in the jejunal mucosa of rrSCF164-treated rats were not
significantly different than those in the vehicle-treated controls. One possible
explanation for these findings, is that endogenous levels of SCF in normal rats are
sufficient to permit near maximal MMC hyperplasia (presumably in response to T cell-
associated cytokines) in the setting of N. brasiliensis infection.
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Taken together these two experiments clearly show SCF to provide a potent
stimulus for PMC growth and/or recruitment while depressing RMCP I expression
and/or storage. Furthermore, intravenous treatment with SCF did not up-regulate
RMCP II expression whereas direct delivery of SCF into the peritoneal cavity did.
This could be due to SCF-induced secretion of IL-3 by the resident population of
mast cells.
In summary, SCF causes significant proliferation and/or recruitment of
connective tissue mast cells in the peritoneal cavity of the rat and that SCF or LNCM
stimulate the up-regulation of RMCP II expression in these cells. This up-regulation
of RMCP II expression is even greater if SCF and LNCM are used in combination
than if either cytokine is used individually.
6. ROLE OF STEM CELL FACTOR IN SUPPORTING MAST
CELL SUB-SETS IN NORMAL RATS
6.1 Introduction
In chapter 5 the effects of exogenous cytokines and growth factors on
peritoneal mast cells were investigated. In this chapter these studies will be extended
to examine the effects of depleting SCF by treatment with antibodies. Mice or rats
with mutations which markedly diminish c-kit tyrosine kinase activity such as W/W
mice (Reed 1989) or W/W rats (Arizono et al 1993) develop no or very few mast
cells in comparison with normal animals. Moreover, treatment of T. spiralis-infected
mice with antibodies to c-kit blocked the intestinal mast cell hyperplasia associated
with parasitic infection (Grencis et a! 1993). In vitro, SCF supports the survival and
growth ofboth rat bone marrow-derived mast cells, which have many of the features
of MMCs, and peritoneal cavity derived CTMC (Haig et al 1994). SCF also promotes
the survival, both in vivo and in vitro, of IL-3 dependent mast cells which otherwise
undergo apoptosis when they are deprived of IL-3 (Iemura, Tsai, Ando, Wershil &
Galli, 1994). Thus, from this evidence, it is clear that SCF and c-kit play an important
role in promoting mast cell growth in vitro, in supporting IL-3 dependent mast cells
and in gastrointestinal nematodiasis-associated mast cell hyperplasia. There is,
however, little or no data on the regulatory role of SCF in vivo on resting mast cell
populations in normal animals. To address this question rats were treated with
polyclonal antibody to SCF to determine what the consequences of blocking these
activities would be for the mucosal and peritoneal mast cell populations.
6.2 Experimental Design
Aim:- to determine whether mast cell populations in normal rats are SCF-
dependent. The approach taken to investigate the role of SCF in regulating mast cell
populations was to attempt to block its function by treating rats with polyclonal
antibodies. However, since SCF has important roles in regulating stem cell
haemopoiesis the effect of such treatment on various haematological parameters was
also monitored.
Protocol 1:
To determine the effects of treatment with anti-SCF antibodies (2.2.6) on mast
cell populations and protease expression, rats were treated with antibody for 4 or 7
days and killed 24 hours after the final inoculation. Samples were collected by
peritoneal lavage for cytosmear and cell pellet preparation. Samples of small intestine,
stomach, lung, tongue and liver were collected into fixative for histology (2.2.8) or
were frozen for subsequent measurement of mast cell protease concentrations by
ELISA (2.2.9, 2.2.10). Mast cells were enumerated in lavage samples and histological
sections and protease phenotypes determined by immunohistochemical localisation of
mast cell proteases. Serum samples were also collected and assayed for the MMC-
associated protease RMCP II (2.2.10).
Protocol 2:
To determine the effects of anti-SCF treatment on haematological parameters a
second experiment was carried out where rats were treated for 4 days with anti-SCF
antibodies or normal IgG. Blood samples were collected from all rats into anti-
coagulant (2.2.7) at the start of the experiment, on day 0, to establish normal
haematological parameters and again at the termination of the experiment on day 5 to
determine the impact that these treatments had on haemopoiesis. The details of these
protocols are described in Materials and Methods (section 2.2.7).
6.3 Results
6.3.1 Effects ofanti-SCF antibody treatment on peritoneal cavity mast cells.
Treatment of normal rats with polyclonal sheep antibodies to rrSCF had a
marked effect on the peritoneal mast cell population. After 4 days of treatment the
numbers of mast cells recovered by peritoneal lavage had decreased by 58% (p <
0.05; Table 11) compared with normal sheep IgG-treated (control) animals and the
total PMC-associated protease, RMCP I, in the cell pellet had decreased by 62% (p <
0.01; Table 11) compared with controls. At the same time the mean RMCP I content
per mast cell was decreased but this did not achieve statistical significance. When the
antibody treatment was continued for 7 days mast cell numbers decreased by 55%
compared with controls (p < 0.05; Table 11), a similar result to that recorded after 4
days of antibody treatment, whilst the RMCP I content of the cell pellet decreased by
47% of control values although, again, this did not achieve statistical significance. The
mean mast cell RMCP I content, after 7 days of antibody treatment, showed an
apparent increase of 86% over control values (Table 11) but this was also not
statistically significant and was probably due to the decrease in control values, from
day 4 to day 7 in the mast cell RMCP I content. This was in contrast with the total
number of cells recovered by peritoneal lavage which showed no decrease after 4 days
of antibody treatment and only a 10% decrease after 7 days, although neither value
was statistically significant. As there was no greater depletion of mast cells or RMCP
I from the peritoneal cavity after 7 days of antibody treatment compared with 4 days
of treatment further analysis was confined to material collected from the 4 day
treatment experiment.
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There is a strong correlation between peritoneal mast cell numbers, regarded as
typical CTMC, and RMCP I content (Figure 15, r = 0.82, p = 0.0067) and therefore
measurement of RMCP I by ELISA was used to assess the systemic effect of anti-
SCF treatment on the CTMC populations in other anatomical sites.
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■ anti-SCF treated A control IgG-treated
Figure 15 Graph showing a plot of peritoneal mast cell number against total
RMCP 1 for peritoneal lavage samples from rats treated with anti-SCF
antibodies or with normal sheep IgG.
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6.3.2 Effects ofanti-SCF treatment on RMCPI concentrations in other organs.
RMCP I concentrations in stomach and small intestine were depleted by 60%
and 65% respectively (p < 0.05 for each, Table 12) which was similar to the level of
depletion from the peritoneal cavity. There was an even greater depletion from liver
(80%, p < 0.001, Table 12) but only a 36% decrease in the RMCP I concentration in
tongue although this was significant (p < 0.05, Table 12). Interestingly the smallest
depletion of RMCP I was from lung where protease concentrations decreased by only
20% compared with control values (p > 0.05).
Table 12 RMCP I levels, measured by ELISA, in several tissues from rats after 4
days treatment with sheep anti-SCF or normal sheep IgG (control) antibodies.
Small
Intestine
Lung Tongue Stomach Liver
Anti-SCF 0.25 ± 0.08* 8.8 ±0.14 61.8 ± 12.0* 2.9 ± 0.96* 0.24 ±0.07***
control 0.7 ±0.02 11.0 ± 1.2 96.0 ± 6.96 7.2 ± 1.3 1.2 ± 0.10
% decrease 65% 20% 36% 60% 80%
The results are expressed as mean ± sern in pg/g wet wt. of tissue
Student's two tailed t-test; * = p < 0.05. *** = p < 0.001
6.3.3 Effects ofanti-SCF treatment on mucosal mast cells and RMCP II levels.
Anti-SCF treatment had a more pronounced effect on the intestinal MMC
population than on CTMC in the peritoneal cavity or in other organs. After 4 days of
treatment the intestinal MMCs were totally ablated with no mast cells being detected
in toluidine blue stained sections ofjejunum (p < 0.001, Table 13). This was refected
in the amounts of RMCP 11 detected in jejunal extracts and in serum by ELISA where
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> 95% reduction was recorded for both (p < 0.01, Table 14). There was a less marked
effect in stomach, for while there was a 73% reduction in mast cell density in the
gastric mucosa compared with control values (p < 0.05, Table 13), there was only
34% decrease in RMCP II content (p > 0.05). Concentrations of RMCP II in liver
were also decreased by 82.5% in anti-SCF-treated animals when compared with
normal IgG-treated (control) animals (p < 0.01, Table 14) which is similar to the level
of decrease noted in the RMCP I content of liver (Table 12). Despite an apparently
large decrease in the RMCP II content of lung (Table 14) the intra-group variability
precluded statistical significance.
Table 13 Mucosal mast cell counts from toluidine blue stained sections of small
intestine or stomach from rats treated with anti-SCF or normal sheep IgG
(control) antibodies.
small intestine stomach
Anti-SCF 0.0 ±0.0*** 5.814.1*
control 6.5+1.3 21.4 + 4.6
% decrease 100% 73%
Results are mean ± sent mast cells/0.2 mm2
Mann-Whitney non-parametric test * = p < 0.05, *** = p < 0.001
Table 14 RMCP II concentrations in tissue extracts and serum from rats treated
for 4 days with sheep anti-SCF or normal sheep IgG (control) antibodies.
lung liver stomach Small Intestine serum (ng/ml)
anti-SCF 5.0 ± 1.22 0.3 ±0.05** 22.615.24 0.4 ±0.25** 7.0 ± 1.92**
control 17.7 ±7.94 1.610.60 34.219.17 342.8 ±45.07 157.0 ± 15.27
% decrease 72.0% 82.5% 34.1% 99.9% 95.6%
Results are mean ± sem pg/g wet wt. of tissue or ng/ml of serum.
Mann-Whitney non-parametric test ** = p < 0.01
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6.3.4 Effects ofanti-SCF treatment on haematological parameters.
Stem cell factor is fundamentally involved in haemopoiesis since mice with a
mutation at the SI locus (Sl/Sr), which encodes for SCF, are not only mast cell
deficient but exhibit severe anaemia (McCulloch, Siminovich, Till, Russel &
Bernstein, 1965). Therefore a number of haematological parameters were measured to
determine the effects of anti-SCF treatment on haemopoiesis.
Red blood cell count, haematocrit and haemoglobin concentration were
unaltered in rats treated for 4 days with either anti-SCF or normal sheep IgG
antibodies when compared with pre-treatment values. The white cell count of the anti-
SCF-treated group was depressed significantly when compared with normal IgG-
treated control rats (p < 0.02; Table 15). Differential cell counts revealed that while
the proportion of circulating neutrophils was significantly depressed in both anti-SCF
and normal IgG-treated groups (p < 0.001 and p < 0.005 respectively; Table 15) the
proportions of lymphocytes, monocytes and eosinophils were unchanged.
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6.4 Discussion
Treatment of normal rats with anti-SCF for 4 days significantly depleted mast
cells from the peritoneal cavity and also depleted RMCP I from other tissues. Perhaps
more surprisingly this treatment also totally ablated the intestinal MMC population
and virtually eliminated circulating RMCP II. An additional effect of anti-SCF
treatment is that it diminished the numbers of all circulating white blood cells,
probably because of an effect on haematopoietic progenitor cells (Williams et al
1991).
One interpretation of these results is that endogenous SCF is necessary for the
survival of mature mast cell populations. rrSCF can maintain mouse mast cell survival
in vitro (Mekori, Oh & Metcalfe, 1993; Iemura et al 1994) or in vivo (Iemura et al
1994) by suppressing apoptosis, and the abrogation of this effect by anti-SCF could
account for the current findings. Of course, rrSCF164 can promote the recruitment of
mast cell precursors in vivo (Tsai et al 1991b; Zsebo, Williams, Geissler, Broudy,
Martin, Atkins, Birkett, Okino & Murdock, 1990) and can favour their development
into mature mast cells (Tsai et al 1991b; Zsebo et al 1990). It can also synergise with
IL-3 to promote rat mast cell proliferation (Haig et al 1994; Tei et al 1994). These
additional effects of SCF may also have been antagonised by anti-SCF treatment.
However, the total ablation of mature MMCs from the intestinal mucosa of
normal rats by anti-SCF cannot easily be explained by a suppression of recruitment of
mast cell precursors alone. The half-life of mucosal mast cells in rat intestine has been
estimated at around 40 days (Enerback & Norrby 1989) and blocking recruitment for
4 days would be expected to have a negligible effect on mast cell numbers. These
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findings can perhaps best be explained by effects of anti-SCF on the SCF-dependent
suppression of mast cell apoptosis. In vitro murine BMMC, maintained in SCF, begin
to undergo apoptosis within hours of the removal of SCF from the culture medium
(Iemura et al 1994). It is interesting to note that whilst mucosal mast cells are totally
ablated by anti-SCF treatment the connective tissue-type mast cells of the peritoneal
cavity, and probably other tissue locations, are only partially depleted. Similarly,
mucosal mast cells in rat jejunum were significantly depleted within hours of treatment
with the corticosteroid dexamethasone (Soda, Kawabori, Perdue & Bienenstock,
1991); a treatment which suppresses cytokine expression (Arya, Wong-Staal & Gallo
1984, Culpepper & Lee 1985). Corticosteroid treatment, on the other hand, has a
negligible effect on rat PMC numbers (King, Miller, Newlands & Woodbury, 1985).
This evidence, taken together, shows that MMC are not only highly dependent on the
T cell-derived cytokines IL-3 and IL-4 but that they also require SCF for their
survival in vivo. On the other hand connective tissue-type mast cells are not only IL-3
and IL-4 independent but also have much less of a dependency on SCF for their
immediate survival.
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7. STEM CELL FACTOR IN MAST CELL HYPERPLASIA
ASSOCIATED WITH INTESTINAL NEMATODIASIS
7.1 Introduction
In murine rodents, infection with intestinal nematodes induces a striking
hyperplasia of intestinal MMCs, which is accompanied by increases in the levels of
MMC-associated neutral serine proteases in intestinal tissues and increases in the
concentrations of these proteases in the blood (Miller et al 1983; Woodbury et al
1984, Huntley et al 1990b). SCF and T cell-dependent mechanisms both contribute to
the intestinal MMC hyperplasia associated with nematode infection. In comparison
with normal mice or rats, those with mutations that markedly diminish c-kit receptor
tyrosine kinase activity, such as W/W mice (Reed 1989) or W*/W rats (Arizono et al
1993), exhibit no or greatly diminished hyperplasia of intestinal MMCs in response to
infection with N. brasiliensis (Reed 1989; Arizono et al 1993) or T. spiralis
(reviewed in Reed 1989). Both intestinal MMC hyperplasia and the spontaneous
expulsion of the parasites are diminished in T. spiralis-infected mice that have been
treated with an antibody to the c-kit receptor (Grencis et al 1993). Moreover,
treatment of normal rats with E. coli-derived rrSCF164, which represents virtually the
entire extracellular ligand domain of SCF and which possesses high biological activity
(reviewed in Galli et al 1994), induces significant hyperplasia of gastrointestinal
MMCs as well as connective tissue-type mast cells (Tsai et al 1991a). On the other
hand, athymic 'nude' mice fail to develop MMC hyperplasia in response to nematode
infection, whereas this response is restored in nude animals treated by adoptive
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transfer of T cells (reviewed in Reed 1989). Moreover, in normal mice, treatment with
either anti-IL-3 or anti-IL-4 antibodies, or, even more effectively, treatment with both
antibodies, significantly suppresses intestinal mast cell hyperplasia in response to N.
brasi/iensis infection (Madden et al 1991). In vitro evidence indicates that SCF and
IL-3 can have synergistic effects in promoting the proliferation of rat mast cells with
phenotypic similarities to MMCs (Haig et al 1994; Tei et al 1994). In addition, during
N. brasi/iensis infection, PMC are induced to begin expressing the MMC protease
RMCP II (Huntley et al 1993). This is in accord with the results reported in chapter 5,
where in vivo treatment of rats with SCF and/or IL-3 also induces PMC to express
RMCP II as well as RMCP I.
Taken together, this evidence indicates that the cytokine-dependent regulation
ofMMC hyperplasia during nematode infection in murine rodents, while complex,
importantly involves both SCF and T cell-derived cytokines such as IL-3 and IL-4.
7.2 Experimental Design
In this chapter the role of SCF in both the mucosal mast cell hyperplasia
associated with nematode infection and the induction of RMCP II expression in PMC
were investigated by treatment ofN. brasi/iensis or T. spiralis-infected rats with a
polyclonal sheep antibody to rat SCF. The objective of these experiments was to
determine whether this treatment would alter mast cell numbers or protease
expression in small intestine or peritoneal cavity. In addition, the effects of anti-SCF
treatment on parasite fecundity were assessed in N. brasiliensis-'mfected rats by
monitoring faecal egg-counts. This data was compared with faecal egg-counts from
the rats treated with rrSCF164 by daily intravenous injection as described in chapter 5.
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Rats were inoculated intraperitoneally with 1 nig sheep anti-rrSCF164 or normal sheep
IgG. Because of the tissue and pulmonary migration of the L3 and L4 larval stages of
N. brasiliensis, rats infected with this parasite were treated on day 3 of infection when
the L4 larvae first reached the intestine and on days 5, 7, 10 and 12 thereafter. For rats
infected with T. spiralis, treatment commenced on day 0 and continued on days 3, 5,
7 and 10.
In the experiment where the rats were infected with N. brasiliensis, groups of
rats were killed on days 6, 10 and 14 after infection and where infection was with T.
spiralis groups were killed on days 6, 10 and 12. In both experiments the rats were
killed by exsanguination under deep anaesthesia followed by cervical dislocation.
Samples of small intestine were collected and fixed in paraformaldehyde for
histological examination (2.2.8) or stored at -20°C for subsequent measurement of
RMCP I and II by ELISA (2.2.9, 2.2.10). Samples were also collected by peritoneal
lavage for evaluation of peritoneal mast cell numbers, phenotype assessment by
immunocytochemistry and assay of RMCP I and II by ELISA. In a separate
experiment, rats infected with N. brasiliensis were treated with anti-SCF antibodies
on days 10 to 13 inclusive, of infection to determine whether an established mast cell
hyperplasia was dependent on SCF. Blood samples were taken, to determine
haematological parameters (2.2.7), at the start of the experiment, on day 0, and again
on day 10 at the commencement of anti-SCF treatment. The animals were killed on
day 14 and blood samples were again collected for haematology and for the
measurement of RMCP II by ELISA. In addition, samples of small intestine were
collected for histology (2.2.8) and ELISA (2.2.9, 2.2.10) on day 14.
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7.3 Results
7.3.1 Anti-SCF treatment: effects of treatment on the mucosal mast cells of the
small intestine.
Since anti-SCF treatment down-regulated the number of peritoneal mast cells in
normal rats (chapter 6), it was important to determine whether anti-SCF treatment in
association with N. brasiliensis or T. spiralis infection had a similar, or different
effect on MMC.
7.3.1.1 Infection with N. brasiliensis.
N. brasiliensis-'m&cted rats were first treated with anti-SCF or with normal sheep
IgG on day 3 of infection, when the worms begin to emerge into the gastrointestinal
tract. As expected, mast cell counts in both control IgG and specific antibody-treated
groups were low on day 6 (Figure 16a). This result is in accord with previously
published data that N. brasiliensis infection produces an initial reduction in mast cell






























Figure 16. Mast cell densities in jejunum of rats infected with N. brasiliensis
or T. spiralis and treated with anti-SCF antibodies.
a) N. brasiliensis-infected rats treated with anti-rrSCF164 (□) or normal sheep
IgG (O), or b) T. spiralis-infected rats treated with anti-rrSCF164 (■) or normal
sheep IgG (•). Mast cell densities in anti-SCF treated rats were compared with
the equivalent time points in control rats by Student's two sample t-test.
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Figure 17. RMCP II content of jejunum of rats infected with N. brasiliensis
or T. spiralis and treated with anti-SCF antibodies.
a) N. brasiliensis -infected rats treated with anti-rrSCF164 (□) or normal sheep
IgG (O), or b) T. spiralis -infected rats treated with anti-rrSCF164 (■) or normal
sheep lgG (•). Jejunal RMCP II concentrations in anti-SCF treated rats were




Figure 18. Serum concentrations of RMCP II in rats infected with N.
brasiliensis or T. spiralis and treated with anti-SCF antibodies,
a) N. brasiliensis-infected rats treated with anti-rrSCF164 (□) or normal sheep
IgG (O), or b) T. spiralis-infected rats treated with anti-rrSCF164 (■) or normal
sheep IgG (•). Serum RMCP II concentrations in anti-SCF treated rats were
compared with the equivalent time points in control rats by Student's two
sample t-test.
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However anti-SCF treatment resulted in significant inhibition of mast cell hyperplasia
(Figure 16a). This effect was most notable on day 10 of infection (p < 0.0001 vs. the
corresponding value in control rats) but was observed throughout the entire time
course of the infection (p < 0.0005 vs. control values by ANOVA). The anti-SCF-
treated rats also had significantly reduced levels of RMCP II in the jejunal mucosa at
all time points tested (Figure 17a) as well as over the entire time course of the
infection (p < 0.0005 vs. control values by ANOVA). This reduced mucosal
concentration of RMCP II was paralleled by a highly significant depression of
RMCP II concentrations in blood 6 and 10 days after infection (p < 0.001 at either
interval, p < 0.0005 over the entire time course of the infection; Figure 18a). Simple
regression analysis of the mast cell densities and RMCP II concentrations in the
jejunum of all N. brasiliensis-'mfected animals gave a highly significant correlation (R
= 0.96, p < 0.0001, Figure 19a).
To determine whether SCF remains a significant factor in MMC hyperplasia or
survival even after the onset of the intestinal MMC response, groups of rats were
treated with anti-SCF or normal sheep IgG daily from day 10 of infection, when mast
cell hyperplasia was well under way (e.g. see Figure 16a). The rats treated with anti-
SCF showed a 32% depletion of RMCP II from the small intestine on day 14
compared with the values for normal sheep IgG-treated controls (p < 0.01; Table 16),
with a concomitant 32% decrease in mast cell density (p < 0.03; Table 16). The 15%
decrease in the serum RMCP II concentrations in the anti-SCF-treated rats was not
statistically significant (Table 16) nor was there any significant alteration in the
haematological parameters measured, as a result of the anti-SCF treatment (Table 17).
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Table 16 Jejunal mast cell densities and RMCP II concentrations in intestine
and serum in rats treated with anti-SCF or normal sheep IgG from day 10 of N.
brasiliensis infection.
Day 0 Day 10 day 14 control day 14 anti-SCF
jejunal mast cells
(cells/0.2 mm2)
ND ND 65+7 44 ±3*
Jejunal RMCP II
(pg/g wet wt.)
ND ND 1752 ±106 1186 ±111**
serum RMCP II
(ng/ml)
95 ±4 360 ±21 453 ±62 386 ± 121
Comparison of day 14 anti-SCF treatment group data with day 14 control data by two-sample
Student's t-test. *p < 0.03, **p < 0.01 vs value, ND = not determined.
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Table 17 Haematological parameters in rats treated with anti-SCF or normal






day 0 10 1.37 ±0.05 6.7 ±0.08 15.7 ±0.2 40.0 ±0.7
day 10 10 1.11 ±0.1 7.1 ±0.2 16.1 ±0.3 39.2 ± 1.2
day 14
control
5 1.2 ±0.05 6.7 ±0.1 15.1 ±0.3 40.4 ±0.8
day 14 anti-
SCF
5 1.1 ±0.1 6.4 ±0.1 14.5 ± 1.6 37.4 ±4.2
The day 0 and day 10 values presented are pooled data from both control and anti-SCF treatment
groups before treatment with antibodies commenced. WBC, white blood cell; RBC, red blood cell;
Hb, haemoglobin; Hct, haematocrit.
7,3.1,2 Infection with T. spiralis.
Infective T. spiralis larvae establish themselves in the intestine within hours of
oral challenge, therefore treatment with anti-SCF was first given at the time of
infection, on day 0. Mast cell hyperplasia occurs sooner during trichinosis than in N.
brasi/iensis-'mfected rats, and anti-SCF treatment significantly depressed mast cell
densities on days 6, 10 and 12 of infection (p < 0.001, p < 0.001 and p < 0.005
respectively; p < 0.0005, by ANOVA over the entire course of the infection; Figure
17b) when compared with values in normal IgG-treated controls. Again this result
was paralleled by values for mucosal concentrations of RMCP II, which were
significantly reduced 6, 10 and 12 days after infection (p < 0.005, p < 0.001 and p <
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0.001 respectively; p < 0.0005, by ANOVA over the entire course of infection; Figure
17b) in anti-SCF treated rats. The relationship between mucosal RMCP II and mast
cell densities, when analysed by simple regression analysis, showed a positive
correlation (R = 0.90, p < 0.0001, Figure 19b). In contrast with responses in
Nippostrongylus-infected rats, the systemic secretion of RMCP II was depressed on
day 6 (p < 0.001) but not at other time points (Figure 18b). As previously reported
(Woodbury et al 1984) it was found that T. spiralis, when compared with N.
brasilietisis infection, was associated with a greater, and earlier, systemic release of
RMCP II (compare Figure 18a and b).
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Mast Cells/0.2 mm2
■ D6anti-SCF □ D 6 control • D10anti-SCF
o D 10 control A D12anti-SCF A D 12 control
Figure 19. Correlation between mast cell densities and RMCP II
concentrations in small intestine of parasitised rats, treated with anti-SCF
antibodies.
Plot a) N. brasiliensis-infeeted rats. Plot b) T. spiralis-infected rats. The control
data are represented by open symbols and the anti-SCF treatment data by
closed symbols.
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7.3.2 Anti-stem cellfactor treatment: effects on peritoneal mast cell populations
in parasitised rats.
N. brasi/iensis-infected rats, treated with anti-SCF, showed a significant
decrease (p < 0.003 by ANOVA) in PMC numbers compared with controls but the
amounts of RMCP I and II per mast cell was not significantly altered. Similarly, in T.
spiralis-infected rats, there was also a significant depletion in PMC numbers at days
10 and 12 of infection. This was accompanied by an apparent increase in the RMCP I
content of the mast cells. However, due to the low numbers of mast cells detected,
this may be due to sampling error and is probably not biologically important. These
data are reported fully in Appendix 1, section 12.1.
7.3.3 Development ofan antibody response to sheep immunoglobulins in rats
treated with the polyclonal sheep anti-SCF antibodies.
Because treatment of rats was with a polyclonal sheep antibody, it was
possible that antibodies to sheep IgG would be generated during treatment. This was
confirmed when, on day 6 of treatment with either sheep anti-SCF or normal sheep
IgG, T. spiralis-infected rats had a sheep IgG-specific antibody titre of 320, as
assessed by ELISA, when compared with pre-treatment sera from the same group of
rats (p < 0.05). Interestingly, although the assay of sera from day 12 of treatment
gave somewhat higher absorbances than that from the day 6 groups the titre remained
at 320 (p < 0.05). To determine whether this was a genuine anti-sheep IgG response
or simply a reflection of up-regulated IgG production as a result of infection, the sera
from N. brasiliensis-'mfected rats which had not been treated with sheep
immunoglobulins were also assayed. No significant difference in absorbance was
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found at day 3, 6, 9 or 12 of infection when compared with serum samples obtained
from the same group of rats prior to infection. The protocol for determining anti-
sheep antibody titre is described in Materials and Methods (2.2.11).
7.3.4 Effect ofrrSCF164 or anti-SCF on parasitefecundity.
The effect of the administration of anti-SCF on the fecundity ofN. brasiliensis
was determined by monitoring egg output in the faeces of the rats. In the experiments
in which rats were treated with anti-SCF or normal sheep IgG, the worm egg-output
was monitored over the latter part of the infection to determine whether depressing
the intestinal mast cell response would lead to an alteration of worm fecundity.
Animals which were treated with anti-SCF (and had reduced densities ofjejunal
MMC) had significantly lower faecal egg-counts on both days 8 and 9 than did the
normal IgG-treated controls (p < 0.03 at both time intervals; Figure 20). Over the
entire time course of the response shown in Figure 20, values for anti-SCF treated
rats were significantly lower than those in control rats by ANOVA (p < 0.001).









Figure 20 Faecal egg-output data from N. brasiliensis- in fee ted rats treated
with sheep anti-SCF.
Anti-SCF-treated (□) or normal sheep IgG-treated, control rats (O).
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7.4 Discussion
These findings provide additional evidence that SCF importantly contributes
to the MMC hyperplasia that occurs during nematode infection in rats, show that this
response can be markedly suppressed by administration of an anti-SCF antibody, and
raise interesting questions about the role of SCF and mast cells in the regulation of
parasite fecundity during N. brasiliensis infection.
To assess the importance of endogenous SCF in the intestinal MMC response
to nematode infection in normal rats a polyclonal sheep anti-rat SCF antibody was
administered to rats infected with N. brasiliensis or T. spiralis. Treatment with anti-
SCF beginning at the time of infection profoundly interfered with mast cell hyperplasia
in the jejunum and significantly diminished the systemic release of RMCP II after
infection with either N. brasiliensis or T. spiralis. These effects were most marked at
the earlier intervals of infection, probably because of the later development of
antibodies to sheep IgGs in the anti-SCF-treated rats. When anti-SCF was
administered to rats that had already undergone expansion of jejunal MMCs in
response to N. brasiliensis infection, anti-SCF treatment resulted in a significant
decrease in both intestinal RMCP II concentrations and mast cell numbers, but
produced neither a significant depression of RMCP II concentrations in the serum nor
a significant change in numbers of peripheral blood white cells.
One interpretation of these findings with anti-SCF is that endogenous SCF is
necessary for the survival of mast cell populations, including both baseline populations
of MMCs in uninfected rats (Chapter 6) and the markedly expanded MMC
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populations in nematode-infected rats. rrSCF164can maintain mouse mast cell survival
in vitro (Mekori et al 1993; Iemura et al 1994) or in vivo (Iemura el al 1994) by
suppressing apoptosis, and the abrogation of this effect by anti-SCF could account for
the current results. Of course, rrSCF164 can promote the recruitment of mast cell
precursors in vivo (Tsai et al 1991b; Zsebo et al 1990) and can favour their
development into mature mast cells (Tsai et al 1991b; Zsebo et al 1990). It can also
synergise with IL-3 to promote rat mast cell proliferation (Flaig et al 1994, Tei et al
1994) probably through up regulation of IL-3 receptors (Liu, Cutler, Mui & Krystal,
1994). These additional effects of SCF also may have been antagonised by anti-SCF
treatment, particularly when treatment was begun at the time of infection.
Rats, infected with N. brasiliensis or T. spiralis and treated with anti-SCF all
showed marked depletion of peritoneal mast cells and, in the T. spiralis-infected rats,
there is an apparent increase in the RMCP I content of the PMC, although is most
probably due to sampling error due to the low numbers of PMC recovered from this
group. The up-regulation of RMCP II expression, so marked in the earlier
experiments (Table 7, Table 8; Chapter 4), was less pronounced, but still significant,
in both N. brasiliensis and I spiralis infections where the rats were treated with
control immunoglobulins (Table 19, Table 20). RMCP II production by serosal mast
cells was significantly reduced, in both infection models, by treatment with anti-SCF
(Table 19, Table 20). This clearly indicates that SCF is a necessary component in the
up-regulation of RMCP II expression by serosal mast cells.
In T. spiralis infection of mice, treatment with an antibody directed against c-
kit, the SCF receptor, not only diminished intestinal mast cell hyperplasia but also
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reduced parasite expulsion (Grencis et al 1993). This finding supports the widely held
view that mast cells can represent an important component of host immunity to
parasite infection. Yet we found that treatment with rrSCF164, which accelerated the
development of the MMC response (chapter 5), did not diminish and actually
somewhat increased parasite fecundity during N. brcisiliensis infection. This effect
was particularly evident at day 8 of infection, the day on which rrSCF164-treated rats
had significantly more jejunal MMCs than did the control rats (chapter 5, Table 9).
Moreover, treatment with anti-SCF, which markedly suppressed the MMC
hyperplasia associated with N. brasiliensis infection, substantially (by > 50%) and
significantly (p = 0.001) diminished N. brasiliensis egg production during the later
stages of infection.
In considering these findings, it should be noted that genetically mast cell
deficient (WAV, Sl/Sf) mice or WAV rats exhibit little or no impairment in their
ability to expel a primary infection with N. brasiliensis (reviewed in Reed 1989;
Arizono el al 1993), findings which suggest that mast cells are not essential host-
protective cells against primary infection with this nematode. The current findings in
rats with a normal genotype raise the interesting possibility that mast cells (and /or
some other SCF-responsive cell type) may actually have some effects which favour
parasite fecundity during N. brasiliensis infection. Perhaps increased numbers of
intestinal MMCs, and the activation of these cells for mediator release, which can
result in increased permeability of gut blood vessels and intestinal mucosa (Scudamore
ei al 1995), promote the nutrition of the parasites. The mechanisms that might
account for the apparent decreased fecundity of N. brasiliensis in rats treated with
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anti-SCF are the subject of further studies. However, it has been shown recently that
suppression of IgE levels can decrease both the worm burden and egg production
associated with primary infection with Schistosoma mansoni in mice (Amiri, Haak-
Frendscho, Robbins, McKerrow, Stewart & Jardieu, 1994). Taken together with the
current results, these findings suggest that, in certain parasite infections, aspects of the
mast cell-and IgE-dependent immune responses that are elicited by the organisms may
have effects which are more advantageous to the parasite than to the host.
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8. STEM CELL FACTOR DEPENDENT HYPERPLASIA OF
MUCOSAL-TYPE MAST CELLS BUT NOT EOSINOPHILS
IN SCHISTOSOMA MANSONI-1NI LC I E1) RATS.
8.1 Introduction
The cellular immune response to many helminth parasites is characterised by
hyperplasia of mast cells and eosinophils both locally, at the site of infection and
systemically. Both of these cell types derive from haemopoietic progenitor lineages in
bone marrow which differentiate and proliferate under the influence of an array of
cytokines and growth factors. The mechanisms regulating mast cells through T cell-
derived cytokines and SCF have been described in detail previously (chapter 5).
IL-3, IL-5 and GM-CSF all have a role in controlling proliferation and
differentiation of eosinophil populations (reviewed by Sanderson, 1991). Additionally,
both IL-3 and IL-5 can act in synergy with SCF in vitro to give enhanced growth of
eosinophils from an eosinophil precursor cell line (Kobayashi 1993). It is clear from
this evidence, therefore that SCF has an important role to play in generating the
cellular immune response to parasites. Both mast cell and eosinophil numbers increase
substantially in the rat in response to infection with the intra-vascular parasite
Schistosoma mansoni. Mast cell numbers are elevated in both intestinal mucosa and
liver (Miller, Newlands, McKellar, Inglis, Coulson & Wilson, 1994) and there is a
significant increase in the numbers of circulating eosinophils (Phillips, Bentley,
Linette, Doughty & Capron, 1983). Rat eosinophils, which mediate worm damage in
vitro (Capron, Bazin, Joseph & Capron, 1981), may have a direct anti-parasite role.
Furthermore, mast cells, which are functionally active during the response to S.
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mansoni, as can be seen from the systemic release of the mucosal mast cell-associated
protease RMCP II (Miller el a/ 1994), may have an accessory role mediated via
anaphylactic release of a range of immune and inflammatory mediators through
membrane bound, parasite-specific, IgE (Capron, Dessaint, Capron, Joseph & Pestel,
1980). In this chapter the role of SCF in mast cell and eosinophil hyperplasia was
examined by treating S. mansoni-infected rats with a polyclonal sheep anti-rat SCF
antibody to determine whether SCF depletion altered mast cell or eosinophil numbers
or concentrations of RMCP II in liver or small intestine.
8.2 Experimental Design
Fischer F344 inbred female rats, were infected with approx. 2500 S. mansoni
cercariae via shaved abdominal skin by the ring technique (Smithers & Terry 1965).
Blood samples were taken on days 18, 21, 24, 27, and 30 after infection by tail-snip
(2.2.7). Serum was harvested and stored at -20°C. The rats were treated with 1 mg
sheep anti-SCF or normal sheep IgG on days 21, 24, 27 and 30 by intraperitoneal
injection. These procedures were carried out at the University of York by Prof. R.A.
Wilson and Dr P. Coulson.
On day 32 the rats were anaesthetised and blood samples taken as before. The
hepatic portal system was perfused to recover adult worms and samples of liver and
small intestine were collected for histology (2.3.5) and measurement of mast cell
proteases by ELISA. Rat mast cell proteases I and II were measured in serum and
tissue extracts by antibody capture ELISA (2.2.9, 2.2.10). Data are presented as mean
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± sem and were analysed by Student's two sample t-test or, for time course data by,
analysis of variance (ANOVA).
8.3 Results and Discussion
Serum concentrations of RMCP II increased in control rats from around 400
ng/ml on day 18 of infection with S. mcinsoni to 1045 ng/ml by day 32. (Figure 21);
this is in good agreement with previously reported results (Miller et al 1994). In test
rats, by day 24 of infection with S. mansoni, three days after the first injection of anti-
SCF antibody, the concentrations ofRMCP II in serum were significantly depressed
(p < 0.0002) when compared with values in the control rats treated with normal
sheep IgG. The RMCP II concentrations in the blood of anti-SCF treated rats
decreased until only 12 ng/ml were detected on day 32 of infection, over 30-fold
lower than on day 21 and 87-fold lower when compared to normal sheep IgG-treated
controls (Figure 21; Newlands, Coulson & Wilson, 1995b). Comparison of the time
course data for serum RMCP II concentrations in anti-SCF-treated and control rats
showed a highly significant difference (p < 0.0005 by ANOVA) between the two
treatments. Systemic concentrations of RMCP II in anti-SCF-treated and control rats
were reflected by both the tissue protease concentrations, and mast cell counts, in
liver and jejunum on day 32 of infection (summarised in Table 18; Newlands et al
(1995b); these values were both reduced by > 95% in each tissue. RMCP I, the
connective tissue mast cell-associated protease, was not detectable in the jejunum of
anti-SCF treated rats whilst there was a > 8-fold lower level (p < 0.001) in liver.
Similarly concentrations of RMCP II in the tissues showed > 25-fold lower values
compared with controls (Table 18). This was in sharp contrast to the numbers of
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eosinophils in both liver and small intestine, which were not significantly altered by
anti-SCF treatment when compared with control animals (Table 18). Fewer worms
were recovered by perfusion of the liver of anti-SCF-treated rats (159 ± 10.7) than
from normal sheep IgG-treated (control) rats (189 ± 15.2) although the difference did
not achieve statistical significance. This slight decrease in parasite numbers is in
keeping with the previous observation that N. brasiliensis fecundity was reduced in
anti-SCF treated rats (Chapter 7), and also that suppression of the IgE response with
anti-IgE antibodies decreased both the worm burden and egg production associated
with S. mansoni infection in mice (Amiri et a/ 1994). These data suggest that, in at
least some parasitic infections, worm survival and fecundity may be enhanced by some
aspect of the mast cell-IgE dependent immune responses.
Unaltered eosinophil numbers in the liver and jejunum of test and control rats
suggest that eosinophil recruitment in parasitic infections is not significantly
dependent on the presence of SCF or of mast cells, although SCF does synergise with
IL-3 or IL-5 in promoting growth in an eosinophil cell line in vitro (Kobayashi, 1993).
Similarly, when mice infected with N. brasiliensis were treated with antibody to IL-3,
which suppressed mast cell hyperplasia, the associated eosinophilia in peripheral blood
was undiminished (Madden el a! 1991) despite the fact that IL-3 is a recognised
eosinophil growth factor. On the other hand S. mansoni infected-mice, treated with
monoclonal antibody to IL-5 showed complete ablation of the eosinophil response to
schistosomula migrating through skin (Sher, Coffman, Hieny & Cheever, 1990)
indicating that IL-5 is the principal cytokine responsible for eosinophil production in
vivo. The above results provide additional evidence for the SCF dependency of
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parasitic infection-associated mast cell hyperplasia while demonstrating that SCF is
not a significant factor in the associated eosinophilia.
The results described in chapter 7 showed that treatment of both normal and
N. brasiliensis or T. spiralis-infected rats with polyclonal anti-SCF antibody
significantly depressed mature mast cell numbers and jejunal and serum RMCP II
concentrations, as well as parasite-associated mast cell hyperplasia (chapter 7).
Similarly, in the experiment described here, mast cell densities and serum protease
concentrations were almost completely ablated. However, in contrast with the
intestinal nematode infections, where the mast cell numbers and protease levels had
begun to increase again by as little as 6 days after the start of antibody treatment
(chapter 7), the mast cell numbers and serum RMCP II levels in S. mansoni-mfected
rats remained depressed after 11 days of treatment with anti-SCF antibodies. This lack
of any rebound response in the mast cells may simply be due to a lower level of
antibody response to sheep IgG, although that was not measured in this study. It
could also indicate that there is a different mechanism controlling mast cell hyperplasia
in schistosomiasis than in the intestinal nematode infections, not involving T cell-
derived cytokines such as IL-3. The role of IL-3 and other T cell-derived cytokines in
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ANOVA; p < 0.0005
Figure 21. RMCP II concentrations in serum of S. mansoni-infected rats treated
with anti-SCF or normal sheep IgG.
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Table 18. Tissue mast cell protease concentrations and mast cell counts on day
32 of infection
RMCPI RMCPII mast cells eosinophils
Jejunum
(anti-SCF)
o** 20.2 ±6.2*** 1.24 ±0.37*** 60.47 ± 5.44
Jejunum
(control)
0.89 + 0.128 524.0 ±35.86 49.76 ±3.15 66.35 ±3.30
Liver
(anti-SCF)
0.69 ± 0.14*** 10.5 ±2.48** 0.27 ±0.11*** 33.74 ±5.92
Liver
(control)
5.58 ± 0.62 260.0 ±73.31 7.61 ± 1.02 44.56 ±4.98
Mast cell protease concentrations expressed in pg/g wet wt. of tissue,
cell counts expressed as cells/0.2 mm2
Student's t-test, ** p < 0.01, *** p < 0.0001 comparing tissues from anti-SCF treated
with control animals.
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9. SOLUBLE STEM CELL FACTOR IS SECRETED INTO
BLOOD OF NEMATODE-INFECTED RATS.
9.1 Introduction
Infection with gastrointestinal parasites induces a substantial hyperplasia of mast
cells in the intestinal mucosa (Miller & Jarrett 1971). This hyperplasia is regulated
through at least two distinct mechanisms; by T cell-derived cytokines like IL-3, 4, 9
and 10 (Madden et al 1991; Schmitt et al 1990; Thompson-Snipes et al 1991) and by
SCF/c-kit (Chapters 5-8; Newlands et al 1995; Grencis et al 1993). The
involvement of SCF and c-kit in mast cell hyperplasia is clearly demonstrated by the
ablation of the intestinal mast cell response in parasitised rodents treated with
antibodies directed against either c-kit or SCF (Grencis et al 1993; Donaldson,
Schmitt, Huntley, Newlands & Grencis, 1996; Chapters 6-8; Newlands et al 1995).
In man soluble SCF is present in blood at concentrations of around 3 ng.mf1 as
measured by enzyme linked immunosorbent assay (ELISA) of sera from normal
individuals (Langley, Bennett, Wypych, Yancik, Liu, Westcott, Chang, Smith &
Zsebo, 1993). In patients with aplastic anaemia the range of serum SCF
concentrations is similar to that found in normal individuals (0.3 - 6.1 ng.mf1) but
those with the most severe clinical symptoms tend to have lower concentrations of
SCF, the majority being below the mean normal value of 3 .3 ng.mf1 (Wodnar-
Filipowicz, Yancik, Moser, Dalle-Carbonare, Gratwohl, Tichelli, Speck & Nissen,
1993). Thus the measurement of SCF in the blood of rats undergoing active mast cell
hyperplasia, in which SCF is known to play an important role, would be invaluable in
the study of the kinetics of the SCF response to parasitic infection. In the work
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described in this chapter a highly sensitive ELISA test was developed to measure
soluble SCF in the serum of normal or parasitised rats as well as rats which were
treated with either rrSCF164 or with polyclonal antibody to SCF. The results presented
here show that SCF can be detected in normal rat serum and that levels are
substantially up-regulated by nematode infection.
9.2 Experimental Design.
The aims of the work described in this chapter were first to develop an assay to
measure physiological concentrations of SCF in the sera of rats and secondly to study
the kinetics of the SCF response in parasitised rats.
9.2.1 Optimisation ofSCF ELISA.
The format of the ELISA was that of an antigen capture-type test. Detection
was with a biotinylated secondary antibody followed by streptavidin-HRPO
(Boehringer-Mannheim, U.K.).
The capture antibody, affinity purified polyclonal sheep anti-SCF, was coated
onto the test plates (Dynatech M129B) at the rate of 0.1, 0.5, 1.0, 5.0 or 10.0 pg.ml"1
in 0.1 M carbonate buffer pH 9.6.
The optimum dilution of the secondary antibody, biotinylated, sheep anti-SCF
for the standard concentration range, was determined by titration of the 1 mg.mf1
stock at 1/125, 1/250, 1/500 and 1/1000. The final steps in the titration ofboth
capture and secondary antibodies was the addition of streptavidin-HRPO,
standardised at a dilution of 1/500 in accordance with the manufacturer's
recommendation, and utilising orthophenylenediamine (Sigma, Poole, UK) at a
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concentration of 0.4 mg.mf1 and H2C>2 (60 pi/10 ml) as substrate. Plates were read at
492 nm on a Titertek MC ELISA plate reader (Titertek-Flow, Paisley, UK).
Samples and standards were prepared by dilution with 5% w/v bovine serum albumin
(Sigma) in phosphate buffered saline (BSA/PBS). Serum samples were diluted 1:20
with BSA/PBS before assay. Standard curves were prepared which covered the range
0.5 pg to 20 ng.ml"1. In order to determine whether the assay would detect
physiological concentrations of SCF in serum, normal rat serum was spiked with
rrSCF164 at a concentration of 1 pg.mf1. A number of dilutions of this spiked serum,
in the range 5 to 750 pg.mf1 were prepared in BSA/PBS for assay.
The different coating antibody densities gave a concentration dependent increase in
absorbance at 492 nm up to 1.0 pg.mf1, with a standard curve which covered the
range 5 to 750 pg.mf1 (Figure 22a), and did not increase significantly at higher
concentrations. Further optimisation of the test was therefore based on plates coated
at 1.0 pg.mf1.
Dilutions of biotinylated sheep anti-SCF at 1/125, 1/250 and 1/500 gave very similar
results, with somewhat lower absorbances for the 1/1000 dilution (Figure 22b). A
1/500 dilution of the biotinylated, sheep anti-SCF, secondary antibody was therefore




Figure 22. Optimisation of the SCF EL1SA.
The graphs show the effects on A492 of varying (A) the capture antibody
concentration (0.1 pg.mf1 0.5 pg.ml1 1.0 pg.ml 1 .A: 5.0 pg.mf1 ,0 or
10.0 pgrnil1 ,|) or (B) the concentration of the streptavidin-HRPO conjugate
(1:125, ■; 1:250, #; 1:500,A or 1:1000, ▼).
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9.2.2 Experiment 1.
To determine the effects of administration of exogenous SCF on circulating
soluble SCF concentrations, recombinant rat stem cell factor164 , modified by the
covalent attachment of polyethylene glycol (Tsai et al 1991a), was administered
intravenously to anaesthetised rats for 14 consecutive days in 1 ml physiological
saline at 25pg/kg of body weight/day, control rats were sham treated with
physiological saline alone. The rats were killed 24 h after the final injection. The
protocols were the same as those described previously (Tsai et al 1991a; Newlands et
al 1995; Chapter 5) and all blood samples were derived from these same sets of
experiments. The mast cell responses have therefore been described previously (Tsai
et al 1991a; Newlands et al 1995; chapter 5).
The blood volume of rats weighing approximately 250g has been estimated at
50 ml/kg of bodyweight and the plasma volume at 30 ml/kg of bodyweight (Schalm et
al 1975); thus the SCF dose/ml/day can be calculated from the following
Equation 10
Dose (fj.g/kg bodyweight) x bodyweight (kg) _ 25 x 0.25 _ 0.833 pg.mr1
Serum volume (ml/kg bodyweight) x bodyweight (kg) 30 x 0.25 of plasma
9.2.3 Experiment 2.
To determine the effects of anti-SCF antibody treatment on circulating SCF
concentrations rats were inoculated with 1 mg sheep anti-rrSCF164 or normal sheep
IgG in 1 ml phosphate buffered saline (PBS) by intraperitoneal injection. Normal rats
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were treated daily for each of 4 consecutive days, as described (Newlands el al 1995;
Chapter 6), to determine the effects on baseline serum SCF concentrations. Rats
infected with N. brcisiliensis were treated with anti-rrSCF164 on days 3, 5, 7, 10 and
12 of infection. For rats infected with T. spiralis, treatment commenced on day 0 and
continued on days 3, 5, 7 and 10. Normal rats were killed 24 hours, and parasitised
rats 48 hours, after the final inoculation (Newlands et al 1995; Chapters 6 and 7).
Blood was collected, allowed to clot at room temperature and the serum subsequently
harvested and stored at -20°C before assay.
9.2.4 Data presentation and analysis
Unless otherwise specified, all data are presented as the mean ± s.e.m. The 2-
tailed Student's t-test was used to analyse data that were normally distributed,
whereas the Mann-Whitney U test was used as the non-parametric test. The time
course of responses in different groups of rats were examined for statistical
significance by using analysis of variance (ANOVA). p < 0.05 was taken to indicate a
significant difference.
9.3 Results
Standard curves, diluted with BSA/PBS, showed that the assay had a functional
range of 1 pg.mf1 to 10 ng.mf1 (Figure 23a and Figure 23b). Assay of normal rat
serum spiked with rrSCF164 detected concentrations of SCF which, when compared
with the values obtained for the standard curve, diluted with BSA/PBS, gave a highly
significant correlation (R2= 0.99; Figure 23c).
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Figure 23. SCF ELISA standard curves.
Standard curves were prepared by diluting rrSCF164 with PBS/BSA to
cover the ranges (A) 0.5 to 1000 pg.ml1 and (B) 125 pg.ml"1 to 20 ng.ml1. (C)
Standard curve prepared from normal rat serum spiked with rrSCF164 to a
concentration of 1.0 pg.ml1 and subsequently diluted with PBS/BSA to cover
the range 50 pg.ml1 to 10 ng.ml"1 and compared with standards diluted with
PBS/BSA alone. The A492 values are shown as closed squares with error bars
and the fitted curve for the standards prepared in PBS/BSA is shown as a line
for comparison.
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9.3.1 SCF concentrations in the blood of rats given rrSCF164 by daily intravenous
injection.
The estimated daily dose of SCF/ml of serum is 833 ng.ml"1, calculated from
Equation 10. Serum samples, collected 24 hours after the final injection of rrSCF164,
from normal rats which had been treated by daily intravenous injection (n = 8) had 9.0
±0.63 ng.ml"1 of SCF and therefore the SCF content of serum had decreased to
around 1% of the daily dose. Control rats, which had been given vehicle (PBS) only,
had 140 ± 140 pg.ml"1 (n = 8).
9.3.2 Soluble SCF concentrations in the blood ofnormal andparasitised rats.
The concentrations of SCF detected in the serum of normal rats, before
infection with N. brasiliensis (n = 10) was in the range 254 - 875 pg.mf1 with a mean
of 578 ± 65 pg.mf1 (Figure 24a). After infection there was a slight, but significant,
decrease in soluble SCF at day 6 compared with pre-infection values (p < 0.05),
followed by a steady increase to 1800 pg.ml"1 at day 14, a three-fold increase
compared with pre-infection controls (Figure 24a). Over the course of the infection
the increase in soluble SCF was highly significant by ANOVA (p<0.0001).
Rats in the group infected with T. spiralis (n = 10) had 337 ± 76 pg.mf1 of serum
before infection and there was a significant increase (p < 0.005) on day 6 compared
with pre-infection values (Figure 24a). The SCF concentration continued to rise
sharply to 3831 pg.ml"1 by day 10 of infection, an increase of 11 fold compared with
pre-infection controls, and then declined to 1561 pg.mf1 by day 12 (Figure 24a).
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These changes were significant by ANOVA (p<0.05) over the course of infection with
T. spiralis.
9.3.3 The effects ofanti-SCF treatment on concentrations ofSCF in serum from
normal and parasitised rats.
The concentration of soluble SCF in serum from normal Wistar rats was 471 ±
57 pg.ml"1 (n = 18) at the start of the experiment. After 4 days treatment with
polyclonal sheep anti-SCF (n = 5) the concentrations of SCF in serum were below the
level of detection for the assay (p < 0.001) compared with pre-infection controls.
Following infection with N. brasiliensis, anti-SCF-treated rats showed a three-fold
decrease in serum SCF compared with pre-infection values (Figure 24b; p = 0.001).
This was followed by a sharp increase, to 5829 pg.mf1, >10 fold more than pre-
infection values at day 10, before falling back to 2400 pg.mf1 by day 14 (Figure 24b).
Over the course of the infection the changes in SCF concentration were highly
significant by ANOVA (p = 0.002). Anti-SCF-treated rats which were infected with
T. spiralis did not show the initial decrease in serum SCF at day 6 which was seen in
N. Z>ras///'e/7s/s-infected animals (Figure 24b). By day 10 SCF concentrations were
increased by 4 fold compared with pre-infection values (Figure 24b) and, as in N.
/ira.sv7/c/?.s7'.s-infected animals, the concentration fell again by day 12 (Figure 24b).
These changes in SCF concentrations were also highly significant by ANOVA (p <
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Figure 24. Concentration of SCF in the sera of N. brasiliensis or T. spiralis-
infected rats treated with (A) control lg or (B) anti-SCF antibodies.
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9.4 Discussion
SCF is expressed in both membrane-bound and soluble forms (Anderson et al
1990) and in man the concentration of the soluble form has been measured at 3.3 ng.
mf1 by ELISA in the sera of normal individuals (Langley et al 1993). In the results
described here the concentrations of soluble SCF detected in the sera of normal
Wistar rats was 578 pg.mf1, which is almost six-fold less than that detected in man.
The ELISA test described here is highly sensitive, detecting SCF in pg
concentrations in serum. The assay gives highly reproducible results over
concentration ranges from 5 pg.mf1 to 20 ng.mf1 with correlation coefficients of 0.96
or greater for the relationship between SCF concentration and absorbance (Figure
23).
Measurement of SCF in the blood of rats which were given rrSCF164 by
intravenous injection revealed that only 1% of the daily dose could be detected 24
hours after the final injection. It is demonstrated here that rrSCF164 added to serum
can be fully detected by the ELISA (Figure 23c) and therefore the decrease in
circulating levels of SCF is probably due to its removal from the circulation. The
receptor for SCF, encoded for by the c-kit proto-oncogene is a trans-membrane
tyrosine kinase (Matsui, Zsebo & Hogan, 1990) which will bind free SCF. The mast
cell proliferation which takes place both locally, at the site of injection, and
systemically following treatment with rrSCF164 (Tsai et a! 1991a) suggests that the
injected cytokine is binding to this receptor in vivo. In man there is also a soluble form
of c-kit receptor, present in 100 fold excess over reported concentrations of SCF; 324
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ng.mf1 kit receptor (Wypych, Bennett, Schwartz, Clogston, Broudy, Bartley, Parker
& Langley, 1995) to 3.3 ng.ml"1 for SCF (Langley et al 1993) which may be
responsible for the complexing and subsequent removal of excess free SCF.
In chapter 7 it was demonstrated that rats infected with N. brasiliensis or I spiralis,
showed the expected pattern of intestinal mast cell hyperplasia associated with
gastrointestinal parasitism (Newlands el al 1995). In addition, similarly infected rats,
which were treated with polyclonal sheep anti-SCF antibodies, show a delay in mast
cell hyperplasia with no mast cells detected at day 10 of infection with either parasite,
followed by a sharp increase in mast cell numbers (chapter 7; Newlands et al 1995).
In this chapter the SCF concentrations in the sera of these same rats was examined
and it is clear that there is a significant increase in the concentrations of soluble SCF
in blood after day 10 of infection with both N. brasiliensis or T. spiralis infections
which coincides with the observed intestinal mast cell hyperplasia in these animals
(chapter 7; Newlands et al 1995).
In rats treated with anti-SCF antibodies the intestinal mast cell hyperplasia seen
in both N. brasiliensis and 71 spiralis infections was almost completely suppressed at
day 10 of infection (Newlands et al 1995). In contrast, whilst there were almost no
mast cells detected in the intestinal mucosa of rats at day 10 of infection with either
parasite (Newlands et al 1995), there are significantly increased concentrations of
SCF (Figure 24b). Although the comparisons must be treated with some caution
because they are from separate experiments, the increase in SCF at day 10 in anti-
SCF-treated rats appears to be greater in N. brasiliensis-\nfected than 71 spiralis-
infected rats (Figure 24b). This may be because the mast cell response to 71 spiralis
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is less dependent on SCF than that directed against N. brasiliensis. The response to
T. spiralis does require some SCF in the initial stages since the hyperplasia is blocked
with antibody (Newlands et al 1995; Donaldson et al 1996) but the later stages may
be more dependent on IL-3 and IL-4 since treatment with antibodies to these
cytokines also blocks mast cell hyperplasia in mice (Madden et aI 1991). It is,
perhaps, surprising that there is an increase in detectable SCF after treatment with
anti-SCF antibodies and several possible explanations suggest themselves. It may be
that because mucosal mast cell hyperplasia has been blocked there are simply fewer
receptor sites around to which the SCF can bind. An alternative explanation may be
that SCF secretion is regulated through a feed-back loop where a decrease in the
concentrations of circulating SCF, for example by being complexed to antibody,
stimulates up-regulation of expression.
In summary the assay described here allows the kinetics of expression of the soluble
factor to be followed in detail and since the soluble and membrane-bound forms of
SCF are encoded for by the same gene, this may reflect the total expression of this
potent haemopoietic growth factor.
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10. GENERAL DISCUSSION.
Mast cell hyperplasia is a prominent feature of the host's immune response to
gastrointestinal helminth parasites and, is associated with increased concentrations of
total and of parasite-specific IgE (Jarrett & Miller 1981). The activation of mast cells
through IgE-mediated immediate hypersensitivity reactions may be important in
protection against certain nematode parasites. Mast cells are a source of many potent
mediators of immune and inflammatory processes. In this thesis the glycoforms and
activity of one of these mediators, the secretory granule-associated chymase, MMCP-
1, in the mouse are examined. This study was followed with an examination of the
mechanisms regulating both mast cell protease expression and the survival, growth
and proliferation of mast cells in normal and parasitised animals.
The studies of murine chymases revealed that not only is there a diversity of
proteases synthesised by murine mast cells (Newlands et al 1987; Reynolds et al
1990; McNeil et a! 1992) but also that the first identified of these, MMCP-1
(Newlands el al 1987) is synthesised in at least 5 different glycoforms (chapter 3).
These glycoforms were identified as variants of MMCP-1 by a variety of techniques,
including N-terminal sequencing, and were shown to have different enzymic
properties against low molecular weight substrates (chapter 4). The major questions
raised by these findings are:
1) Do the different glycoforms represent genuine variants of the protease or do
they simply represent a number of intermediates in the glycosylation process? This is
probably best addressed by analysis of the structure of the carbohydrate moieties of
each of the variants. This would provide valuable information on whether there is an
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identifiable series of intermediates which would fit into a known series of steps in the
processing of carbohydrate side chains.
2) Are the different glycoform synthesised by different sub-sets of the MMC
population depending on their anatomical distribution or indeed by mast cells at
different stages of maturation? To identify whether there is a differential distribution
of the glycoforms it would be necessary to develop a panel of monoclonal antibodies
which were specific for the carbohydrate moieties, since the variants all share the
same core polypeptide. This may prove difficult as carbohydrate epitopes are
notoriously heterogeneous and often shared by many proteins. Alternatively it may be
possible to characterise the carbohydrates through the use of a panel of lectins.
3) If the glycoforms do represent variants of the mature enzyme, what is their
function in vivo and what are their native substrates? RMCP II, the rat MMC protease
increases vascular and epithelial permeability (Scudamore et al 1995) either by
proteolysis of epithelial tight junction proteins between cells or through proteolysis of
thrombin-type protease-activated receptors. It would be very interesting to compare
the enzymic properties of the MMCP-1 variants using tight junction components such
as occludin as substrates.
The regulation of mast cell protease expression has been investigated in vitro in
both BMMC, generated from bone marrow and in CTMC derived from the peritoneal
cavity. When bone marrow from rats or mice is cultured in the presence of IL-3 or T
cell conditioned medium mast cells are produced which, in the rat, closely resemble
MMC in terms of morphology, staining properties etc. and more specifically that they
express abundant RMCP II (Haig et aI 1988). Cultured murine BMMC are, however
heterogeneous in terms of their protease content with protease phenotypes resembling
both MMC and CTMC (Newlands el' al 1991). Indeed when murine BMMC are
grown in IL-3 alone they do not express MMCP-1 unless they are concomitantly or
sequentially exposed to IL-10 (Ghildyal el al 1992). By contrast, rat CTMC are IL-3-
independent and do not proliferate significantly when cultured with this cytokine alone
(Haig et a/ 1994). However, when they are cultured in the presence of SCF, CTMC
proliferate rapidly (Tsai el al 1991b; Haig et al 1994). On addition of IL-3 to the
culture medium the two factors work in synergy to increase the rate of mast cell
growth (Haig et al 1994). An additional effect of this treatment is that it induces
CTMC to begin expressing RMCP II (Haig et al 1994). All these data are derived
from in vitro culture experiments and little is known about the in vivo regulatory
mechanisms. The effects of exogenous cytokines on mast cell populations in vivo
were therefore examined.
Intravenous or intraperitoneal treatment of rats with rrSCF164, which has high
biological activity (Galli et al 1994), confirmed the in vitro finding that SCF provides
a potent proliferative signal for CTMC but that it suppressed protease expression
(chapter 5). It is interesting to note that while intravenous SCF did not promote
RMCP II expression in CTMC the direct delivery of SCF into the peritoneal cavity
did (chapter 5), suggesting that the local concentration of SCF may be important to
generate the synergistic effect with the background concentrations of IL-3. This
could be readily tested in an in vivo experiment where groups of rats were treated
with a range of different concentrations of SCF.
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LNCM, a rich source of IL-3, which is a potent, in vitro growth factor for
BMMC, did not stimulate an increase in the numbers of CTMC but did induce them
to start expressing RMCP II (chapter 5), an effect which was increased by the
addition of SCF. Thus it is clear that both SCF and IL-3 are closely involved in the in
vivo regulation of mast cell chymases in the rat.
In order to further investigate the role of SCF in the regulation of mast cell
populations in the rat a sheep polyclonal antibody to rrSCF164 was developed. This
reagent was initially used in vivo to block the effects of SCF on mast cell populations
in normal rats (chapter 6). The results of this treatment were that there was a 50%
depletion of CTMC from the peritoneal cavity indicating that either a sub-set of
peritoneal cavity CTMC are dependent on SCF for their in vivo survival or that the
dosage rate for the antibody was inadequate (chapter 6). The former explanation
seems more likely since, in the same rats, this treatment results in complete ablation of
MMC from the small intestinal mucosa (chapter 6). This is probably as a result of the
mast cells undergoing apoptosis in the absence of SCF (Iemura et al 1994). There
was also a moderate depletion of leukocytes from blood. This appeared to be a
generalised effect since the relative proportions of white blood cells, neutrophils,
lymphocytes, monocytes etc. remained constant in both anti-SCF treated and control
rats, (chapter 6). To more fully investigate the effects of this type of treatment on the
haemopoietic system, it would be necessary to undertake in-depth studies of bone
marrow stem cells, which also bear the c-kit receptor for SCF.
The almost total ablation of MMC in normal intestine was somewhat
unexpected and showed that SCF has a more important role in maintaining the
viability of MMC than had been formerly thought. To extend the findings that SCF is
essential for MMC survival, its role in mast cell proliferation was examined in
parasitised rats which undergo substantial mast cell hyperplasia as part of the immune
response to the parasites. Rats infected with N. brasiliensis or T. spiralis were
treated with anti-SCF antibodies throughout the course of infection and in both
experiments the expected MMC hyperplasia was significantly delayed but not
completely abrogated since both mast cell numbers and RMCP II concentrations in
blood had reached near normal levels by the end of the experiments (chapter 7).
Interestingly, even when antibody treatment was not started until day 10 of infection,
by which time the MMC hyperplasia was well established, there was still a significant
depletion in mast cell numbers when compared with controls (chapter 7). This
demonstrates that even when there is a predominantly T cell-driven hyperplasia
(athymic 'nude' mice do not develop MMC hyperplasia [Reed, 1985]) these mast cells
are, at least in part, SCF dependent.
The development of a mast cell hyperplasia in parasitised rats, treated with
polyclonal sheep anti-SCF antibodies (chapter 7) may have several causes. It is clear
that the rats used in these experiments rapidly developed an antibody response to the
sheep immunoglobulin (chapter 7) which would, presumably, reduce the efficacy of
the treatment and thus allow the SCF to fulfil its function. On the other hand, in rats
treated with anti-SCF antibodies there is at least a two-fold increase in the
concentrations of circulating, soluble SCF when compared with controls treated with
normal sheep IgG (chapter 9). It seems likely, therefore, that there is a regulatory
feed-back mechanism which up-regulates SCF production in response to low
concentrations of soluble SCF in blood. SCF is expressed in both soluble and
membrane-bound forms (Anderson et al 1990) and it is therefore difficult to estimate
the contribution of the membrane-bound product to mast cell hyperplasia. Assaying
the soluble product in blood by ELISA may not reflect the level of up-regulation of
the membrane-bound form since production of soluble SCF is dependent on release of
the extracellular domain by proteolytic processing (Anderson et al 1990). This could
be addressed by an immuno-histochemical study aimed at identifying which cells
express surface SCF and perhaps obtaining a semi-quantitative measurement of
membrane-bound SCF by image analysis. There may also be a strain-dependent
component to the recovery of the mast cell response since F344 rats, infected with S.
mansoni showed a complete ablation of intestinal mast cells following anti-SCF
treatment and did not recover by the end of the experiment 12 days later (chapter 8).
It is also interesting to note that, in the rats which had their MMC hyperplasia
suppressed by anti-SCF treatment, the female worms had a lower level of fecundity
compared with those in control rats (chapter 7). This is the opposite effect to that
which might have been expected if the mast cell response was a significant part of the
protective immune response against the parasite. This is similar to the effects found
when mice, infected with S. mansoni, were treated with anti-IgE antibodies (Amiri et
al 1994). Mice treated in this way had fewer worms and there were fewer eggs
produced per worm (Amiri et aI 1994). This suggests that the parasites in these
infection models have evolved to cope with the hostile environment provided by their
host and that, in fact, the activation of mast cells through parasite-specific IgE may
facilitate their survival.
In conclusion, therefore the mast cell response may, under certain
circumstances, favour parasite survival and under others promote worm expulsion.
Based on the recent studies by Scudamore et al (1995) the soluble chymases RMCP
II and MMCP-1 may promote epithelial permeability and this in turn will facilitate
translocation of plasma proteins into the gut lumen. Such a mechanism may initially
prove favourable to lumen-dwelling parasites like N. brasiliensis but as parasite-
specific antibodies become more abundant the mast cell-mediated leak lesion may
promote a less favourable environment for worm survival.
Since it is increasingly recognised that mast cell proteases can regulate cell
proliferation and production of cytokines like IL-8, probably via thrombin-type
protease-activated receptors (Cairns & Walls, 1996), the abundance, specificity and
function of mast cell chymases and tryptases and their different glycoforms will be of
increasing interest.
In this thesis and in ongoing work with my collaborators it is clear that chymase
expression is modulated by cytokines and that a better understanding of the
mechanisms regulating the tissue-specific expression of the soluble MMC chymases
MMCP-1 and RMCP II and their functions at mucosal surfaces may provide
important insights into the function of MMC.
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12. APPENDIX.
12.1 Anti-stem cell factor treatment: Effects 011 peritoneal mast cell populations
in parasitised rats.
These are the results, from the experiments described in chapter 7, of the effects
of anti-SCF treatment on peritoneal mast cell populations in N. brasiliensis or T.
spiralis-infected rats.
12.1,1,1 Effects in N. brasiliensis-'mkcted rats.
Infection with N. brasiliensis increased the total number of cells recovered by
peritoneal lavage from control rats treated with normal sheep immunoglobulins, at
days 6 and 10 of infection, compared with baseline values (Table 10, chapter 6; Table
19). There was, however, no significant difference between infected rats treated with
control IgG or anti-SCF antibodies (Table 19). The number of mast cells recovered by
lavage from the anti-SCF-treated rats, over the course of infection was significantly
decreased compared with controls (p = 0.003 by ANOVA; Table 19) but the RMCP I
content of these cells was unaltered except for a slight decrease in the controls at day
6 compared with baseline values reported in chapter 6 (p < 0.05; Table 19, Table 10).
In this experiment, infection with N. brasi/iensis was accompanied by a slight
increase in mast cell RMCP II content of > 4-fold over baseline values. This was in
sharp contrast with the previous experiment where N. brasiliensis infection caused a
340-fold increase in RMCP II (Table 19, Table 8). However, even this relatively slight
increase in RMCP II content was completely abolished by treatment with anti-SCF (p
= 0.026, Table 19). The relatively low RMCP II levels in the controls was reflected in
the percentage of mast cells which stained for the presence of RMCP II by
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immunofluorescence. The fluorescence was maximal at day 10 of infection when
5.8% of the detected mast cells stained RMCP II+ (Table 19). This immuno¬






































































































































































































































































































12.1.1.2 Effects in T. spiralis-infected rats.
The total number of cells recovered by lavage from the control rats, which were
infected with T. spiralis and treated with normal sheep immunoglobulins, was
increased compared with baseline levels (Table 20, Table 10). This increased cellularity
was significantly decreased in the anti-SCF-treated group compared with controls (p <
0.0005 by ANOVA; Table 20). In this experiment infection with T. spiralis had no
effect on serosal mast cell numbers in the control rats when compared with baseline
values (Table 20, Table 10) whilst the rats treated with anti-SCF showed a marked
depletion of mast cells, over the course of infection, compared with controls (p <
0.0005 by ANOVA, Table 20). The mean mast cell RMCP I content was not
significantly altered by infection and treatment with control IgG whereas treatment
with anti-SCF increased the levels of RMCP I substantially (p = 0.008, Table 20).
Infection with T. spiralis, like N. brasiliensis, stimulated synthesis of RMCP II in the
peritoneal mast cell population in both the control and anti-SCF-treated groups
although there was less protease detected in the lavage obtained from the anti-SCF-
treated group (p = 0.018, Table 20).
12.2 Discussion
Rats, infected with N. brasiliensis or T. spiralis and treated with anti-SCF both
showed marked depletion of peritoneal mast cells and, in the T. spiralis-infected rats,
the mean RMCP I content increased substantially. The increased content of RMCP I
may be caused by the removal of down-regulating SCF by antibody or by some aspect
of the potent T cell response generated against T. spiralis infection. The up-regulation
of RMCP II expression, so marked in the earlier experiments (Table 7, Table 8;
Chapter 5), was less pronounced, but still significant, in both N. brasiliensis and I
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spiralis infections where the rats were treated with control immunoglobulins (Table
19, Table 20). RMCP II production by serosal mast cells was significantly reduced, in
both infection models, by treatment with anti-SCF (Table 19, Table 20). This clearly
indicates that SCF is a necessary component in the up-regulation ofRMCP II
expression by serosal mast cells.
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Biochemical and immunoiogicai characterization of multiple glycoforms of
mouse mast ceil protease 1: comparison with an isolated murine serosal
mast cell protease (MMCP-4)
George F. J. NEWLANDS,*J David P. KNOX,* Steven R. PIRIE-SHEPHERD* and Hugh R. P. MILLERt
'Moredun Research Institute, 408 Gilmerton Road, Edinburgh EH17 7JH,
and tDepartment of Veterinary Clinical Studies, Edinburgh University Veterinary Field Station, Easter Bush, near Roslin, Midlothian EH25 9RF, U.K.
Five highly soluble, chymotrypsin-like, neutral serine proteases,
with molecular masses in the range 30-33 kDa, were isolated
from Trichinella spiralis-infected mouse small intestine. These
enzymes were closely related antigenically on Western blotting
and by Ouchterlony double diffusion using a polyclonal, cross-
absorbed, sheep antibody raised against mouse mast cell
protease-1 (MMCP-1), and, on the basis of N-terminal amino
acid sequence analysis, were identified as variant forms of
MMCP-1. Substrate and inhibitor analysis confirmed that the
five variants (MMCP-1 A-E) had similar characteristics, al¬
though highly significant (P = 0.025 to P < 0.0001) variations in
Km and kcM were detected. Against human aq-proteinase inhibitor
the Kt for MMCP-1 C (45 pM) was significantly (P < 0.0001)
greater than those for the other proteases (0.76-2.2 pM). The
differences in electrophoretic mobility are probably a result of
variable glycosylation, since removal of N-linked carbohydrate
produced a polypeptide of approx. 28 kDa in each case which
was, like the native enzyme, immunoreactive on Western blotting.
A much less soluble 28 kDa enzyme was isolated from serosal
mast cells and identified as MMCP-4 by N-terminal amino acid
sequencing. Like MMCP-1 it has chymotrypsin-like substrate
specificities with activity at neutral pH. However, it was anti¬
genically distinct from MMCP-1 and, using sheep anti-MMCP-
1, was not detected on Western blotting or by Ouchterlony
double diffusion, e.l.i.s.a. or immunohistochemistry. This last
technique established that the MMCP-1 variants were uniquely
present in enteric mast cells, thereby providing a highly selective
means of distinguishing the mucosal and connective tissue mast
cell subsets in the mouse.
INTRODUCTION
Neutral serine proteases have been identified as major secretory
granule components in the mast cells of several species, including
the mouse (Du Buske et al., 1984; Newlands et al., 1987), rat
(LagunoffandPritzl, 1976; Woodbury et ah, 1978), dog (Caughey
et ah, 1987; Vanderslice et ah, 1990) and man (Schwartz et ah,
1981; Schechter et ah, 1986). The distinctive, apparently tissue-
specific, distribution of mast cell proteases in man and rodents
suggests that different mast cell populations may respond ac¬
cording to the type of protease secreted.
Rat connective tissue mast cells (CTMC), typified by those
found at serosal surfaces, contain the chymotrypsin-like enzyme
rat mast cell protease I (RMCP I) (Lagunoff and Pritzl, 1976),
while mucosal mast cells (MMC), found predominantly in the
mucosa of the gastrointestinal tract, contain the similar, but
antigenically distinct and more soluble, enzyme, RMCP II
(Woodbury et ah, 1978). Quantification of the distribution and
of the systemic secretion of RMCP II during intestinal immuno¬
logical reactions have been facilitated by the development of
highly sensitive e.l.i.s.a.s (reviewed in Miller et ah, 1990), and it
is clear from these studies that RMCP II serves a very different
function from that of RMCP I.
Mouse mast cell protease (MMCP-1), isolated from the
intestinal mucosa of mice infected with the parasite Trichinella
spiralis, shares 74 % amino acid sequence identity with RMCP II
and also has a very similar tissue distribution and biochemical
properties (Newlands et ah, 1987; Miller et ah, 1988; Le Trong
et ah, 1989; Huntley et ah, 1990a). However, the protease
content of murine mast cells is apparently more complex than
that of the rat. Murine bone marrow-derived mast cells (BMMC),
often regarded as in vitro analogues of MMC (Sredni et ah,
1983), contain four mast cell proteases in the molecular mass
range 28-33 kDa, including MMCP-1 as determined by Western
blotting and e.l.i.s.a. (Newlands et ah, 1991). Four esterases of
similar or identical molecular masses which bind the specific
serine protease inhibitor [:!H]di-isopropylfluorophosphate (DFP)
have also been found in BMMC (Du Buske et ah, 1984). Five
proteases have been identified in CTMC and/or virus-
immortalized mast cell lines on the basis of N-terminal amino
acid sequences and molecular masses, and designated MMCP-
2-MMCP-6 (Serafin et ah, 1990; Reynolds et ah, 1990). All but
one (MMCP-3) of these proteases have been cloned and se¬
quenced. MMCP-1 is expressed only in MMC and MMCP-2 is
expressed in intestinal mucosa and Kirsten sarcoma virus-
immortalized mast cells (KiSV-MC) (Serafin et ah, 1991).
MMCP-4 is transcribed in intestinal mucosa, CTMC and KiSV-
MC (Serafin et ah, 1991), and MMCP-5 in CTMC and KiSV-
MC (Huang et ah, 1991; McNeil et ah, 1991). MMCP-6, identified
as a tryptase by its predicted amino acid sequence, appears to be
exclusive to CTMC and KiSV-MC (Reynolds et ah, 1991).
The purpose of the present study was to define more fully the
Abbreviations used: a,-PI, a,-proteinase inhibitor; BMMC, bone marrow-derived mast cells; Cbz-L-Tyr-4NPE, carboxybenzoyl-L-tyrosine-4-
nitrophenyl ester; CTMC, connective tissue mast cells; DFP, di-isopropylfluorophosphate; FITC, fluorescein isothiocyanate; HBSS, Hanks balanced salt
solution; HRP, horseradish peroxidase; KiSV-MC, Kirsten sarcoma virus-immortalized mast cells; MMC, mucosal mast cells; MSMCP, mouse serosal
mast cell protease; MMCP, mouse mast cell protease; PMSF, phenylmethanesulphonyl fluoride; RMCP, rat mast cell protease; Succ-Ala-Ala-Pro-Phe-
4NA, succinyl-alanine-alanine-proline-phenylalanine-4-nitroanalide; t-PA, tissue plasminogen activator.
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MMCP-l-like proteases present in Trichinella-'mkcted mouse
intestine (Miller et al., 1990) and to compare their enzymic and
antigenic properties with those of a novel, highly insoluble
protease isolated from murine serosal mast cells.
MATERIALS AND METHODS
Male and female NIH mice, 8-10 weeks old, bred and maintained
under conventional conditions at the Department of Zoology,
University of Nottingham, U.K., were infected with 300 T.
spiralis muscle larvae as described previously (Wakelin and
Lloyd, 1976). Female Balb/c mice, 6 weeks old, were infected
with 300 Nippostrongylus brasiliensis 13 by subcutaneous injection.
The mice were killed by cervical dislocation 10 days after
infection. The small intestine of each mouse was removed and
the lumen flushed through with Hanks balanced salt solution
(HBSS) to remove digesta before storage at —20 °C or fixation
in Carnoy's fluid and subsequent processing to paraffin wax for
immunohistochemistry as described previously (Newlands et al.,
1990). Porton mice, 6 months old, bred and reared at Moredun
Research Institute, were used for isolation of murine serosal
mast cell protease (MSMCP).
isolation of enzymes
Murine intestinal mast cell proteases were isolated by a modifi¬
cation of the previously published method (Newlands et al.,
1987). Briefly, after thawing, 10 g of small intestine was chopped
finely with scissors and homogenized in 20 mM Tris/HCl, pH 7.5
(3 ml/g) with a Polytron homogenizer (Northern Media Supplies
Ltd., North Cave, North Humberside, U.K.). The homogenate
was centrifuged at 5000 g for 5 min and the resulting supernatant
was centrifuged at 50000 g for 15 min. The final supernatant was
applied to a 16 mm x 65 mm CM-Sepharose cation-exchange
column (Pharmacia, Milton Keynes, Bucks., U.K.) equilibrated
with 20 mM Tris/HCl, pH 7.5. Bound proteins were eluted with
a 0-1.0 M NaCl gradient over 90 ml. Fractions (5 ml) were
collected and screened for chymase activity against the synthetic
substrate carboxybenzoyl-L-tyrosine 4-nitrophenyl ester (Cbz-L-
Tyr-4NPE) (Sigma) as described previously (Knox et al., 1986).
Those fractions which contained enzyme activity were pooled
and applied to a 16 mm x 160 mm column of Sephadex G25
(Pharmacia) in order to rapidly desalt and exchange the buffer
for 50 mM Mes (Sigma), pH 6.0. The desalted material was
applied to a Mono-S cation-exchange column (Pharmacia)
equilibrated with 50 mM Mes, pH 6.0, and eluted with a
50-150 mM NaCl gradient over 20 ml. Individual peaks were
collected and those with activity against Cbz-L-Tyr-4NPE were
diluted 5-fold with 50 mM Mes, pH 6.0, re-applied to Mono-S
and again eluted with a 50-150 mM NaCl gradient.
Analysis of MSMCP
Mice were killed by cervical dislocation following anaesthesia
with Halothane (May and Baker) and cells were recovered from
the peritoneal cavity by lavage with 5 ml of HBSS containing
0.1 % (w/v) gelatin (Hanks/gelatin). Cells were sedimented by
centrifugation (400 £ for 10 min), washed once with Hanks/
gelatin and resuspended in 1 ml of Hanks/gelatin. Mast cell
numbers were evaluated using a haemocytometer after staining
with 1 % (w/v) Methylene Blue in 50% (v/v) propylene glycol.
The cell suspension was again sedimented by centrifugation; the
supernatant fluid was discarded and the cell pellet was stored at
-20 °C.
A mast cell granule preparation was prepared by the method
of Lagunoff and Pritzl (1976). Briefly, a thawed cell pellet was
resuspended in 1 ml of distilled water and the cells were fully
disrupted by sonication (MSE Sonicator) at 16 pm amplitude for
3x 10 s with a 3 mm diameter probe. Granules were isolated
from the lysate by a differential centrifugation technique, first at
200 g to remove nuclei and larger cell debris followed by
centrifugation at 50000 £ for 15 min to sediment the mast cell
granules. The granule pellet was washed twice with PBS and
finally solubilized in 1 ml of 2 M NaCl. The pellet extract was
further centrifuged at 8000 g for 2 min in an Eppendorf
bench-top centrifuge and the supernatant fluid was applied
to a Sephacryl S-200 (Pharmacia) size exclusion column
(10 mm x 200 mm) equilibrated with 1.0 M NaCl in 20 mM
Tris/HCl, pH 7.5. Fractions (1 ml) were collected and tested for
enzyme activity against Cbz-L-Tyr-4NPE. Those containing
activity were pooled, diluted to a final concentration of 0.5 M
NaCl with 20 mM Tris/HCl (pH 7.5) and applied to the
Mono-S cation-exchange column equilibrated with 0.5 M NaCl
in 20 mM Tris/HCl, pH 7.5. The column was eluted with a
0.5-1.0 M NaCl gradient over 10 ml. All centrifugation and
extraction steps were carried out at 4 °C.
Protein estimations
Protein concentrations were estimated using a Pierce BCA protein
assay kit (Pierce and Warriner, Cheshire, U.K.), using BSA as
standard, in accordance with the manufacturer's instructions.
SDS/PAGE analysis
Discontinuous SDS/PAGE was carried out as described by
Laemmli (1970) on 15% mini slab gels (Mini Protein II; Bio-
Rad) run at 200 V for 1.5 h, or on large format (Protean II xi;
Bio-Rad) 10% tricene/SDS/PAGE gels (Schagger and von
Jagow, 1987) run overnight at 100 V (constant) to prepare
samples for amino acid sequence analysis. A range of molecular
mass standards was included in each run: lysozyme (14.4 kDa),
soybean trypsin inhibitor (21.5 kDa), bovine carbonic anhydrase
(30 kDa), ovalbumin (45 kDa), BSA (66.2 kDa) and phosphoryl-
ase B (97.4 kDa). Protein bands were visualized by staining with
Coomassie Blue or by silver staining.
Electroblotting
Proteins in SDS/PAGE gels were transferred to nitrocellulose
membranes (Schleicher and Schuell, Dassel, Germany) or
poly(vinylidene difluoride) membranes (Immobilon P; Millipore)
using a semi-dry transfer apparatus (Kyhse-Andersen, 1984)
with a current of 0.1 mA/cm2 of gel for 1 h. After transfer,
nitrocellulose membranes were incubated in a solution of 0.1 %
(w/v) Tween 20 (Sigma) in PBS, pH 7.5 (PBS/T20), for 30 min
at room temperature to block non-specific protein adsorption to
the membranes. Following the blocking procedure the mem¬
branes were rinsed in fresh PBS/T20 (all subsequent washes and
antibody dilutions were in PBS/T20) and transferred to optimally
diluted sheep anti-MMCP-1, rabbit anti-MMCP-1 or rabbit
anti-RMCP I for 1 h at room temperature. The membranes were
subsequently washed (3x5 min) and probed with optimally
diluted pig anti-sheep IgG-horseradish peroxidase (HRP) con¬
jugate prepared according to the method of Nakane and Kawaoi
(1974), or with sheep anti-rabbit IgG-HRP conjugate (Sera, W.
Crawley, Sussex, U.K). Peroxidase activity was revealed with
diaminobenzidine/H20., (Graham and Karnovsky, 1966). Im¬
mobilon membranes with protein bands for sequence analysis
were stained with Coomassie Blue immediately after transfer was
completed, and destained in methanol.
Mouse mast cell proteases 129
Deglycosylation
Aliquots of the proteases (20-25 /d), containing approx. 2 jig of
protein, were denatured by heating in a boiling-water bath for
10 min and then cooled to room temperature. Denatured samples
were incubated with 10/<1 of deglycosylation buffer [150 mM
phosphate buffer, pH 7.0, 50 mM EDTA and 1 % (v/v) 2-
mercaptoethanol] and 1 /d (0.2 unit) of peptide-N-glycosidase F
or endo-a-acetylgalactosaminidase (Boehringer-Mannheim,
Lewes, E. Sussex, U.K.) at 37 °C overnight. An additional
0.2 unit of glycosidase was then added and incubation was
continued for a further 24 h.
E.l.i.s.a.
MMCPs were quantified by an antibody capture e.l.i.s.a. de¬
scribed previously (Huntley et al., 1990a) except that the capture
antibody was affinity-purified sheep anti-MMCP-1, which was
diluted to 1 //g/ml for coating e.l.i.s.a. plates.
Immunohistochemistry
Tissue sections were stained with Toluidine Blue, pH 0.5
(Enerback, 1966), or with sheep anti-MMCP-1 directly conju¬
gated to fluorescein isothiocyanate (FITC) (Rinderknecht, 1962),
by the following method. Rehydrated sections (5 /tm thick) were
incubated in 5% (w/v) BSA (Sigma, Grade IV) in PBS for
30 min before transfer to sheep anti-MMCP-l-FITC, optimally
diluted in 5% BSA/PBS for 1 h at room temperature. After
washing (3x5 min in PBS), sections were mounted in Citifluor
non-fluorescent mountant (Citifluor Ltd., London, U.K.).
Specific anti-protease antibodies
Rabbit antiserum to MMCP-1 was prepared as described pre¬
viously (Newlands et al., 1987). Rabbit anti-RMCP I antibodies
were raised, absorbed against MMCP-l-Sepharose and affinity
purified on RCMP I-Sepharose as described previously (Miller
et al., 1988). Antiserum to MMCP-1 was raised in sheep by
intramuscular injection of 100 jug of MMCP-1 in Freund's
complete adjuvant. Two subsequent injections of MMCP-1 in
Freund's incomplete adjuvant were given 4 and 7 weeks after the
first. The sheep was bled at 2-week intervals after the final
injection and batches of serum with an antibody titre > 1:16 by
double diffusion against MMCP-1 were applied to an MMCP-
l-Sepharose affinity column and eluted anti-MMCP-1 antibodies
were cross-absorbed against RMCP I as described for rabbit
anti-MMCP 1 (Miller et al., 1988).
Binding of [3H]DFP
Protease samples (40 /d) containing 4-8 jug of protein were
incubated with 10/<Ci of [:iH]DFP (5.8 Ci/mmol; Amersham
International pic) at 37 °C for 15 min. The samples were
prepared for electrophoresis by the addition of 50 /<1 of reducing
sample buffer (Laemmli, 1970) and heating to > 90 °C for 3 min.
After electrophoresis the gels were prepared for autoradiography
by the method of Laskey and Mills (1975). Radiographs were
exposed at —70 °C and developed after 21 days.
Substrate kinetics
All kinetic measurements were made using a Beckman DU 600
spectrophotometer. Rates of hydrolysis of five concentrations
(0.125-2 mM) succiny!-alanine-alanine-proline-phenylalanine-4-
nitroanalide (Succ-Ala-Ala-Pro-Phe-4NA) were measured by
adding 2 /d of substrate solution to 48 /d of enzyme solution in
0.1 M Tris/HCl, pH 7.5. The increase in absorbance was con¬
tinuously measured at 410 nm, and the spectrophotometer's on¬
board software was used to calculate the kinetic constants Km
and kM from the initial rates of substrate hydrolysis.
Concentrations of protease were determined by active-site
titration of the MMCP-1-like proteases against the fluorogenic
substrate 4-methylumbelliferyl-p-(jWA'-trimethylammonium)-
cinnamate (Sigma) (Jameson et al., 1973). Fluorescence was
measured on a Perkin-Elmer 3000 fluorescence spectro¬
photometer with an excitation wavelength of 365 nm and an
emission wavelength of 445 nm. Unknown samples were
measured, in triplicate, against a standard curve prepared with
7-hydroxy-4-methylcoumarin (Aldrich Chemical Co. Ltd.).
Inhibitor sensitivity
The sensitivity of isolated enzymes to the following specific
protease inhibitors was studied using Cbz-L-Tyr-4NPE as
substrate: 2.0 mM phenylmethanesulphonyl fluoride (PMSF),
20 /<M 3,4-dichloroisocoumarin, 200 /<M V-[V-(L-3-/ranj-car-
boxyoxiran-2-carbonyl)-L-leucyl]-amido-(4-guanido)butane
(E64), 2 mM 1,10-phenanthroline and 1 mM pepstatin (all
reagents supplied by Sigma). The assay of enzyme activity was as
follows. Samples of 2.5 /d of enzyme preparation and 2.5 /d of
inhibitor were preincubated with 40 /d of 0.1 M Tris/HCl buffer,
pH 7.5, at 22 °C for 1 h. The enzyme concentration in the
incubation mixture was 50 nM and the inhibitor concentrations
were those given above. After preincubation, 5 fi\ of substrate
was added and incubated for a further 3 min. Enzyme activity
was quenched by the addition of 450 /d of 70 % (v/v) methanol.
Absorbance was measured at 410 nm and the percentage in¬
hibition was calculated in comparison with an enzyme prep¬
aration incubated without inhibitor.
The association constant (kass.) for the reaction between the
MMCP-1-like proteases and human cq-proteinase inhibitor (cq-
PI; Sigma) was determined by preincubating equimolar enzyme
and cq-PI for periods of 15-120 s before continuous measurement
of the rate of hydrolysis of the substrate Succ-Ala-Ala-Pro-Phe-
4NA. The kass for each reaction was calculated by non-linear
regression as described previously (Pirie-Shepherd et al., 1991).
The inhibition constant (K,) for the reaction between each
protease and oq-PI was determined by incubating the protease
with various inhibitor concentrations (0.25-1.75 molar equiv¬
alents) for 35 x ti (the time to half-inhibition for an equimolar
reaction, calculated from the equation /i = l/kass £0, where E0 is
the initial enzyme concentration). The apparent K, (K1app) was
calculated by non-linear regression, as described previously
(Pirie-Shepherd et al., 1991), and the true Ki was calculated from
the equation Kt = Ajapp/(1 + S0/Km), where S0 is the initial
substrate concentration.
Amino acid analysis
N-terminal sequence analyses of MMCP-1 A-E were performed
on soluble proteins in 50 mM Mes directly from ion exchange on
an Applied Biosystems 477A protein microsequencer by the
Welmet Protein Characterization Facility, Biochemistry De¬
partment, University of Edinburgh. MSMCP, immobilized on
Immobilon-P following tricene/SDS/PAGE and Western blot¬
ting, was sequenced in the Microchemical Facility, AFRC
Institute of Animal Physiology and Genetics Research,
Babraham, Cambridge, U.K.




Cation-exchange chromatography of small intestinal homogen-
ate in 20 mM Tris/HCl buffer, pH 7.5, on CM-Sepharose, when
eluted with a linear 0-1.0 M NaCl gradient, gave one major peak
which contained all the detectable enzyme activity against the
synthetic substrate Cbz-L-Tyr-4NPE. After buffer exchange into
50 mM Mes, pH 6.0, the enzyme activity was resolved into five
distinct peaks by f.p.l.c. cation-exchange chromatography on
Mono-S (Figure 1). Each peak containing enzyme activity was
collected separately, and after 5-fold dilution it was re-
chromatographed on Mono-S, where each eluted at a different
molarity (88, 92, 103, 109 and 115mM NaCl for peaks 1-5
respectively). These fractions were labelled MMCP-1A to - IE, in
order of elution, for identification.
Analysis of the peaks by SDS/PAGE under reducing con¬
ditions (Figure 2a) showed MMCP-1A to contain two poly¬
peptides of 32 and 33 kDa of different staining intensities, which
were not resolved by the techniques used. MMCP-1B and -1C
each contained single proteins of 31 kDa, and MMCP-1D and
-IE each contained a single band of 30 kDa.











Size-exclusion chromatography of the serosal mast cell granule
extract on Sephacryl S-200 resolved two major peaks, the second
of which contained enzyme activity which hydrolysed Cbz-L-
Tyr-4NPE. When this material was applied to Mono-S cation
exchanger, a single peak of bound material was eluted at 0.77 M
NaCl. The protein resolved by cation-exchange chromatography
hydrolysed Cbz-L-Tyr-4NPE and contained a single 28 kDa
polypeptide on SDS/PAGE (Figure 2a).
Biochemical characterization
The MMCP-1 polypeptides in the 30-33 kDa range all bound the
group-specific inhibitor [3H]DFP (Figure 3), indicating the pres¬
ence of serine esterase activity. The autoradiograph of the labelled
16
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Fraction no. (0.5 ml)
Figure 2 Analysis of MMCP-1 peaks
Characterization of MMCP-1 peaks from Mono-S cation-exchange on an SDS/15%-PAGE gel
(silver staining). Peaks 1A-E from Mono-S were loaded in lanes 1-5 respectively. MSMCP is
in lane 6, and RMCP I in lane 7. (b) and (e) Western blot analysis showing MMCP peaks 1A-E
from Mono-S in lanes 1-5 respectively, MSMCP in lane 6,104 purified mouse serosal mast
cells in lane 7 and RMCP I in lane 8 probed with rabbit anti-MMCP-1 (b) or sheep anti-MMCP-
1 absorbed to remove anti-RMCP I activity (c). Isolated enzymes were loaded at the rate of








Figure 3 Autoradiograph of MMCP-1 peaks A-E labelled with the specific
serine esterase inhibitor [3H]DFP
Lanes 1-5 contain peaks A-E respectively.
Figure 1 Mono-S cation-exchange chromatogram showing the resolution
of five peaks of enzyme activity (arrowheads) against Cbz-L-Tyr-4NPE
The column was equilibrated with 50 mM Mes, pH 6.0, and eluted with a segmented gradient
of 50-150 mM NaCl.
proteins showed the same pattern as the silver-stained SDS/
PAGE gel (Figure 2a), except that MMCP-ID had an additional
polypeptide of 27 kDa labelled with [3H]DFP which was not
detectable on the stained gel (Figure 3). This additional poly-
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Table 1 Substrate specificities of multiple forms of MMCP-1 and of MSMCP
Enzyme activity is expressed in nkat/mg of protein; 1 nkat is that activity which hydrolyses 1 nmol of substrate in 1 s. Bz, benzoyl; NA, no activity detected.
Activity (nkat/mg)
Substrate 1A 1B 1C 1D 1E MSMCP
Chymotryptic Cbz-L-Tyr-4NPE 63.0 42.0 31.0 33.0 21.0 259.0
(esterase) Cbz-L-Trp-4NPE 14.0 10.0 6.0 5.0 4.0 9.0
Cbz-L-Phe-4NPE 0.3 0.9 NA 0.2 NA NA
Elastinolytic Cbz-L-Ala-4NPE 15.0 6.0 4.0 9.0 4.0 41.0
(esterase) Cbz-D-Ala-4NPE 8.0 2.0 2.0 5.0 2.0 22.0
Typtic Cbz-L-Lys-4NPE NA NA NA NA NA NA
(esterase)
Chymotryptic Bz-L-Tyr-4NA 1.0 NA NA NA NA 2.0
(amide) Succ-Phe-4NA 0.8 0.2 NA NA 0.3 5.0
Tryptic Cbz-L-Arg-4NA 2.0 NA NA 0.4 NA 8.0
(amide) Bz-DL-Arg-4NA 1.0 0.3 0.001 NA NA NA
Table 2 Substrate and inhibitor kinetics of the MMCP-1-like proteases
Conditions for substrate kinetics were 0.1 M Tris/HCI, pH 7.5, at 22 °C. Results were means+ S.E.M.
*cat 10~5 X * A)
MMCP (fiM) (S~1) (M~1 - s ) (M-'-s"') (pM)
1A 922 ±73.7 2.33 ± 0.10 2.5 ±0.09 7.67 ±1.50 0.76 ±0.18
1B 991 ±59.9 1.66 ±0.04 1.7 ±0.07 12.30 ± 0.35 1.02 ±0.10
1C 663 ±49.9 2.84 ± 0.12 4.3 ±0.22 3.29 ±0.48 45.40 ±7.90
1D 936 ±83.9 2.54 ± 0.12 2.7 ± 0.13 4.07 ±0.62 2.20 ±0.34
1E 832 ±56.9 1.25 ±0.04 1.5 ±0.07 11.40 ±0.22 1.51 ±0.12
n 4 4 4 3 3
ANOVA P = 0.026 P < 0.0001 P < 0.0001 P< 0.001 P< 0.0001
Table 3 Inhibition characteristics of mast cell proteases MMCP-1A-E and
MSMC
Results are the percentage inhibition after 60 min of incubation with the inhibitor; n = 3 for
each preparation.
Table 4 MMCP concentrations and mast cell numbers in N. brasiliensis-
infected and normal mice
Jejunal mast cell counts are expressed as cells per villus/crypt unit (vcu). 'A, mast cells were








1A 10 1C 1D 1E MSMC
100 100 100 100 100 100
100 100 100 100 100 100
5 18 5 9 0 0
8 5 11 5 0 0













183 + 23.7 0.5 ± 0.12
7 ±0.7 A*
6 + 0.3 0
peptide may represent a degradation product generated during
incubation with [:!H]DFP.
The five MMCP-l-like enzymes and MSMCP were screened
against a range of low-molecular-mass synthetic protease sub¬
strates and were found to exhibit chymotrypsin-like esterase
activity, as reported previously for MMCP-1 (Newlands et al.,
1987); the results are summarized in Table 1. MSMCP also had
chymotrypsin-like substrate specificities (Table 1). Using Succ-
Ala-Ala-Pro-Phe-4NA as substrate, kinetic constants were calcu¬
lated for each of the five MMCP-l-like enzymes. There were
significant differences in Km values (P = 0.025) with this sub¬
strate, and highly significant differences in both kM and kCM /Km
(P < 0.0001 for each) by one-way analysis of variance. These
results are summarized in Table 2.. The pH optima lay in the
range pH 7.5-7.8 for all of the isolated enzymes (results not
shown).
The five intestinal MMCPs and MSMCP were all completely
inhibited by PMSF and 3,4-dichloroisocoumarin, both of which
are inhibitors of serine proteases, but not by 1,10-phenanthroline,
E64 or pepstatin, which inhibit metallo-, thiol and aspartic
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Figure 4 Photomicrographs showing normal mouse small intestine, T. spiralis-infected mouse small intestine and normal mouse tongue stained with
Toluidine Blue, pH 0.5 (A-C respectively), or sheep anti-MMCP-1-FITC (D-F).
proteases respectively (Table 3). The MMCP-l-like proteases
were also inhibited by human at-PI while MSMCP, like RMCP
I in the rat (Pirie-Shepherd et al., 1991), was not. The association
constants (/cass) for the reactions between the MMCP-l-like
proteases and a^-PI showed highly significant differences by one¬
way analysis of variance (P — 0.001). Inhibition constants ob¬
tained for the interaction of the MMCPs with PI showed K{s
in the picomolar range, with the of MMCP-1C being almost
60-fold greater than that of MMCP-1A (P < 0.0001; Table 2).
Immunological analysis
The isolated MMCPs were all identified by the rabbit antiserum
raised against MMCP-1 (Newlands et al., 1987; Figure 2b) on
Western blots, as was the 28 kDa MSMCP (Figure 2b). When a
similar blot was probed with sheep anti-MMCP-1, cross-
absorbed against RMCP I, only the highly soluble antigens
isolated from small intestine were identified (Figure 2c).
The five MMCP-l-like enzymes shared complete lines of
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1 5 10 15 20 25 29
MMCP-1A i i G G V E A R P H S R P Y M A H L K I I T D R G S E D R
MMCP-1B i i G G V E A R P H S R P Y M
MMCP-1C i i G G V E A R P H S R P Y M A H L K I I T D R G S E D R
MMCP-1D i l G G V E A R P H S R P Y M A H L K I I T D R G
MMCP-1E i i G G V E A R P H S R P Y M A H L K I I T D R G
MSMCP i i G G V E S R P H S R P Y M A H L E I
Figure 5 N-termina! amino acid sequences of the variant glycoforms of
MMCP-1 (A-E) and MSMCP (MMCP-4)
The single letter code is used to identify amino acids.






Figure 6 Silver-stained SDS/PAGE gel showing MMCP-1A to -1E before
(lanes 1, 3, 5, 7 and 9 respectively) and after (lanes 2, 4, 6, 8 and 10
respectively) removal of N-linked carbohydrate with peptide-N-glycosidase
F
identity in gel diffusion against sheep anti-MMCP-1, whereas no
precipitation occurred with MSMCP (results not shown). When
sheep anti-MMCP-1 was substituted with sheep anti-(RMCP I)
a precipitin line was uniquely present against MSMCP and there
was no reaction against MMCP-1 (results not shown).
All five MMCPs (0.5-12 ng/ml) were detected by e.l.i.s.a.
using sheep anti-MMCP-1 as capture antibody, whereas
MSMCP, RMCPI and RMCPII were not detected at 270 ng/ml,
2.5 /tg/ml and 5.0 /rg/ml respectively. After establishing the
specificity of the e.l.i.s.a., samples of small intestine from N.
brasiliensis-mkcted mice were assayed and MMCP-1 concentra¬
tions were found to be increased 14-fold when compared with
uninfected control mice (Table 4). In contrast, tongues from
control mice had no detectable MMCP-1 despite being rich in
mast cells (Table 4; Figure 4). Small quantities of MMCP-1 were
detected in tongues from infected mice (Table 4) and, as described
previously (Huntley et al., 1990a), this is probably derived from
the blood.
Immunohistochemical studies using the directly labelled sheep
anti-MMCP-l-FITC conjugate confirmed the e.l.i.s.a. results, in
that there were increased numbers of mast cells in the intestinal
mucosa of parasitized mice which fluoresced after incubation
with sheep anti-MMCP-l-FITC when compared with uninfected
controls (Figure 4; Table 4). There were no mast cells detected by
immunofluorescence in tongues of either control or parasitized
mice despite the presence of abundant mast cells which stained
with Toluidine Blue (Figure 4).
N-terminal sequencing
To determine whether the five intestinal mast cell proteases were
separate gene products or differed because of post-translational
processing, the N-terminal amino acid sequence was determined
for each protease (Figure 5). The first 15-29 N-terminal residues
of the intestinal mast cell proteases proved to be identical in each
case and were in agreement with the previously published
sequence for mouse intestinal mast cell protease (Le Trong et al.,
1989). The amino acid sequence determined for MSMCP showed
complete identity over the first 20 residues with that published
for MMCP-4 (Reynolds et al., 1990).
Deglycosylation
To further investigate whether the differences between MMCP-
1A-E are post-translational and a consequence of differential
glycosylation, samples of each enzyme preparation were incu¬
bated with endo-a-acetylgalactosaminidase to remove O-linked
carbohydrate, or with peptide-N-glycosidase F to remove N-
linked carbohydrates. No change in the apparent molecular mass
of any of the MMCPs, as determined by SDS/PAGE, was
detected even after prolonged treatment with O-glycosidase.
Following treatment of the five MMCPs with peptide-N-
glycosidase F, however, there was degradation of each MMCP
resulting in the appearance of a new polypeptide with an apparent
molecular mass of 28 kDa (Figure 6). This 28 kDa polypeptide
remained strongly antigenic on Western blot when probed with
sheep anti-MMCP-1 (results not shown).
DISCUSSION
The five proteases isolated from T. spiralis-infected mouse small
intestine can be identified as MMCP-1 by several criteria. Like
MMCP-1, they are highly soluble, chymotrypsin-like proteases
active at neutral pH. They are closely related antigenically both
on Western blots and by Ouchterlony double diffusion, and are
readily distinguished from MSMCP on the basis of their anti¬
genicity. Finally, they share complete amino acid sequence
identity over the first 15-29 N-terminal residues (Le Trong et al.,
1989) which further distinguishes the MMCP 1 group of proteases
from MMCPs 2-6 (Serafinet al., 1990; Reynolds et al., 1990), all
of which differ from MMCP-1 within the first 10 N-terminal
residues.
The differences in electrophoretic mobility between these
variant forms of MMCP-1 are probably a result of variable
glycosylation, since removal of N-linked carbohydrate moieties
produced a new polypeptide of approx. 28 kDa from each of
MMCP-1 A-E which was antigenically similar to native MMCP-
1. Analysis of the carbohydrate content of each enzyme prep¬
aration might prove helpful in further distinguishing between the
different glycoforms of MMCP-1. It may be that each is produced
by mast cells in different regions of the intestine or, more likely,
by mast cells at varying stages of maturation, since intestinal
nematodiasis induces massive mucosal mastocytosis with ex¬
tensive recruitment and differentiation of intestinal mast cells
(Miller et al., 1989).
Variable glycosylation occurs in other serine proteases, notably
in the subunits of human mast cell tryptase (Cromlish et al.,
1987) and tissue plasminogen activator (t-PA) (Wittwer et al.,
1989). Human t-PA is synthesized in two forms, I and II, which
share N-terminal amino acid sequences but have disparate
carbohydrate side groups, the composition of which appears to
be dependent on the cell line from which the t-PAs are derived
(Wittwer et al., 1989). In the presence of a fibrinogen fragment
stimulator, t-PA II will catabolize a synthetic substrate up to five
times faster than does t-PA I (Wittwer et al., 1989), while type I
is more resistant to cleavage by plasmin (Wittwer and Howard,
1990).
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The kinetic data presented here show that there are significant
differences in the rates at which the MMCP-1 proteases catalyse
a low-molecular-mass substrate. This may be due to steric
hindrance of substrate binding by the carbohydrate and suggests
that glycosylation may be important in the catalysis of macro-
molecular protein substrates, possibly in aiding recognition of
specific cleavage sites. The influence of glycosylation on the
catalytic properties of MMCP-1 will not be fully understood
until the native substrates are fully characterized.
The inhibition studies of the various glycoforms of MMCP-1
with human aq-PI also clearly show that the catalytic properties
of these enzymes are modified through their carbohydrate
moieties, with highly significant variations in how rapidly they
associate with inhibitor and how tightly they are bound. This
may be important in prolonging enzyme activity in situations
where immediate hypersensitivity reactions have increased vas¬
cular permeability, bathing surrounding tissues in serum con¬
taining high concentrations of serine protease inhibitors.
MSMCP, isolated from peritoneal CTMC, is, as far as we are
aware, the first murine CTMC protease to be isolated in its
native form and characterized biochemically. MSMCP is a
neutral 28 kDa serine protease with chymotrypsin-like substrate
specificities, properties it has in common with MMCP-1. It
differs from MMCP-1 in that it is highly insoluble and, on
cation-exchange chromatography, behaves like RMCP I which
has a net charge of +18 (Le Trong et al., 1987). In contrast,
MMCP-1 has similar chromatographic properties to RMCP II
and has a net charge of + 3 at neutral pH (Le Trong et al., 1989).
N-terminal amino acid sequence analysis of MSMCP shows
complete identity over the first 20 residues with the CTMC
protease MMCP-4 (Reynolds et al., 1990; Serafin et al., 1991),
differing at residues 7 and 19 from MMCP-1 A, C, D and E
(MMCP-1B was not sequenced beyond residue 15). Based on
this evidence, we can identify MSMCP as MMCP-4.
Immunological techniques have proved to be particularly
useful in the analysis of protease distribution and function. For
example, Woodbury et al. (1978) showed that RMCP I and II
were readily distinguished by gel diffusion although they share
74 % amino acid sequence identity. However, it was not possible
to determine the cellular distribution of RMCP I and II without
first preparing monospecific polyclonal antibodies by cross-
absorption (Gibson and Miller, 1986) or by raising a monoclonal
antibody against RMCP II (Huntley et al., 1990b). The dis¬
tinction between the MMCP-1 family and MMCP-4 was, how¬
ever, readily achieved with polyclonal sheep anti-MMCP-1 cross-
absorbed against RMCP I and affinity purified on MMCP-
1-Sepharose 4B. This was observed with gel diffusion. Western
blotting, e.l.i.s.a. and immunohistochemistry. It was thus poss¬
ible, using this antibody for immunohistochemistry, to confirm
e.l.i.s.a. results (Huntley et al., 1990a) showing that the MMCP-
1 family of proteases is not present in CTMC. As yet no
antibodies are available which allow distinction between MMCP-
1A-E, so it is not clear whether the different glycoforms are
present in distinct regions of the small intestine or are being
produced by MMC of varying maturity.
Using cDNA probes and Northern blotting, Serafin et al.
(1991) detected expression of MMCP-4 in the intestines of
parasitized mice. This may be in agreement with our findings of
an RMCP I-like antigen expressed in mast cells in the gastro¬
intestinal mucosae of T. spiralis-infected mice (Miller et al.,
1988) although, in the rat, RMCP I is not present in intestinal
mucosal mast cells (Huntley et al., 1990b). Serafin et al. (1991)
were, however, unable to detect MMCP-4 in bone marrow-
derived cultured mast cells by Northern blotting, although
transcription of MMCP-4 has recently been reported in BMMC
grown in medium containing the c-kit ligand growth factor
(Gurish et al., 1992). An RMCP I-like antigen in murine BMMC,
detected with anti-(RMCP I) by immunofluorescence and by
immunoblotting of cell lysates, has a very similar or identical
electrophoretic mobility to the mouse CTMC protease now
identified as MMCP-4 (Newlands et ah, 1991). It is therefore
probable that MMCP-4 is present in BMMC grown in T-cell-
conditioned medium, and the failure to detect it by Northern
blotting may simply be due to the low levels of transcription. For
example, murine BMMC contain < 120 ng of MMCP-1/106
cells (Newlands et al., 1991), compared with up to 34 fig of
RMCP 11/10® rat BMMC (Haig et al., 1988). These results again
emphasize the potential value of highly specific antibodies in the
analysis of protease distribution.
In summary, the five proteases isolated from mouse small
intestine are identified as variant glycoforms of MMCP-1, and
the novel CTMC protease is identified as MMCP-4. The
biological significance of so many forms of MMCP-1 will only
become clear when their native substrates and specific inhibitors
are identified and their interactions characterized.
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SUMMARY
Stem cell factor (SCF) is a growth factor with multiple
activities which acts on numerous cell types including
primordial germ cells, haemopoietic stem cells, melano¬
cytes and mast cells. SCF is critical for the development
of the mast cell hyperplasia associated with infection with
the intestinal parasites Nippostrongylus brasiliensis and
Trichinella spiralis. In the present study we have assessed
the role ofSCF in the mast cell and eosinophil responses to
Schistosoma mansoni in the rat by blocking its effects
in vivo with polyclonal antibody to SCF. Rats treated
with sheep anti-SCF antibody on days 21, 24, 27 and 30
of infection with S. mansoni showed a rapid decrease in
serum concentrations of the mucosal mast cell-associated
protease rat mast cell protease II (RMCP II) by day 24,
compared with normal sheep IgG-treated controls. Simi¬
larly, the number of mucosal mast cells and RMCP II
levels in both small intestine and liver were also signifi¬
cantly reduced by day 32 of infection. In contrast with the
depeletion ofmast cells and mast cell proteases, eosinophil
numbers in liver or intestine did not change significantly
after anti-SCF treatment compared with controls. These
results confirm that mast cell survival and hyperplasia are
dependent on the presence of SCF whilst demonstrating
that the eosinophil recruitment to liver and intestine
associated with S. mansoni infection is SCF-independent.
Keywords stem cell factor, kil-ligand, mast cells,
S. mansoni
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INTRODUCTION
The cellular immune response to many helminth para¬
sites is characterized by hyperplasia of mast cells and
eosinophils both at the site of infection and systemically.
Each of these cell types derive from haemopoietic
progenitor lineages in bone marrow which differentiate
and proliferate under the influence of an array of
cytokines and growth factors. For mast cells these
processes are regulated by interleukin (IL) 3, IL-4, IL-9
and IL-10 which are derived from T cells and possibly
from other sources (Ihle, Pepersack & Rebar 1981,
Schmitt et al. 1987, Hultner et al. 1990, Thompson-
Snipes et al. 1991). In addition to this T cell-driven
mechanism mast cell growth is regulated also by a
ligand for c-kit, a tyrosine kinase receptor encoded
for by the c-kit proto-oncogene, called stem cell factor
(SCF) (Williams et al. 1990). SCF, produced by Fibro¬
blasts and other stromal cells, some epithelial cells
and vascular endothelial cells, has multiple activities
which regulate the development of c-kit+ cell lineages
including haemopoietic progenitor cells (Zsebo et al.
1990) and mast cells (Anderson et al. 1990) as well as
primordial germ cells and melanocytes. IF-3, IF-5 and
granulocyte-macrophage-colony stimulating factor
(GM-CSF) all have a role in controlling proliferation
and differentiation of eosinophil populations (reviewed
by Sanderson 1991). Additionally, both IF-3 and IF-5
can act in synergy with SCF in vitro to give enhanced
growth of eosinophils from an eosinophil precursor cell
line (Kobayashi 1993). It is clear from this evidence that
SCF has a role to play in generating the cellular immune
response to parasites. Both mast cell and eosinophil
numbers increase substantially in the liver and intestinal
tract of rats, in response to infection with the intra¬
vascular parasite Schistosoma mansoni (Miller et al.
1994). Rat eosinophils, which mediate worm damage
in vitro (Capron et al. 1981), may have a direct anti-
parasite role. Furthermore, mast cells, which are
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Figure 1 RMCP II concentrations in serum of
S. mansoni-infected rats treated with anti-SCF or normal
sheep IgG. The data presented are mean ± SEM for five animals
per group at each time point. ANOVA: P < 0 0005.
functionally active during the response to S. mansoni,
(Miller et al. 1994), may have an accessory role. This may
be mediated via anaphylactic release of a range of
immune and inflammatory mediators through mem¬
brane bound, parasite-specific, IgE (Capron et al.
1980). The present study examined the role of SCF
in mast cell and eosinophil hyperplasia by treating
S. mansoni-infected rats with a polyclonal sheep anti-
rat SCF antibody to determine whether SCF depletion
altered mast cell or eosinophil numbers or concentra¬
tions of RMCP II in liver or small intestine.
MATERIALS AND METHODS
Fischer F344 inbred female rats, purchased from Harlan
Olac (Bicester Oxon. UK), six to eight weeks old and
weighing approximately 150g, were used. They were
maintained under standard conditions with water
and pelleted diet freely available. Infection with 2500
5. mansoni cercariae via shaved abdominal skin was by
the ring technique (Smithers & Terry 1965). carried out
under anaesthesia with optimal doses of Hvpnorm/
Hypnovel administered by intra-peritoneal injection.
Blood samples (approximately 300/.d per rat) were
taken by tail-snip, under halothane anaesthesia, on
days 18, 21, 24. 27, and 30 after infection. The blood
was allowed to clot at room temperature and the serum
was harvested and stored at —20°C. The rats were treated
with 1 mg of affinity purified sheep anti-SCF antibodies
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or normal sheep IgG on days 21, 24, 27 and 30 by
intraperitoneal injection. An interval of at least 2h was
allowed between blood-sampling and administration
of antibody. On day 32 the rats were anaesthetized by
intraperitoneal injection of Hypnorm/ Hypnovel and
blood samples taken as before. The hepatic portal
system was perfused to recover adult worms (Smithers
& Terry 1965). The liver was excised and a portion
weighed prior to storage at -20 C. Slices cut from the
remainder were fixed by immersion in 4% paraform¬
aldehyde for 6h and subsequently in 70% ethanol
(Newlands et al. 1987). Similarly, a portion of jejunum
was excised, flushed through with PBS and divided into
two parts for storage at —20;C or fixation. Fixed tissues
were processed and embedded in paraffin wax before
sectioning and staining with either toluidine blue for
the demonstration of mast cells or carbol chromotrope
for eosinophils. Rat mast cell proteases I and II (RMCP I
and II) were measured in serum and tissue extracts by
antibody capture ELISA (Huntley et al. 1990). Cell
counts were performed as described previously (Miller
et al. 1994) and the results expressed as cells per 0-2 mnr.
Data are presented as mean ± SEM and were analysed
by Student's two sample ?-test or, for time course data
by analysis of variance (ANOVA).
RESULTS
Serum concentrations of RMCP II increased in control
rats from around 400ng/ml on day 18 of infection with
S. mansoni to 1045ng/ml by day 32 (Figure 1); this
accords with previously reported results (Miller et al.
1994). The concentrations of RMCP II in serum were
significantly depressed (P < 0-0002) in test rats, by day
24 of infection with 5. mansoni (three days after the
first injection of anti-SCF antibody) when compared
with values in the controls treated with normal sheep
IgG. The RMCP II concentrations in the blood of rats
given anti-SCF antibodies decreased until only 12ng/ml
were detected on day 32 of infection, over 30-fold lower
than values on day 21 and 87-fold lower when compared
to controls (Figure 1).
Comparison of the time course data for serum RMCP
II concentrations in treated and control rats showed a
highly significant difference (P < 0 0005 by ANOVA).
Systemic concentrations of RMCP II in anti-SCF-
treated and control rats were reflected by both the
tissue protease concentrations, and mast cell counts, in
liver and jejunum on day 32 of infection (summarized
in Table 1); these values were reduced by >95% in
each tissue. RMCP I. the connective tissue mast cell-
associated protease, was not detectable in the jejunum
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Table 1 Tissue mast cell protease concentrations and mast cell counts on day 32 of infection
RMCP 1 RMCP 11 Mast cells Eosinophils
Jejunum (anti-SCF) 0*» 20-2 ± 6-2*** 1 -24 ± 0-37*** 60-47 ± 5-44
Jejunum (control) 0-89 ±0-128 524-0 ± 35-86 49-76 ±3-15 66-35 ±3-30
Liver (anti-SCF) 0-69 ±0-14*** 10-5 ± 2-48** 0-27 ±0-11*** 33-74 ± 5-92
Liver (control) 5-58 ±0-62 260-0 ±73-31 7 61 ± 1 02 44-56 ±4-98
n = 5 for each group. Mast cell protease concentrations expressed in /xg/g wet wt. of tissue. Cell counts expressed as cells/0-2 mm2.
Student's two sample r-test. ** P < 0 01. ***p < 0-0001 comparing tissues from anti-SCF treated with control animals.
of anti-SCF treated rats whilst there was a >8-fold
reduction/P < 0-0001) in liver. Concentrations of
RMCP II in the tissues similarly showed >25-fold
lower values compared with controls (Table 1). This
was in sharp contrast to the numbers of eosinophils in
both liver and small intestine, which were not altered
significantly by anti-SCF treatment (Table 1). Fewer
worms were recovered by perfusion of the liver of
treated rats (159 ±10-7) than from control rats
(189 ±15-2), although the difference did not achieve
statistical significance.
DISCUSSION
The present results provide additional evidence for the
dependency on SCF of mast cell hyperplasia associated
with parasitic infection while demonstrating that SCF
is not a significant factor in the associated eosinophilia. A
previous study showed that treatment of both normal
and N. brasiliensis or T. spiralis-infected rats with poly¬
clonal anti-SCF antibody significantly depressed mature
mast cell numbers and jejunal and serum RMCP II
concentrations, as well as parasite-associated mast cell
hyperplasia (Newlands et al. 1995). Similarly, in the
experiment described here, mast cell densities and
serum protease concentrations were almost completely
ablated. However, in contrast to the intestinal nematode
infections, in which the mast cell numbers and protease
values had begun to increase again by 6 days after
the start of antibody treatment (Newlands et al. 1995),
the mast cell numbers and serum RMCP II values in
5. w«ns'o«/-infected rats remained depressed after 11 days
of treatment with anti-SCF antibodies. The lack of any
rebound response in mast cells may be due simply to a
weaker antibody response to sheep IgG. It could indicate
also that there is a different mechanism controlling
mast cell hyperplasia in schistosomiasis than in the
intestinal nematode infections, not involving T cell-
derived cytokines such as IL-3.
Unaltered eosinophil numbers in the liver and jejunum
of test and control rats suggest that eosinophil recruit¬
ment in parasitic infections is not significantly dependent
on the presence of SCF or of mast cells, although SCF
does synergise with IL-3 or IL-5 in promoting growth in
an eosinophil cell line in vitro (Kobayashi et al. 1993).
Similarly, when mice infected with N. brasiliensis were
treated with antibody to IL-3, which suppressed mast cell
hyperplasia, the associated eosinophilia in peripheral
blood was undiminished (Madden et al. 1991) despite
the fact that IL-3 is a recognized eosinophil growth
factor. On the other hand, S. mansoni infected-mice,
treated with monoclonal antibody to IL-5 showed com¬
plete ablation of the eosinophil response to schistoso-
mula migrating through skin (Sher et al. 1990) indicating
that IL-5 is the principal cytokine responsible for eosi¬
nophil production in vivo.
Expulsion of T. spiralis is substantially delayed in
mast cell deficient, W/Wv mice (Alizadeh & Murrell
1984) and ablation of intestinal mast cells from mice by
treatment with antibody to c-kit, the SCF receptor,
abolished parasite expulsion (Grencis et al. 1993) con¬
firming the mast cell dependent nature of the expulsion
mechanism for T. spiralis. In contrast, N. brasiliensis was
expelled normally from mast cell deficient, Ws/Ws rats
(Arizono et al. 1993) and parasite fecundity was reduced
in both Ws/Ws rats (Arizono et al. 1993) and anti-SCF
treated rats (Newlands et al. 1995). Additionally suppres¬
sion of the IgE response with anti-IgE antibodies
decreased both the worm burden and egg production
associated with S. mansoni infection in mice (Amiri et al.
1994). These data suggest that, whilst mast cells are
probably an essential component of the expulsion
mechanism of T. spiralis they are less important in the
immune mechanisms directed against N. brasiliensis
and S. mansoni. despite the fact that the mast cells are
functionally active as evidenced by the systemic secretion
of mast cell proteases (Miller et al. 1983, 1994). Indeed
these data, coupled with the decrease in the number of
parasites recovered from mast cell depleted rats reported
here (not statistically significant) suggest that in some
(Q 1995 Blackwell Science Ltd. Parasite Immunology. 17, 595-598 597
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parasitic infections, worm survival and fecundity may be
enhanced by some aspect of the mast cell-IgE dependent
immune responses.
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Stem Cell Factor Contributes to Intestinal Mucosal Mast Cell Hyperplasia in
Rats Infected With Nippostrongylus brasiliensis or Trichinella spiralis, but
Anti-Stem Cell Factor Treatment Decreases Parasite Egg Production During
N brasiliensis Infection
By George F.J. Newlands, Hugh R.P. Miller, Anne MacKellar, and Stephen J. Galli
We assessed the effects of the c-fc/f ligand, stem cell factor
(SCF), in the jejunal mucosal mast cell hyperplasia that oc¬
curs during infection with the intestinal nematodes, Nippo¬
strongylus brasiliensis or Trichinella spiralis in rats. Com¬
pared with vehicle-treated rats, rats treated with SCF (25
/ng/kg/d, intravenous [IV] for 14 days) during N brasiliensis
infection exhibited significantly higher levels of the rat mu¬
cosal mast cell (MMC)-associated protease, rat mast cell pro¬
tease II (RMCP II) in the jejunum and serum on day 8 of
infection, but not on days 10 or 15 of infection. By contrast,
in comparison to rats treated with normal sheep IgG, rats
treated with a polyclonal sheep antirat SCF antibody exhib¬
ited markedly decreased numbers of jejunal MMCs, levels
of jejunal RMCP II, and serum concentrations of RMCP
II during infection with either nematode, particularly at the
earlier intervals of infection (sday 10). Taken together, these
findings indicate that SCF importantly contributes to MMC
hyperplasia and/or survival during N brasiliensis or Tspiralis
infection in rats, but that levels of endogenous SCF are ade¬
quate to sustain near maximal MMC hyperplasia during in¬
fection with these nematodes. Notably, treatment of rats
with SCF somewhat increased, and treatment with anti-SCF
significantly decreased, parasite egg production during N
brasiliensis infection. This finding raises the interesting pos¬
sibility that certain activities of intestinal MMCs may contrib¬
ute to parasite fecundity during infection with this nema¬
tode.
© 1995 by The American Society of Hematology.
AT LEAST TWO distinct mechanisms regulate mast cell
Z*. proliferation, differentiation, and survival in murine
rodents. One of these is mediated by a ligand for c-kit, which
is a tyrosine kinase receptor that is encoded by the c-kit
protooncogene.'"4 The c-kit ligand is a growth factor that is
produced by many cells, including fibroblasts and other stro¬
mal cells, some epithelial cells, and vascular endothelial
cells; this growth factor has multiple activities that influence
the development of c-kit+ lineages, including hematopoietic
progenitor cells and mast cells, as well as primordial germ
cells, melanocytes, and certain other cell types.'3 The c-kit
ligand has been named Steel factor, fa'r-ligand, mast cell
growth factor and stem cell factor (SCF), the designation
that will be used herein.'3 Several lines of evidence indicate
that, under physiological conditions in vivo, SCF is critical
for the development and survival of all mouse and rat mast
cells, including connective tissue-type mast cells, such as
serosal mast cells, and intestinal mucosal mast cells
(MMCs).3'4 The other mechanism that regulates mast cell
From the Moredun Research Institute, Edinburgh; the Department
of Veterinary Clinical Studies, Royal (Dick) School of Veterinary
Studies, University of Edinburgh, Edinburgh, UK; and the Depart¬
ments of Pathology, Beth Israel Hospital and Harvard Medical
School, Boston, MA.
Submitted January 13, 1995; accepted April 14, 1995.
Supported in part by the Scottish Office Agriculture and Fisheries
Department, by United States Public Health Service Grants No. AI
22674 and AI 23990 and by AMGEN, Inc. Dr Galli has performed
research funded by AMGEN, Inc, and consults for AMGEN, Inc,
under terms that are in accord with Beth Israel Hospital and Har¬
vard Medical School conflict of interest guidelines.
Address reprint requests to George F.J. Newlands, FIMLS, Divi¬
sion of Parasitology, Moredun Research Institute, 408 Gilmerton
Rd, Edinburgh. EH17 7JH UK.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
© 1995 by The American Society of Hematology.
0006-4971795/8605-0026S3,00/0
development in mice and rats is mediated by T cells and
possibly other sources of interleukin-3 (IL-3), IL-4, IL-9,
and IL-10, cytokines that can promote and/or copromote
the proliferation and/or survival of certain murine mast cell
populations, including the MMC-like bone marrow-derived
mast cells that can be generated in vitro.3"6
In murine rodents, infection with intestinal nematodes in¬
duces a striking hyperplasia of intestinal MMCs, which is
accompanied by increases in the levels of MMC-associated
proteases in the intestinal tissues and increases in the concen¬
trations of these proteases in the blood.7*10 Previous work
indicates that both SCF- and T-cell-dependent mechanisms
contribute to the intestinal MMC hyperplasia associated with
nematode infection. In comparison to normal mice or rats,
mice or rats with mutations that markedly diminish c-kit
receptor tyrosine kinase activity, such as W/W mice" or Ws!
lTs rats,12 exhibit no or greatly diminished hyperplasia of
intestinal MMCs in response to infection with N bra¬
siliensis"'l2 or Tspiralis." Both intestinal MMC hyperplasia
and the spontaneous expulsion of the parasites are dimin¬
ished in T spiralis-infected mice that have been treated with
an antibody to the c-kit receptor.13 Moreover, treatment of
normal rats with Escherichia coli-derived recombinant rat
SCF'64 which represents virtually the entire extracellular li¬
gand domain of SCF and possesses high biologic activity,3
induces a significant hyperplasia of gastrointestinal MMCs,
as well as connective tissue-type mast cells.14 On the other
hand, athymic "nude" mice fail to develop MMC hyperpla¬
sia in response to nematode infection, whereas this response
is restored in nude animals treated by adoptive transfer of T
cells." Moreover, in normal mice, treatment with either anti-
IL-3 or anti-IL-4 antibodies or, even more effectively, treat¬
ment with both antibodies, significantly suppresses intestinal
MMC hyperplasia in response to N brasiliensis infection.15
Finally, in vitro evidence indicates that SCF and IL-3 can
have synergistic effects in promoting the proliferation of rat
mast cells with phenotypic similarities to MMCs.16'17
Taken together, this evidence indicates that the cytokine-
dependent regulation of MMC hyperplasia during nematode
infection in murine rodents, while quite complex, impor-
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tantly involves both SCF- and T-cell-derived cytokines,
such as IL-3 and IL-4. In the present study, we assessed
whether the administration of exogenous rrSCF164 in
amounts sufficient to induce MMC hyperplasia in normal
(uninfected) rats, influenced either the jejunal MMC hyper¬
plasia or the changes in levels of jejunal or serum MMC-
associated RMCP II in rats infected with N brasiliensis.
We also assessed whether treatment of normal or nematode -
infected rats with a polyclonal sheep antibody to rat SCF
altered MMC numbers, RMCP II levels, or, in N bra-
siliensis-infected rats, parasite fecundity.
MATERIALS AND METHODS
Rats
Random-bred female Wistar rats, weighing 250 to 300 g and
maintained under conventional conditions at Moredun Research In¬
stitute, were used in all studies.
Parasites
Rats were infected with 2,500 to 3,000 N brasiliensis third-stage
larvae by subcutaneous injection' or with 750 to 1,000 T spiralis
muscle larvae per os.'° For both of these procedures, the rats were
anesthetized with Halothane (May and Baker, Dagenham, Essex,
UK).
Stem Cell Factor
Recombinant rat stem cell factor'64 (rrSCF,164 Amgen, Inc., Thou¬
sand Oaks, CA) modified by the covalent attachment of polyethylene
glycol14 was administered intravenously to anesthetized rats, at 25
pglkg of body weight/day in 1 mL physiological saline, for 14
consecutive days; control rats were sham treated with physiological
saline alone. The protocols were the same as those described pre¬
viously.14
Antibodies
Polyclonal anti-rrSCF164 antibodies were produced by inoculating
sheep intramuscularly into both hind legs with 100 pg of rrSCF,164
suspended in 4 mL of Complete Freund's Adjuvant. This procedure
was repeated 4 and 8 weeks after the initial injection, except that
Incomplete Freund's Adjuvant was used for the subsequent inocula¬
tions. Blood samples were taken 3 weeks after the final inoculation
and the serum tested by enzyme-linked immunosorbent assay
(ELISA) for anti-rrSCF'64 activity. Immune sera that gave absor-
bances more than fivefold greater than the background absorbance
of preimmunization serum when tested at dilutions of up to 1/80,000
by ELISA were used to prepare specific antibody. The anti-SCF
antibody preparation virtually abolished the effects of rrSCF164 on
the survival and proliferation of in vitro-derived rat mast cells, but
had no detectable effect on the IL-3-dependent proliferation of these
cells (submitted for publication).
An immuno-affinity column was prepared by coupling 1.6 mg
of rrSCF to CNBr-activated Sepharose-4B (Pharmacia Biotech, St
Albans, Herts, UK) in accordance with the manufacturer's instruc¬
tions. Aliquots of serum (5 mL) were applied to the column, which
had been equilibrated with phosphate buffered saline (PBS), and the
column was subsequently eluted with 0.1 mol/L citric acid pH 2.2
+ 0.5 mol/L NaCl to recover bound specific antibody. For control
purposes, sheep immunoglobulin was prepared by precipitation of
normal sheep serum with 50% saturated ammonium sulphate fol¬
lowed by gel filtration chromatography of the redissolved precipitate
on Sephacryl S-200 (Pharmacia Biotech). Immunoglobulin prepara¬
tions were concentrated by vacuum dialysis in a collodion thimble
apparatus (Sartorious, Epsom, Surrey, UK) against PBS.
Treatment With Anti-SCF Antibodies
Rats were inoculated intraperitoneally with 1 mg sheep anti-
rrSCF164 or normal sheep IgG in 1 mL PBS. Normal rats were treated
daily for each of 4 or 7 days to assess the effects of treatment on
resting mast cell populations. Because of the tissue and pulmonary
migration of the L3 and L4 larval stages of N brasiliensis, rats infected
with this parasite were treated on day 3 of infection when the L5
larvae first reached the intestine and then on days 5, 7, 10, and 12.
A further experiment was performed with N brasiliensis-infected
rats to determine whether treatment with anti-SCF had an effect
on mast cell populations already expanded in response to parasitic
infection. In this experiment, rats were treated with anti-SCF daily
on days 10 to 13 after infection. For rats infected with T spiralis,
treatment commenced on day 0 and continued on days 3, 5, 7, and
10. Normal rats were killed 24 hours after, and parasitized rats 24
or 48 hours after, the final inoculation by exsanguination under deep
Halothane anesthesia followed by cervical dislocation.
Hematologic Studies
Blood samples were obtained by tail-snip under halothane anes¬
thesia with the blood collected into heparinized tubes. Total red
blood cell and leukocyte counts were performed on a model ZM
Coulter counter, hemoglobin concentrations were measured on a
Coulter hemoglobinometer and packed cell volume by micohemato-
crit. Blood films were stained with Leishman's stain for differential
cell counts in which 100 leukocytes were counted per blood film.
Material Collected Postmortem
Peritoneal cells were collected by lavage of the peritoneal cavity
with 20 mL of PBS containing 0.1% wt/vol bovine serum albumin
(BSA) (PBS/BSA). Small intestine (mid-jejunum) was also collected
for analysis and the tissues were either stored frozen at —20°C, or
fixed by immersion in 4% wt/vol paraformaldehyde in PBS for 6
hours followed by 70% vol/vol ethanol overnight 14 before pro¬
cessing to paraffin wax, before further processing. Serum was also
stored at -20°C. Peritoneal lavage samples were sedimented by
centrifugation at l,000g for 20 minutes at +4°C. The cells were
resuspended in 1 mL PBS/BSA, recentrifuged at l.OOOg for 5 min¬
utes and finally resuspended in 1 mL PBS/BSA for estimation of
mast cell numbers. Mast cell counts were performed by diluting a
10-^L aliquot of the cell suspension with 90 ph of a mast cell stain
containing 0.5% wt/vol methylene blue in 50% vol/vol propylene
glycol. Blue staining mast cells were counted using an Improved
Neubauer hemocytometer.
Concentrations of Rat Mast Cell Proteases I or II (RMCP I or
II) were measured in serum and tissue homogenates by ELISA as
described previously.8
Assessment of Rat Antisheep Antibodies
Because ruminant proteins are likely to have been included in the
rats' diet, and the experimental rats may have mounted an immune
response against sheep proteins, an ELISA was developed to quan¬
tify the antibody response against sheep immunoglobulins. ELISA
plates (Dynatech M129B) were coated with a solution of normal
sheep immunoglobulin, prepared as described above, in 0.1 mol
carbonate buffer pH 9.6 (50 /uL/well). The plate was incubated at
+4°C overnight and then washed six times with PBS containing
0.05% vol/vol Tween 20 (Sigma, Poole, Dorset, UK) before loading
with samples. Sera from the animals that had been treated with anti-
rrSCF164 or normal sheep IgG, and pretreatment serum samples from
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Table 1. Effects of SCF Treatment on Jejunal Mast Cell Density and Mast Cell Protease Content in Rats Infected With N brasiliensis
Day of Infection
SCF Control* (not infected) 8 10 15
Mast cells/0.2 mm2 n = 5 n = 3 n = 5 n = 7
- 26 ± 1.2 0.0 ± Ot 72 ± 16+ 238 ± 274
+ 49 ± 4.2§ 13 ± 6.8|| 69 ± 24 221 ± 404
RMCP 1 Dg/g) - 3.0 ± 0.9 1.0 ± 0.4 1.0 ± 0.2 7.0 ± 2.3
+ 6.0 ± 1.5 2.0 ± 0.4 4.0 ± 0.9 20 ± 5.8
RMCP II (Mg/g) - 426 ± 59 19 ± 4.7|| 423 ± 181 2,464 ± 6074
+ 470 ± 60 375 ± 79H 776 ± 281 8,711 ± 3,839
* These rats were treated with SCF or vehicle for 14 days and were killed for analysis of jejunal histology and RMCP I and RMCP II content
1 day later.




H P < .05 v values for SCF untreated group at the same time point.
the same rats, were prepared in serial dilutions in PBS and loaded,
in triplicate, onto the plate (50 /aL/well) and then incubated at room
temperature for 1 hour. The ELISA plate was washed six times
with PBS/Tween 20 and a sheep antirat IgG-horseradish peroxidase
conjugate (Sigma), optimally diluted with PBS/Tween 20, was ap¬
plied. The plate was again incubated at room temperature for 1 hour,
washed six times as before and the color reaction developed, using
orthophenylenediamine (0.4 mg/mL in citrate/phosphate buffer pH
5.0, 50 /rL/well) as substrate, for 10 minutes and the reaction was
terminated by the addition of 25 gL of 2.5 mol H2S04. The plate
was read on a Titertek Multiskan MC ELISA plate reader (Titertek,
Paisley, UK) at 492 nm. Samples that had absorbances, which were
significantly higher by Student's t-test than the pretreatment control
samples, were considered to be positive.
Histological sections (5 ^m thick) were stained with Toluidine
blue (0.5% wt/vol, pH 0.5) and mast cells in the jejunal mucosa
(epithelium and lamina propria) were enumerated on a Leitz Dialux
microscope with a X25 objective lens and X12.5 eyepieces equipped
with a 100 mm2 graticule. A minimum of five fields were counted
per section.
Data Presentation and Statistical Analysis
Unless otherwise specified, all data are presented as the mean ±
SEM. The two-tailed Student's t-test was used to analyze data that
were normally distributed, whereas the Mann-Whitney U-test was
used as the nonparametric test. The time course of responses in
different groups of rats were examined for statistical significance by
using analysis of variance (ANOVA). P < .05 was taken to indicate
a significant difference.
RESULTS
Effects of rrSCF'64 Treatment on Jejunal MMC Numbers
and Mast Cell-Associated Proteases in
N brasiliensis-/«/ecfet/ Rats
Infection of rats with N brasiliensis causes an initial deple¬
tion of MMC from the jejunum, followed by a massive MMC
hyperplasia.7 The data in Table 1 confirm that mast cells
were depleted from the jejunum at day 8 of infection (0 ±
0 MMC/0.2 mm2; n = 3) compared with control values in
noninfected rats (26 ± 1.2 MMC/0.2 mm2; n = 5, P < .02;
Table 1). By day 15 of infection, mast cell densities in the
jejunum of vehicle-treated rats were increased ninefold over
control values (P < .0001; Table 1). The concentrations of
RMCP II reflected the MMC counts in the jejunum, with a
5.8-fold increase on day 15 when compared with control
values in rats not treated with rrSCF164 (P < .02; Table 1).
Treatment of parasitised rats with rrSCF,164 beginning on
day 0, resulted in a significant (—85%) elevation of mean
jejunal mast cell density at baseline, a result that is in good
agreement with our previous report.14 However, the mast
cell densities at 8, 10, or 15 days of infection in the rrSCF164-
treated or -untreated rats were not significantly different.
There were more mast cells at day 8 in the specimens from
rrSCF164- versus -untreated rats, but with a group size of 3,
this difference was not significant. On the other hand, the
—20-fold difference in jejunal RMCP II content on day 8
between rrSCFl64-treated and -untreated parasitized rats was
significant (P < .05; Table 1).
Data for RMCP I content confirm previous findings show¬
ing that the concentration of RMCP I in the rat jejunum is
several orders of magnitudes less than that of RMCP II,9
and these values changed to a lesser extent than values for
RMCP II as a result of N brasiliensis infection (Table 1).
Effects ofrrSCF'64 Treatment on Systemic Secretion of
RMCP II During Infection
Daily intravenous injection of rrSCF164 had no effect on
the systemic secretion of RMCP II in control (uninfected)
rats, in which serum values remained at =300 ng/mL in both
SCF-treated and -untreated controls throughout the course
of the experiment (Fig 1). The concentration of RMCP II
increased to 2350 ng/mL in the control parasitised group by
day 10 of infection, but the peak of serum RMCP II values
occurred earlier, on day 8, in the rrSCF164-treated group. The
day 8 values in the SCF-treated infected group (individual
values = 3,250, 4,250 and 6,450 ng/mL, mean ± SEM =
4,650 ± 945 ng/mL) were substantially higher than the corre¬
sponding values in the vehicle-treated infected rats (individ¬
ual values = 1,200, 1,650, and 2,150 ng/mL, mean ± SEM
= 1,670 ± 274 ng/mL). While the number of observations




















Fig 1. Serum concentrations of RMCP II in uninfected rats treated
with rrSCF'64 (•) or vehicle alone (■) compared with N brasiliensis-
infected animals treated with rrSCF16" (♦) or vehicle controls {▲) (n
= 4 to 8 for each interval in each group except for the day 8 values;
n = 3 for this interval in both groups).
was relatively small at this time point (n = 3/group), there
were no overlapping values in the two groups, and the differ¬
ence between the groups was significant at the P < .05 level.
Together with the data in Table 1, this result shows that, at
day 8 of infection, rrSCF164 treatment results in both in¬
creased jejunal RMCP II content and increased secretion of
this mast cell protease. Moreover, by ANOVA, serum levels
of RMCP II over the entire time course of the infection were
significantly higher in the rrSCF154-treated than in the control
group not treated with the cytokine (P = .001).
Effects of Treatment of Rats With Anti-SCF
Development of an antibody response to sheep Igs in rats
treated with the polyclonal sheep anti-SCF antibodies. On
day 6 of treatment with either sheep anti-SCF or normal
sheep IgG, Tsp/ra/is-infected rats had an antisheep Ig anti¬
body titre of 320, as assessed by ELISA, when compared
with pretreatment sera from the same group of rats (P <
.05). Interestingly, although the assay of sera from day 12
of treatment gave somewhat higher absorbances than that
from the day 6 groups, the titre remained at 320 (P < .05).
To determine whether this was a genuine antisheep IgG
response or simply a reflection of upregulated IgG produc¬
tion as a result of infection, the sera from N brasiliensis-
infected rats that had not been treated with sheep Igs were
also assayed. No significant difference in absorbance was
found on days 3, 6, 9, or 12 of infection when compared
with serum samples obtained from the same group of rats
before infection.
Effects of treatment with anti-SCF in normal (uninfected)
rats. When compared with rats treated with normal sheep
IgG, 4 days of treatment with polyclonal sheep anti-rrSCF
depleted serosal mast cells in the peritoneal cavity by greater
than 56% (P < .05) and decreased the concentration of the
major serosal mast cell-associated protease (RMCP I) in the
cell pellet obtained at peritoneal lavage by 65% (Table 2).
These levels of depletion did not increase by prolonging the
treatment with anti-rrSCF for 7 days (data not shown).
No mast cells at all were detected after anti-SCF treatment
in sections of jejunum (P < .001 v values for control rats)
and both RMCP I and RMCP II concentrations were depleted
at this site (P < .05 or P < .0001. respectively, Table 2).
The depression of jejunal mast cell densities and RMCP II
concentrations were reflected in the systemic levels of
RMCP II, which were depleted by 96% in the serum of anti-
SCF-treated rats (Table 2).
Anti-SCF treatment for 4 days also resulted in a 45%
reduction in peripheral blood white blood cells, as assessed
in rats killed for hematological analysis on day 5 (P < .02)
(Table 3). From the differential cell counts, this appeared to
represent an effect on all types of leukocytes (Table 3). The
proportion of neutrophils counted in both the anti-SCF and
normal IgG-treated control groups was depressed compared
with pretreatment values (Table 3), possibly as a result of the
stress induced by daily handling for inoculation and blood
sampling and/or in response to the foreign protein.
Infection with N brasiliensis. N brasiliensis-infected
rats were first treated with anti-SCF or normal sheep IgG on
day 3 of infection when the worms begin to emerge into the
gastrointestinal tract. As expected, mast cell counts in both
control and treated groups were low on day 6 of infection
(Fig 2). This result is in accord with previous work indicating
that N brasiliensis infection produces an initial reduction in
Table 2. Effects of Anti-SCF Treatment for Four Days







Jejunum - 6.5 ± 1.4 0.84 ± 0.22 343 ± 45
+ 0.0 ± Ot 0.24 ± 0.084 0.4 ± 0.25§
Peritoneal mast
cells (XI05/ - 5.1 ± 1.0 98 ± 8.6 ND
lavage) + 2.2 ± 0.64 34 ± 154 ND
Serum (ng/mL) - NA NA 157 ± 15
+ NA NA 7.0 ± 1.95
Each of the two groups (+ or - anti-SCF treatment) contained five
rats that were killed 24 hours after the last injection of anti-SCF or
normal sheep IgG.
Abbreviations: NA, not applicable; ND, not determined.
* RMCP I was measured per lavage in peritoneal mast cells, and is
expressed for peritoneal mast cells only as //g/lavage.
t P < .001 by two-tailed Student's f-test v values for anti-SCF-un-
treated animals.
t P < .05.
§ P< .0001.
1972 NEWLANDS ET AL
Table 3. Hematologic Parameters of Rats Treated for Four Days With Sheep Anti-SCF (anti-SCF)
or With Normal Sheep IgG (Control) Compared With Pretreatment (Day 0) Controls
Differential Count (%)
WBC RBC
(x 1010/L) (x101z/L) Hb (g/dLI Hct (%) Neutrophils Lymphocytes Monocytes Eosinophils
DayO 1.1 ± 0.05 6.7 ± 0.1 15.4 ± 0.3 40.5 ± 0.5 14.9 ± 1.5 78 ± 2.0 6.1 ± 0.7 1.1 ± 0.4
anti-SCF 0.6 ± 0.04* 6.3 ± 0.2 14.6 ± 0.6 39.4 ±1.1 5.0 ± 1.1 85 ± 2.5 7.8 ± 1.9 1.8 ± 0.7
Day 5
control 1.1 ± 0.16 6.1 ± 0.4 14.9 ± 0.8 38.8 ± 1.6 5.2 ± 1.6 88 ± 1.8 5.0 ± 1.4 1.8 ± 0.7
Day 5
Each of the groups contained five rats that were killed 24 hours after the last injection of anti-SCF or normal sheep IgG. Thus, n = 10 for day
0 values (after blood was drawn on day 0, 5 of the 10 rats received anti-SCF treatment, and the other 5 received normal sheep IgG treatment),
whereas n = 5 for the day 5 values.
* P < .02 by two-tailed Student's f-test v day 5 control.
mast cell densities in the intestines16 and other, distant,
sites.17 However anti-SCF treatment resulted in significant
inhibition of mast cell hyperplasia (Fig 2A). This effect was
most notable on day 10 of infection (P < .001 v the corre¬
sponding value in control rats), but was observed throughout
the entire time course of the infection (P < .0005 v control
values). The anti-SCF treated rats also exhibited significantly
reduced levels of RMCP II in the jejunal mucosa at all time
points tested (Fig 3A), as well as over the entire time course
6 8 10 12 14
Days after Infection
Fig 2. Mast cell densities in jejunum of rats infected with (A) N
brasiliensis and treated with anti-rrSCF164 (□) or normal sheep IgG
(O), or (B) T spiralis and treated with anti-rrSCF164 (■) or normal
sheep IgG (•) (n = 5 for each interval in each group).
of the infection (P < .0005 v control values). This reduced
intestinal concentration of RMCP II was paralleled by a
highly significant depression of RMCP II levels in the blood
at 6 or 10 days after infection (P < .001 at either interval,
P < .0005 over the entire course of the infection; Fig 4A). At
14 days after infection, the anti-SCF-treated rats developed
MMC hyperplasia and increases in jejunal and serum levels
of RMCP II, perhaps partly as a result of the development
of an antibody response that diminished the efficacy of the
0 2 4 6 8 10 12 14
Days after Infection
Fig 3. RMCP II content of jejunum of rats infected with (A) N
brasiliensis and treated with anti-rrSCF164 (□) or normal sheep IgG
(O), or (B) T spiralis and treated with anti-rrSCF164 (■) or normal
sheep IgG (•) (n = 5 for each interval in each group).
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sheep anti-SCF antibodies. Simple regression analysis of
mast cell densities and RMCPII concentrations in the jejunal
mucosa of all N brasiliensis-irifecled animals gave a highly
significant correlation (R = .96, P < .0001, Fig 5A).
To determine whether SCF remains a significant factor in
MMC hyperplasia or survival even after the onset of the
intestinal MMC response, groups of rats were treated with
anti-SCF or normal sheep IgG daily from day 10 of infection,
when mast cell hyperplasia was well under way (eg, see Fig
2A). The rats treated with anti-SCF showed a 32% depletion
of RMCP II from the small intestine on day 14, compared
with values for normal sheep IgG-treated controls (P < .01;
Table 4), with a concomitant 32% decrease in mast cell
density (P < .03; Table 4). The 15% decrease in serum
RMCP II concentrations in anti-SCF-treated rats was not
significant (Table 4), nor were there any significant alter¬
ations in hematological parameters as a result of the anti-
SCF treatment (Table 5).
Infection with T spiralis. Infective T spiralis larvae es¬
tablish themselves in the intestine within hours of oral chal¬
lenge, therefore treatment with anti-SCF was first given at
the time of infection on day 0. Mast cell hyperplasia occurs
sooner during trichinosis than in N brasiliensis-mftci&d rats,
and anti-SCF treatment significantly depressed mast cell den¬
sities on day 6, 10, and 12 of infection (P < .001, P < .001,
2 4 6 8 10 12
Days after Infection
Fig 4. Serum concentrations of RMCP II in rats infected with (A)
A/ brasiliensis and treated with anti-rrSCF161 (□) or normal sheep IgG
(O) or (B) Tspiralis and treated with anti-rrSCF164 (■) or normal sheep


















Fig 5. Correlation between mast cell densities and RMCP II con¬
centrations in small intestine of rats infected with (A) N brasiliensis
or (B) T spiralis. The data from control rats are represented by open
symbols and those from anti-SCF treated rats by closed symbols In
= 5 for each interval in each group). (A) (■), D 6 anti-SCF; (□), D 6
control; (•), D 10 anti-SCF; (O) D 10 control; (A), D 14 anti-SCF; (A),
D 14 control. IB) (■), D 6 anti-SCF; (□), D 6 control; (•), D 10 anti-
SCF; (O), D 10 control; (A), D 12 anti-SCF; (A), D 12 control.
and P < .005, respectively; P < .0005 over the entire course
of the infection; Fig 2B) when compared with values in
normal IgG-treated controls. Again, this result was paralleled
by values for mucosal concentrations of RMCP II, which
were significantly reduced 6, 10, or 12 days after infection
(P < .005, P < .001, and P < .001, respectively; P < .0005
over the entire course of the infection; Fig 3B) in anti-SCF-
treated rats. The relationship between mucosal RMCP II
and mast cell densities, when analyzed by simple regression
analysis, was significantly correlated (R = .90, P < .0001,
Fig 5B). In contrast with responses in Nippostrongylus-in¬
fected rats, the systemic secretion of RMCP II was depressed
on day 6 (P < .001), but not at other time points (Fig 4B).
As previously reported,10 we found that T spiralis infection,
in comparison to N brasiliensis infection, was associated
with a greater, and earlier, systemic release of RMCP II
(compare Fig 4A and B).
Effects of treatment with rrSCF'64 or anti-SCF on parasite
fecundity. The effects of the administration of rrSCF164 or
anti-SCF on the fecundity of N brasiliensis was determined
by monitoring egg output in the feces of the rats. Egg output
was maximal on day 6 of infection in both rrSCF164-treated
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Table 4. Jejunal Mast Cell Densities and RMCP II Concentrations in
Intestine and Serum in Rats Treated With Anti-SCF or Normal
Sheep IgG (Control) From Day 10 to 13 of A/ brasiliensis Infection
A
250000
Day 14 Day 14
Day 0 Day 10 Control Anti-SCF
Jejunal mast cells
(cells/0.2 mm2) ND ND 65 ± 7 44 ± 3*
Jejunal RMCP II
(fig/g wet wt) ND ND 1,752 ± 106 1,186 ± lilt
Serum RMCP II
(ng/ml_) 95 ± 4 360 ± 21 452 ± 62 386 ± 121
Each of the groups contained five rats that were killed 24 hours
after the last injection of anti-SCF or normal sheep IgG. Thus, n = 10
for day 0 and day 10 values (after blood was drawn on day 10, 5 of
the 10 rats received anti-SCF treatment, and the other 5 received
normal sheep IgG treatment), whereas n = 5 for the day 14 values.
* P < .03.
t P< .01 by two-tailed Student's f-test vday 14 control values.
and vehicle-treated (control) rats and diminished until no
eggs were detected by day 11 (Fig 6A). While values for
fecal egg output were greater in the rrSCF164-treated as op¬
posed to the control rats at many intervals of the infection,
these differences did not achieve statistical significance.
In the experiments in which rats were treated with anti-
SCF or normal sheep IgG, the worm egg output was moni¬
tored over the latter part of the infection to determine
whether depressing the intestinal mucosal mast cell response
would also lead to an alteration of the normal worm expul¬
sion kinetics. Interestingly, we found that the animals that
were treated with anti-SCF (and had reduced densities of
jejunal MMCs) had significantly lower fecal egg-counts on
both days 8 and 9 than did the normal IgG-treated controls
(P < .03 at both intervals, Fig 6B). Over the entire time
course of the response shown in Fig 6B, values for anti-SCF
treated rats were significantly lower than those in control
rats by ANOVA (P = .001). Flowever, egg output had virtu¬
ally ceased by day 11 in both groups.
DISCUSSION
Our findings provide additional evidence that SCF im¬
portantly contributes to the MMC hyperplasia that occurs
during nematode infection in rats, show that this response
can be markedly suppressed by administration of an anti-
10 11
Day after Infection
Fig 6. Fecal egg-output from A/ brasiliensis-infected rats treated
with (A) rrSCF164 (■) or vehicle (control) (•) or (B) anti-SCF (□) or
normal sheep IgG (control) (O) (n = 5 for each interval in each group
except for days 10, 11, and 12 in (A), in which n = 4 for these three
intervals in both groups).
SCF antibody, and raise interesting questions about the role
of SCF and mast cells in the regulation of parasite fecundity
during N brasiliensis infection.
In confirmation of our previous study,'4 we found that
treatment of uninfected rats with rrSCF164 at 25 /ig/kg/d,
intravenous (IV) for 14 days produced a significant (85%)
increase in jejunal MMC numbers. However, in contrast to
our previous study,14 the elevation in jejunal RMCP II con¬
tent in rrSCF164-treated versus vehicle-treated rats did not
achieve statistical significance. On the other hand, rrSCF164
Table 5. Hematologic Parameters in Rats Treated With Anti-SCF or Normal Sheep IgG (Control)
From Day 10 to 13 of N brasiliensis Infection
WBC RBC Hb (g/dL) Hct %
(X1017L) (x1012/L)
Day 0 10 1.4 ± 0.05 6.7 ± 0.1 15.7 ± 0.2 40.0 ± 0.7
Day 10 10 1.1 ± 0.11 7.1 ± 0.2 16.1 ± 0.3 39.2 ± 1.2
Day 14 control 5 1.2 ± 0.05 CT> l+ O 15.1 ± 0.3 40.4 ± 0.8
Day 14 anti-SCF 5 1.1 ± 0.12 6.4 ± 0.1 14.5 ± 1.6 37.4 ± 4.2
Rats were killed 24 hours after the last injection of anti-SCF or normal sheep IgG. Day 0 and day 10 values are from all 10 rats (the 5 that
later received anti-SCF treatment and the 5 that later received normal sheep IgG treatment; the treatments began after blood was drawn on
day 10).
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treatment had only modest effects on the changes in jejunal
MMC numbers, or on the jejunal or serum levels of RMCP
II, that were associated with N brasiliensis infection. Com¬
pared with vehicle-treated rats, rrSCF164-treated rats had
higher levels of jejunal MMCs and significantly higher levels
of jejunal RMCP II at day 8 of infection. Also, the peak
mean levels of serum RMCP II occurred earlier (day 8 v.
day 10) and reached a roughly twofold higher maximum in
rrSCF164-versus vehicle-treated rats. These findings indicate
that administration of exogenous SCF can increase the kinet¬
ics and magnitude of jejunal MMC development and RMCP
II production during N brasiliensis infection. However, later
during the infection, numbers of jejunal MMCs and serum
levels of RMCP II were quite similar in rrSCF164- and vehi¬
cle-treated rats, and, due to the broad range of individual
values, the higher mean levels of RMCP II in the jejunal
mucosa of rrSCF164-treated rats were not significantly differ¬
ent than those in the vehicle-treated controls. One possible
explanation for these findings, which we favor, is that endog¬
enous levels of SCF in normal rats are sufficient to permit
near maximal MMC hyperplasia (presumably, in response to
T-cell-associated cytokines) in the setting of N brasiliensis
infection.
To assess the importance of endogenous SCF in the intes¬
tinal MMC response to nematode infection in normal rats,
we administered a polyclonal sheep antirat SCF antibody to
rats infected with N brasiliensis or T spiralis, as well as to
normal rats. Treatment of normal rats with anti-SCF for 4
days totally ablated the intestinal MMC population and virtu¬
ally eliminated circulating RMCP II; it also significantly
reduced numbers of peritoneal mast cells and diminished
numbers of all circulating white blood cells, probably be¬
cause of an effect on hematopoietic progenitor cells. Treat¬
ment with anti-SCF beginning at the time of infection pro¬
foundly interfered with mast cell hyperplasia in the jejunum
and significantly diminished the systemic release of RMCP
II after infection with either N brasiliensis or T spiralis.
These effects were most marked at the earlier intervals of
infection, probably because of the later development of anti¬
bodies to sheep IgGs in the anti-SCF-treated rats. When
anti-SCF was administered to rats that already had under¬
gone expansion of jejunal MMCs in response to N bra¬
siliensis infection, anti-SCF treatment resulted in a signifi¬
cant decrease in both intestinal RMCP II concentrations and
mast cell numbers, but produced neither a significant depres¬
sion of RMCP II concentrations in the serum nor a significant
change in numbers of peripheral blood white cells.
One interpretation of our findings with anti-SCF is that
endogenous SCF is necessary for the survival of mast cell
populations, including both baseline populations of MMCs
in uninfected rats and the markedly expanded MMC popula¬
tions in nematode-infected rats. rrSCF164 can maintain mouse
mast cell survival in vitro18,19 or in vivo19 by suppressing
apoptosis, and the abrogation of this effect by anti-SCF could
account for our findings. Of course, rrSCF164 can promote
the recruitment of mast cell precursors in vivo14,20 and can
favor their local development into mature mast cells. It also
can synergize with IL-3 to promote rat mast cell prolifera¬
tion.1617 These additional effects of SCF also may have been
antagonized by anti-SCF treatment, particularly when treat¬
ment was begun at the time of infection.
However, the total ablation of mature MMCs from the
intestinal mucosa of normal rats by anti-SCF cannot easily
be explained by a suppression of recruitment of mast cell
precursors. The half-life of mucosal mast cells in rat intestine
has been estimated at around 40 days,21 and blocking recruit¬
ment for only 4 days would be expected to have a negligible
effect on mast cell numbers. Nor can an effect solely on
recruitment of precursors readily explain the depletion of
MMCs from the intestinal mucosa that was observed when
anti-SCF treatment was started on day 10 of infection, when
T-cell-driven mastocytosis was already well established.
These findings can, perhaps, best be explained by effects of
anti-SCF treatment on the SCF-dependent suppression of
mast cell apoptosis.
In T spiralis infection in mice, treatment with an anti-c-
kit receptor antibody not only diminished intestinal mast cell
hyperplasia, but also reduced spontaneous parasite expul¬
sion.13 This finding supports the widely held view that mast
cells can represent an important component of host immunity
to parasite infection. Yet we found that treatment with
rrSCF164 which accelerated the development of the MMC
response, did not diminish and actually somewhat increased
parasite egg production during N brasiliensis infection. This
effect was particularly evident at day 8 of infection, the day
on which rrSCF164-treated rats had significantly more jejunal
MMCs than did control rats (Table 1). Moreover, treatment
with anti-SCF, which markedly suppressed the MMC hyper¬
plasia associated with N brasiliensis infection, substantially
(by >50%) and significantly (P = .001) diminished N bra¬
siliensis egg production during the later stages of the infec¬
tion.
In considering these findings, it should be noted that genet¬
ically mast cell-deficient (WtW, Sl/Sld) mice or (Ws/Ws) rats
exhibit little or no impairment in their ability to expel a
primary infection with N brasiliensis (reviewed in11,12), find¬
ings which suggest that mast cells are not an essential com¬
ponent of the host immune response to this nematode. In¬
deed, Arizono et al12 found that, at the peak of egg output
on day 8 of N brasiliensis infection, parasite egg production
was ~ 3.5-fold greater in the congenic +/+ normal rats than
in mast cell-deficient Ws/Ws rats (133,300 v. 38,100 eggs/g
of feces, P < .01); egg production in both the Ws/Ws and
+/+ rats declined rapidly thereafter, so that there was no
significant difference in the low levels of egg output ob¬
served on day 11 of infection.
Both the findings in Ws/Ws and congenic +/+ rats12 and
our findings in normal rats raise the interesting possibility
that mast cells (and/or other SCF-responsive cells) may actu¬
ally have some effects that favor parasite fecundity during
N brasiliensis infection. For example, perhaps the activation
of increased numbers of intestinal MMCs for mediator re¬
lease, and the resulting increased permeability of gut blood
vessels and intestinal mucosa, promotes the nutrition of the
parasites. Whatever mechanism(s) might account for the ap¬
parent increased fecundity of N brasiliensis in rats treated
with anti-SCF, it has been shown recently that suppression
of IgE levels can decrease both the worm burden and the
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parasite egg production associated with primary infection
with Schistosoma mansoni in mice.22 Taken together with
our results and those of Arizono et al12 in rats infected with
N brasiliensis, these findings suggest that, in certain parasite
infections, aspects of the mast cell- and/or IgE-dependent
immune responses that are elicited by the organisms may
have effects which are more advantageous to the parasite
than to the host.
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